https://flcube.com/brii-biosciences-appoints-dr-brian-alvin-johns-as-chief-scientific-officer-to-lead-pipeline-strategy/2024-10-29T10:01:06+08:00https://flcube.com/genscipt-subsidiary-legend-biotech-finalizes-licensing-deal-with-novartis-for-dll3-car-t-therapies/2024-10-29T09:57:45+08:00https://flcube.com/sino-biopharmaceutical-ltd-secures-exclusive-rights-for-generic-everolimus-in-china/2024-10-29T09:48:59+08:00https://flcube.com/bio-thera-solutions-grants-macter-international-exclusive-rights-to-avzivi-in-pakistan-and-afghanistan/2024-10-29T09:31:10+08:00https://flcube.com/boehringer-ingelheim-partners-with-suzhou-ribo-life-science-to-develop-sirna-therapies-for-nash-mash/2024-10-29T09:28:06+08:00https://flcube.com/sciwind-biosciences-ecnolgutide-shows-promising-phase-iii-results-in-type-2-diabetes-treatment/2024-10-29T09:25:02+08:00https://flcube.com/bayer-ag-leads-series-d-investment-in-jixing-pharmaceuticals-eyeing-commercialization-rights/2024-10-28T23:04:06+08:00https://flcube.com/merck-in-licenses-inspirnas-ompenaclid-for-advanced-colorectal-cancer-eyes-market-potential/2024-10-28T23:01:29+08:00https://flcube.com/boehringer-ingelheim-teams-up-with-3t-biosciences-for-next-gen-t-cell-cancer-therapies/2024-10-28T22:57:52+08:00https://flcube.com/novo-nordisk-expands-u-s-ties-collaborates-with-flagship-pioneering-on-cardiometabolic-advances/2024-10-28T22:54:58+08:00https://flcube.com/menarinis-stemline-signs-500m-license-with-insilico-for-cancer-drug-candidate/2024-10-28T22:42:03+08:00https://flcube.com/shanghai-pharmaceuticals-subsidiary-reprimanded-again-for-monopolisitic-pricing-of-polymyxin-b-sulfate/2024-10-28T22:31:17+08:00https://flcube.com/akeso-biopharma-submits-new-indication-application-for-cadonilimab-in-gastric-cancer-treatment/2024-10-28T22:27:53+08:00https://flcube.com/jw-therapeutics-secures-nmpa-review-for-car-t-therapy-in-mantle-cell-lymphoma/2024-10-28T22:24:12+08:00https://flcube.com/chinas-ministry-of-education-launches-professional-guidelines-for-healthcare-talent-training/2024-10-28T22:21:22+08:00https://flcube.com/suzhou-elite-analytical-instruments-secures-over-14-million-in-initial-funding-round/2024-10-28T22:17:19+08:00https://flcube.com/jiangsu-vcare-pharmatech-submits-nda-to-us-fda-for-vicagrel-a-p2y12-receptor-antagonist/2024-10-28T22:15:32+08:00https://flcube.com/allorion-therapeutics-and-avenzo-seal-deal-for-global-rights-to-cdk2-inhibitor/2024-10-28T22:11:04+08:00https://flcube.com/cspc-pharmaceuticals-sys6020-receives-nmpa-approval-for-myasthenia-gravis-clinical-trial/2024-10-28T18:31:05+08:00https://flcube.com/eli-lillys-ebglyss-shows-positive-results-in-phase-iii-study-for-atopic-dermatitis-patients-previously-treated-with-dupilumab/2024-10-28T18:24:55+08:00https://flcube.com/canbridge-pharmaceuticals-scales-back-us-operations-focuses-on-china-for-rd-and-commercialization/2024-10-28T18:17:09+08:00https://flcube.com/biogens-felzartamab-demonstrates-promising-results-in-phase-ii-study-for-iga-nephropathy/2024-10-28T18:10:05+08:00https://flcube.com/ribox-therapeutics-circular-rna-therapy-rxrg001-gets-fda-green-light-for-dry-mouth-clinical-trial/2024-10-28T17:56:47+08:00https://flcube.com/astrazenecas-zoladex-receives-nmpa-approval-for-higher-dosage-form-in-breast-cancer-treatment/2024-10-28T17:52:00+08:00https://flcube.com/micurx-pharmaceuticals-antibiotic-mrx-5-completes-successful-phase-i-clinical-trial-in-australia/2024-10-28T17:45:53+08:00https://flcube.com/nmpas-cde-prioritizes-marketing-filings-for-innovative-drugs-with-priority-review-status/2024-10-28T17:36:23+08:00https://flcube.com/wantai-biologicals-p85-ab-detection-kit-receives-nmpa-approval-for-nasopharyngeal-carcinoma-screening/2024-10-28T17:28:39+08:00https://flcube.com/chinese-adcs-from-escugen-hansoh-and-medilink-therapeutics-eye-breakthrough-designations-in-china/2024-10-28T17:22:56+08:00https://flcube.com/gsk-commits-usd-800-million-to-new-state-of-the-art-manufacturing-facility-in-pennsylvania/2024-10-28T17:16:01+08:00https://flcube.com/immuneonco-biopharmaceuticals-partners-with-yangtze-river-pharmaceutical-to-boost-pipeline-development/2024-10-28T17:10:02+08:00https://flcube.com/astellas-zolbetuximab-faces-fda-rejection-due-to-manufacturing-facility-deficiencies/2024-10-28T17:01:43+08:00https://flcube.com/zhuhai-beihai-biotechs-beizary-receives-fda-clearance-for-multiple-cancer-indications/2024-10-28T16:48:46+08:00https://flcube.com/remegens-telitacicept-receives-priority-review-status-from-chinas-cde-for-gmg-treatment/2024-10-28T16:38:19+08:00https://flcube.com/chinas-pharmaceutical-trade-reaches-usd-147-491-billion-in-first-three-quarters-export-growth-outpaces-imports/2024-10-28T16:32:23+08:00https://flcube.com/astrazeneca-secures-exclusive-rights-to-omnioses-enzyme-platform-for-bacterial-vaccine-development/2024-10-28T14:31:57+08:00https://flcube.com/chinas-nhsa-aims-to-balance-drug-prices-with-new-monitoring-system-by-march-2024/2024-10-28T14:29:58+08:00https://flcube.com/abbvie-partners-with-umoja-biopharma-to-develop-next-generation-car-t-therapies/2024-10-28T14:27:20+08:00https://flcube.com/weigao-blood-purification-aims-for-usd-190-million-in-shanghai-stock-exchange-ipo/2024-10-28T14:25:23+08:00https://flcube.com/chinas-nmpa-issues-guidelines-for-inspection-of-third-party-online-drug-trading-platforms/2024-10-28T14:14:35+08:00https://flcube.com/novartis-strikes-deal-with-argo-biopharma-for-global-rights-to-sirna-drug-candidates/2024-10-28T14:12:52+08:00https://flcube.com/novartis-to-fully-acquire-sanreno-therapeutics-to-expand-kidney-drug-portfolio-in-china/2024-10-28T14:10:03+08:00https://flcube.com/microport-cardioflow-medtechs-anchorman-system-receives-nmpa-approval-as-first-semi-closed-laa-occluder-in-china/2024-10-28T14:05:13+08:00https://flcube.com/ningbo-linstant-polymer-materials-secures-over-usd-14-million-in-series-b-financing-to-boost-production-and-global-reach/2024-10-28T14:02:16+08:00https://flcube.com/lion-tcr-partners-with-maxcyte-to-develop-mrna-based-tcr-t-therapies-for-solid-tumors-and-viral-diseases/2024-10-28T14:00:05+08:00https://flcube.com/oncusp-therapeutics-secures-oversubscribed-usd-100-million-series-a-financing-for-cdh6-targeting-adc/2024-10-28T13:57:28+08:00https://flcube.com/johnson-johnson-to-acquire-ambrx-biopharma-in-a-deal-valued-at-usd-2-billion/2024-10-28T13:53:37+08:00https://flcube.com/eisais-alzheimers-drug-leqembi-earns-marketing-approval-in-china/2024-10-28T13:37:24+08:00https://flcube.com/3sbio-inc-receives-nmpa-approval-for-otc-minoxidil-foam-for-male-hair-loss-treatment/2024-10-28T13:30:11+08:00https://flcube.com/eli-lilly-appoints-first-female-leader-for-china-unit-with-huzur-devletsah-at-the-helm/2024-10-28T13:19:30+08:00https://flcube.com/jiangxi-jemincare-group-receives-clinical-trial-approvals-for-two-innovative-biologics-in-the-us-and-china/2024-10-28T13:16:42+08:00https://flcube.com/jiangxi-jemincare-secures-first-generic-approval-for-gsks-requip-in-china/2024-10-28T13:15:36+08:00https://flcube.com/shuwen-biotechs-mammatyper-diagnostic-kit-receives-nmpa-approval-for-breast-cancer-molecular-classification/2024-10-28T13:13:11+08:00https://flcube.com/allist-pharmaceuticals-furmonertinib-and-astrazenecas-enhertu-earn-breakthrough-designations-in-china-for-nsclc-treatments/2024-10-28T13:10:35+08:00https://flcube.com/thedermas-tap-1503-cream-receives-priority-review-status-for-pediatric-atopic-dermatitis-treatment-in-china/2024-10-28T13:07:56+08:00https://flcube.com/innovent-biologics-mazdutide-achieves-positive-results-in-phase-iii-clinical-trial-for-overweight-or-obesity/2024-10-28T13:05:37+08:00https://flcube.com/abbisko-therapeutics-pimicotinib-earns-orphan-drug-designation-from-ema-for-tgct-treatment/2024-10-28T12:59:34+08:00https://flcube.com/gileads-descovy-receives-additional-indication-approval-from-chinas-nmpa-for-hiv-1-prep/2024-10-28T12:57:05+08:00https://flcube.com/bebig-medical-group-secures-over-usd-14-million-in-series-b-financing-to-boost-radiotherapy-technology/2024-10-28T12:53:59+08:00https://flcube.com/csbios-multi-kinase-inhibitor-cscjc3456-gets-green-light-for-clinical-trials-in-advanced-solid-tumors/2024-10-28T12:35:51+08:00https://flcube.com/triastek-partners-with-kangerjia-to-develop-3d-printed-modified-drugs-for-sleep-disorders/2024-10-28T12:32:49+08:00https://flcube.com/aidea-pharmaceutical-receives-nmpa-approval-to-clinically-test-hiv-1-treatment-acc017/2024-10-28T12:30:14+08:00https://flcube.com/wuxi-biologics-expands-manufacturing-capacity-to-36000-liters-at-worcester-facility/2024-10-28T12:27:15+08:00https://flcube.com/biocytogen-strikes-exclusive-licensing-deal-with-us-based-radiance-biopharma-for-innovative-bsadc/2024-10-28T12:21:41+08:00https://flcube.com/biocytogen-and-abl-bio-forge-partnership-to-advance-bispecific-adc-development/2024-10-28T12:18:53+08:00https://flcube.com/biocytogen-and-biocopy-ag-collaborate-on-tcr-mimic-antibody-development-for-cancer-therapies/2024-10-28T12:18:29+08:00https://flcube.com/biocytogen-expands-reach-to-india-with-gvsap-partnership-for-biomice-models/2024-10-28T12:17:33+08:00https://flcube.com/biocytogen-secures-us-patent-for-renlite-fully-human-common-light-chain-mouse-platform/2024-10-28T12:17:02+08:00https://flcube.com/biocytogen-strikes-exclusive-deal-with-sotio-biotech-for-next-gen-adcs/2024-10-28T12:16:29+08:00https://flcube.com/biocytogen-strikes-licensing-deal-with-ideaya-for-potential-first-in-class-bsadc-program/2024-10-28T12:15:58+08:00https://flcube.com/gsks-acquisition-of-aiolos-bio-bolsters-respiratory-medicine-portfolio-with-aio-001/2024-10-28T00:43:15+08:00https://flcube.com/wuxi-apptec-expands-peptide-manufacturing-capacity-with-two-new-plants-in-china/2024-10-28T00:40:43+08:00https://flcube.com/sino-medical-sciences-ht-supreme-drug-eluting-stent-system-gains-market-approval-in-bangladesh/2024-10-28T00:38:10+08:00https://flcube.com/novartiss-cosentyx-secures-additional-indication-for-psoriatic-arthritis-in-china/2024-10-28T00:35:47+08:00https://flcube.com/pfizer-and-genmabs-tivdak-earns-priority-review-from-fda-for-full-registration/2024-10-28T00:33:42+08:00https://flcube.com/meizhong-jiahe-medical-debuts-on-hong-kong-stock-exchange-below-ipo-price/2024-10-28T00:25:18+08:00https://flcube.com/abbvie-launches-continuous-infusion-therapy-for-advanced-parkinsons-disease-in-eu/2024-10-28T00:22:31+08:00https://flcube.com/obi-pharma-gets-us-fda-green-light-for-trop2-targeting-adc-cancer-therapy-clinical-study/2024-10-28T00:20:31+08:00https://flcube.com/bio-link-partners-with-verdot-to-distribute-innovative-bioprocessing-products-in-china/2024-10-28T00:15:31+08:00https://flcube.com/synvida-raises-nearly-rmb-200-million-in-series-a-funding-to-advance-clinical-studies/2024-10-28T00:12:32+08:00https://flcube.com/sinocare-partners-with-illumina-to-localize-iscan-chip-scanners-for-precision-health-applications/2024-10-28T00:09:11+08:00https://flcube.com/corruption-investigations-target-former-hsa-officials-in-guizhou-and-hainan-amid-nationwide-crackdown/2024-10-28T00:06:20+08:00https://flcube.com/henlius-biotech-secures-exclusive-rights-to-sermonixs-lasofoxifene-for-breast-cancer-treatment-in-china/2024-10-28T00:04:40+08:00https://flcube.com/genfleets-sls009-receives-fast-track-and-orphan-drug-designations-from-u-s-fda-for-lymphoma-and-leukemia/2024-10-28T00:02:42+08:00https://flcube.com/gsk-secures-second-indication-approval-for-nucala-in-china-for-severe-eosinophilic-asthma/2024-10-28T00:00:42+08:00https://flcube.com/china-resources-medical-laboratory-partners-with-qlife-lab-for-comprehensive-mass-spectrometry-solutions/2024-10-27T23:30:14+08:00https://flcube.com/wuxi-biologics-partners-with-biontech-to-develop-next-gen-antibodies-in-20-million-deal/2024-10-27T23:04:17+08:00https://flcube.com/junshi-biosciences-regains-global-rights-to-js006-as-coherus-terminates-licensing-agreement/2024-10-27T23:01:46+08:00https://flcube.com/chinas-nhc-unveils-strategy-to-enhance-pediatric-healthcare-by-2025/2024-10-27T22:59:11+08:00https://flcube.com/amgen-licenses-xeriject-technology-from-xeris-biopharma-for-subcutaneous-tepezza-development/2024-10-27T22:57:28+08:00https://flcube.com/eli-lilly-secures-nmpa-approval-for-emgality-as-preventive-migraine-treatment-in-china/2024-10-27T22:55:12+08:00https://flcube.com/sanofi-ceo-paul-hudson-rules-out-glp-1-competition-eyes-next-gen-weight-management-therapies/2024-10-27T22:49:14+08:00https://flcube.com/ant-insurance-reports-23-surge-in-health-insurance-payouts-processing-4-69-million-claims-in-2023/2024-10-27T22:12:22+08:00https://flcube.com/myrobalan-therapeutics-secures-24-million-in-series-a-funding-with-strong-chinese-investor-support/2024-10-27T22:10:36+08:00https://flcube.com/huadong-medicines-relmapirazin-approval-filing-accepted-by-nmpa-for-gfr-measurement/2024-10-27T22:08:55+08:00https://flcube.com/lepu-medical-secures-nmpa-approval-for-innovative-coronary-intravascular-impact-waveguide-tube/2024-10-27T22:06:55+08:00https://flcube.com/boehringer-ingelheim-expands-greek-facility-to-boost-production-of-jardiance-and-other-medications/2024-10-27T22:02:46+08:00https://flcube.com/novo-nordisks-icosema-shows-promise-in-late-stage-trial-for-type-2-diabetes-management/2024-10-27T21:57:08+08:00https://flcube.com/abbvies-lutikizumab-advances-to-phase-iii-for-hidradenitis-suppurativa-after-positive-mid-stage-results/2024-10-27T21:54:36+08:00https://flcube.com/bio-thera-solutions-receives-nmpa-approval-for-combined-phase-ib-ii-study-of-bat7104-and-bat4706/2024-10-27T21:49:36+08:00https://flcube.com/eisais-lemborexant-sleep-aid-lemborexant-filed-for-nmpa-approval-in-china/2024-10-27T21:47:24+08:00https://flcube.com/astellas-pharma-appoints-zhao-ping-as-chairman-of-china-operations/2024-10-27T21:44:53+08:00https://flcube.com/bayers-elinzanetant-achieves-primary-endpoint-in-late-stage-menopause-symptom-trial/2024-10-27T21:43:55+08:00https://flcube.com/takeda-and-astellas-join-forces-with-sumitomo-mitsui-to-launch-drug-discovery-joint-venture/2024-10-27T21:43:29+08:00https://flcube.com/keylights-biotechnology-raises-14-million-in-series-b-to-expand-ivd-instrument-range/2024-10-27T21:40:46+08:00https://flcube.com/joincare-pharmaceuticals-partner-fermion-gets-nmpa-green-light-for-pain-drug-clinical-study/2024-10-27T21:38:52+08:00https://flcube.com/gansu-deshengtang-partners-with-relex-solutions-to-enhance-supply-chain-efficiency/2024-10-27T21:37:00+08:00https://flcube.com/biontech-acquires-pre-clinical-asset-and-adc-technology-from-portuguese-biotech-cellmabs/2024-10-27T21:34:42+08:00https://flcube.com/nvidia-expands-healthcare-reach-with-amgens-decode-partnership-at-jp-morgan-conference/2024-10-27T21:31:26+08:00https://flcube.com/alphabets-isomorphic-labs-inks-pharma-partnerships-with-eli-lilly-and-novartis/2024-10-27T21:27:46+08:00https://flcube.com/chinas-nhsa-unveils-measures-to-secure-volume-based-procurement-supply/2024-10-27T21:17:30+08:00https://flcube.com/bmss-mavacamten-used-to-treat-first-patient-with-hypertrophic-cardiomyopathy-in-hainan/2024-10-27T21:15:43+08:00https://flcube.com/shanghais-enjosim-secures-tens-of-millions-in-pre-series-a-funding-for-expansion/2024-10-27T21:13:02+08:00https://flcube.com/pfizer-eyes-further-adc-expansion-potentially-in-china-says-chief-oncology-officer/2024-10-27T21:11:10+08:00https://flcube.com/carsgen-therapeutics-gets-nmpa-approval-for-car-t-therapy-ct011-in-hepatocellular-carcinoma/2024-10-27T21:02:39+08:00https://flcube.com/simcere-pharmaceutical-group-gets-nmpa-green-light-for-usp1-inhibitor-sim0501/2024-10-27T21:00:31+08:00https://flcube.com/china-regulators-chart-steady-path-for-huiminbao-medical-insurance-schemes/2024-10-27T17:53:13+08:00https://flcube.com/mindray-partners-with-wakemed-for-comprehensive-patient-monitoring-solutions/2024-10-27T17:45:21+08:00https://flcube.com/3d-medicines-secures-registration-for-envafolimab-in-macau-for-advanced-solid-tumors/2024-10-27T17:42:44+08:00https://flcube.com/hope-medicine-initiates-phase-ii-trial-for-hmi-115-in-endometriosis-treatment/2024-10-27T17:39:18+08:00https://flcube.com/neuboron-medtech-secures-clinical-trial-approval-for-first-bnct-drug-in-china/2024-10-27T17:36:49+08:00https://flcube.com/astrazeneca-china-announces-leadership-changes-and-new-biopharmaceutical-unit/2024-10-27T17:34:14+08:00https://flcube.com/chinas-state-council-unveils-26-initiatives-to-enhance-grey-hair-economy/2024-10-27T17:27:47+08:00https://flcube.com/china-grand-pharma-to-acquire-63-stake-in-duoputai-for-rmb-442-million/2024-10-27T17:25:11+08:00https://flcube.com/bayers-asklepios-biopharmaceutical-launches-phase-ii-trial-for-aav-therapy-in-heart-failure/2024-10-27T17:22:48+08:00https://flcube.com/novartis-acquires-calypso-biotech-for-usd-250-million-to-bolster-il-15-pipeline/2024-10-27T17:13:48+08:00https://flcube.com/cytokinetics-attracts-big-pharma-interest-amid-aficamtens-phase-iii-success/2024-10-27T17:08:48+08:00https://flcube.com/remegen-secures-fast-track-designation-for-rc88-in-platinum-resistant-ovarian-cancer/2024-10-27T17:04:14+08:00https://flcube.com/cspc-pharmaceutical-secures-fda-approval-for-clinical-study-of-jmt106-in-gpc3-positive-tumors/2024-10-27T17:01:21+08:00https://flcube.com/regenxbios-one-time-gene-therapy-for-wet-amd-shows-promise-in-phase-ii-study/2024-10-27T16:58:35+08:00https://flcube.com/takedas-hyqvia-approved-by-fda-for-chronic-inflammatory-demyelinating-polyneuropathy/2024-10-27T16:55:53+08:00https://flcube.com/qilu-pharmaceuticals-iruplinalkib-gains-additional-indication-approval-in-china-for-alk-positive-nsclc/2024-10-27T16:51:05+08:00https://flcube.com/roches-tecentriq-sc-receives-european-nod-as-first-subcutaneous-pd-l1-therapy/2024-10-27T16:44:29+08:00https://flcube.com/sino-biopharmaceutical-commences-phase-iii-trial-for-semaglutide-biosimilar-in-china/2024-10-27T16:41:25+08:00https://flcube.com/ocumension-therapeutics-sells-56-66-million-stake-in-eyepoint-pharmaceuticals/2024-10-27T16:38:15+08:00https://flcube.com/yifan-pharmaceutical-wins-nod-for-generic-diazoxide-oral-suspension-in-china/2024-10-27T16:35:10+08:00https://flcube.com/china-medical-system-holdings-secures-exclusive-rights-to-promote-xihong-biopharmas-aesthetic-fillers/2024-10-27T16:32:41+08:00https://flcube.com/wuhan-easydiagnosis-biomedicine-partners-with-ailex-technology-group-for-global-glycated-hemoglobin-testing-market/2024-10-27T16:29:32+08:00https://flcube.com/remegens-msln-targeted-adc-rc88-clears-to-begin-phase-i-iia-study-in-china/2024-10-27T16:26:53+08:00https://flcube.com/wuxi-biologics-innovative-bispecific-platform-wuxibody-secures-us-patent/2024-10-27T16:24:05+08:00https://flcube.com/drug-farms-df-003-earns-fda-rare-pediatric-disease-designation-for-rosah-syndrome/2024-10-27T16:21:48+08:00https://flcube.com/zuellig-pharma-partners-with-substipharm-biologics-for-japanese-encephalitis-vaccine-distribution/2024-10-27T16:15:05+08:00https://flcube.com/innocare-pharma-receives-us-fda-ind-approval-for-bcl2-inhibitor-icp-248/2024-10-27T16:09:16+08:00https://flcube.com/chipscreen-newway-biosciences-initiates-phase-i-trial-for-pd-1-cd40-bispecific-antibody-candidate-nwy001/2024-10-27T16:06:09+08:00https://flcube.com/remegens-taitaxipu-receives-cde-acceptance-for-new-indication-application-in-china/2024-10-27T11:11:18+08:00https://flcube.com/eisai-and-medivirs-combo-therapy-advances-in-liver-cancer-with-positive-trial-results/2024-10-27T01:26:06+08:00https://flcube.com/sandoz-strikes-deal-to-acquire-coherus-biosimilar-for-ophthalmic-treatment/2024-10-27T01:25:25+08:00https://flcube.com/beijing-aosaikang-initiates-phase-iii-trial-for-advanced-gastric-cancer-treatment/2024-10-27T01:22:20+08:00https://flcube.com/zhejiang-dian-diagnostics-partners-with-gulf-medical-university-for-middle-east-expansion/2024-10-27T01:20:14+08:00https://flcube.com/fda-approves-casgevy-the-first-crispr-based-gene-editing-therapy-for-%ce%b2-thalassemia/2024-10-27T01:18:25+08:00https://flcube.com/sun-yat-sen-university-researchers-develop-ai-model-for-early-ovarian-cancer-detection/2024-10-27T01:15:45+08:00https://flcube.com/shanghai-based-nk-celltech-earns-fda-ind-clearance-for-non-genetically-modified-nk-cell-therapy/2024-10-27T01:13:58+08:00https://flcube.com/hainan-province-unveils-measures-to-support-innovative-drugs-and-medical-devices-development/2024-10-27T01:09:21+08:00https://flcube.com/shanghai-medical-products-administration-issues-trial-measures-for-pharmaceutical-quality-and-safety-personnel/2024-10-27T01:05:30+08:00https://flcube.com/uspto-invalidates-key-seagen-held-patent-in-adc-conjugation-dispute-with-daiichi-sankyo/2024-10-27T01:03:39+08:00https://flcube.com/bayer-unveils-new-operating-model-to-drive-profitable-growth-amid-challenges/2024-10-27T01:00:09+08:00https://flcube.com/hansoh-pharmaceutical-advances-schizophrenia-treatment-with-hs-10509-clinical-trial-approval/2024-10-27T00:51:56+08:00https://flcube.com/sino-biopharmaceutical-receives-nmpa-approval-for-generic-revolade-equivalent/2024-10-27T00:49:54+08:00https://flcube.com/luye-pharmas-biosimilar-bevacizumab-gets-gmp-certification-in-brazil/2024-10-27T00:47:38+08:00https://flcube.com/abbott-initiates-clinical-study-for-volt-pfa-system-in-australia-for-cardiac-arrhythmias/2024-10-27T00:43:01+08:00https://flcube.com/abbvie-grants-enigma-biomedical-group-rights-to-next-generation-pet-imaging-biomarkers/2024-10-27T00:40:28+08:00https://flcube.com/sichuan-health-commission-issues-directive-to-strengthen-oversight-of-external-prescriptions/2024-10-27T00:38:14+08:00https://flcube.com/shaanxi-panlong-pharmaceutical-partners-with-xian-medical-university-for-multifaceted-collaboration/2024-10-27T00:36:28+08:00https://flcube.com/tasly-pharmaceuticals-gets-nmpa-go-ahead-for-clinical-trial-of-stem-cell-therapy-in-heart-failure/2024-10-27T00:33:21+08:00https://flcube.com/sinocelltech-granted-nmpa-approval-for-phase-i-clinical-trial-in-hematological-malignancies/2024-10-27T00:31:22+08:00https://flcube.com/sanofis-dupixent-receives-fda-label-update-for-atopic-dermatitis-patients-with-hand-or-foot-involvement/2024-10-27T00:29:33+08:00https://flcube.com/luzhu-biotechnologys-lz901-herpes-zoster-vaccine-trial-fully-enrolls-26000-participants/2024-10-27T00:26:30+08:00https://flcube.com/danaher-corporation-to-establish-northern-china-headquarters-in-beijings-changping-district/2024-10-27T00:23:53+08:00https://flcube.com/glorious-med-and-illumina-join-forces-for-advanced-urinary-tract-infection-detection/2024-10-27T00:21:39+08:00https://flcube.com/carsgen-therapeutics-ct041-shows-promising-results-in-advanced-solid-tumors-at-asco-gi-2024/2024-10-27T00:19:06+08:00https://flcube.com/ultrasound-biotechnology-earns-fda-nod-for-disposable-endoscopic-ultrasound-probes/2024-10-27T00:16:29+08:00https://flcube.com/sinovac-biotech-ltd-dismisses-uk-private-equitys-nominal-share-acquisition-offer/2024-10-27T00:10:31+08:00https://flcube.com/lees-pharmaceutical-to-develop-windtrees-cardiovascular-drugs-in-greater-china/2024-10-27T00:07:46+08:00https://flcube.com/digital-precision-medicine-secures-over-28-million-in-series-c-financing/2024-10-26T22:37:52+08:00https://flcube.com/nmpa-grants-marketing-approval-for-hui-sheng-bio-pharmaceuticals-janagliflozin/2024-10-26T22:35:34+08:00https://flcube.com/novartis-lutathera-combo-therapy-shows-significant-progress-in-gep-nets/2024-10-26T22:33:35+08:00https://flcube.com/astrazenecas-imfinzi-meets-primary-endpoint-in-hepatocellular-carcinoma-trial/2024-10-26T22:31:20+08:00https://flcube.com/jjs-balversa-receives-full-fda-approval-for-urothelial-carcinoma-treatment/2024-10-26T22:28:15+08:00https://flcube.com/shandong-province-launches-initiatives-to-accelerate-pharmaceutical-innovation-and-growth/2024-10-26T22:25:31+08:00https://flcube.com/everest-medicines-projects-sharp-revenue-increase-for-2023-on-new-product-launches/2024-10-26T22:23:28+08:00https://flcube.com/uni-bio-science-group-wins-nmpa-nod-for-generic-forteo-injection-for-osteoporosis/2024-10-26T22:21:09+08:00https://flcube.com/endoso-life-raises-over-14-million-in-series-a-to-expand-endoscope-product-lines/2024-10-26T22:17:23+08:00https://flcube.com/convalife-pharmaceuticals-and-divamics-inc-join-forces-to-advance-drug-discovery-with-ai/2024-10-26T22:15:39+08:00https://flcube.com/hightide-therapeutics-to-extend-nash-treatment-reach-into-hebei-province/2024-10-26T22:09:10+08:00https://flcube.com/ai-driven-biotech-insilico-medicine-teams-up-with-hutao-tech-for-precision-medicine-robotics/2024-10-26T22:03:21+08:00https://flcube.com/innocare-makes-minjuvi-combo-treatment-available-to-patients-in-chinas-gba/2024-10-26T22:00:30+08:00https://flcube.com/guangdong-aims-to-boost-biomedicine-industry-with-incentives-and-strategic-development/2024-10-26T21:57:59+08:00https://flcube.com/establishment-labs-launches-motiva-breast-implants-in-china/2024-10-26T21:55:35+08:00https://flcube.com/jiuzhou-pharmaceutical-expands-with-42-million-investment-in-japanese-cro-services/2024-10-26T21:52:56+08:00https://flcube.com/zylox-tonbridge-medical-technology-secures-nmpa-nod-for-innovative-iliac-vein-stent-system/2024-10-26T21:46:12+08:00https://flcube.com/eisais-uric-acid-excretion-drug-urece-accepted-for-review-in-china/2024-10-26T21:43:56+08:00https://flcube.com/hansoh-pharmaceutical-gets-nmpa-approval-for-type-2-diabetes-and-obesity-drug-trial/2024-10-26T21:40:20+08:00https://flcube.com/jiangsu-wuzhong-pharmaceuticals-aesthetics-subsidiary-wins-approval-for-facial-filler-in-china/2024-10-26T21:38:15+08:00https://flcube.com/lepu-medical-technology-gains-nmpa-approval-for-innovative-coronary-device/2024-10-26T21:35:41+08:00https://flcube.com/lifeshield-medical-launches-china-hq-and-advanced-heart-system-factory-in-suzhou/2024-10-26T21:33:42+08:00https://flcube.com/tencents-wedoctor-teams-up-with-guiyang-for-digital-health-community-initiative/2024-10-26T21:31:34+08:00https://flcube.com/huidagene-therapeutics-crispr-therapy-earns-orphan-drug-status-for-duchenne-muscular-dystrophy/2024-10-26T21:26:30+08:00https://flcube.com/pudong-new-area-aims-to-boost-healthcare-with-comprehensive-reform-plan/2024-10-26T21:23:45+08:00https://flcube.com/astrazeneca-wins-fda-nod-for-airsupra-in-asthma-treatment/2024-10-26T21:21:50+08:00https://flcube.com/nhc-unveils-updated-anti-tumor-drug-guidelines-for-2023-with-new-drug-additions/2024-10-26T21:16:26+08:00https://flcube.com/jiangsu-recbio-technology-strikes-licensing-deal-with-spimaco-for-9-valent-hpv-vaccine/2024-10-26T21:12:09+08:00https://flcube.com/suzhou-jade-biomedical-partners-with-hopstem-biotechnology-for-cell-therapy-advancements/2024-10-26T21:08:57+08:00https://flcube.com/eli-lillys-olumiant-patent-invalidated-in-china-generic-version-approved/2024-10-26T18:13:28+08:00https://flcube.com/tcelltechs-b7-h3-targeting-car-t-therapy-tx103-gets-tacit-clinical-approval-for-glioblastoma/2024-10-26T18:03:41+08:00https://flcube.com/mercks-bavencio-shows-promising-survival-data-in-real-world-urothelial-carcinoma-studies/2024-10-26T18:01:27+08:00https://flcube.com/bristar-immunotechs-lilrb4-targeted-cell-therapy-yts104-gets-tacit-approval-for-clinical-trial-in-china/2024-10-26T17:57:15+08:00https://flcube.com/biocytogen-launches-renbiologics-sub-brand-to-expand-antibody-discovery-business/2024-10-26T17:55:29+08:00https://flcube.com/shanghais-reunion-biotech-secures-series-b-funding-to-advance-hydrogel-products/2024-10-26T17:52:40+08:00https://flcube.com/legend-biotechs-carvykti-files-for-european-approval-as-second-line-mm-treatment/2024-10-26T17:50:35+08:00https://flcube.com/wuxi-xdc-partners-with-celltrion-to-support-global-development-and-manufacturing-of-bioconjugated-drugs/2024-10-26T17:45:29+08:00https://flcube.com/visirna-therapeutics-completes-enrollment-in-phase-iii-study-for-fcs-drug-vsa001/2024-10-26T17:41:39+08:00https://flcube.com/shanghai-pharmaceutical-and-sino-biopharmaceutical-form-strategic-partnership-for-pharmaceutical-services/2024-10-26T17:39:30+08:00https://flcube.com/jj-reports-q4-and-full-year-2023-results-with-strong-medtech-and-pharmaceutical-growth/2024-10-26T17:35:50+08:00https://flcube.com/wantai-biological-forecasts-sharp-drop-in-2023-net-profits-amid-hpv-vaccine-sales-slump/2024-10-26T17:29:06+08:00https://flcube.com/eli-lillys-subsidiary-akouos-reports-positive-preliminary-results-for-gene-therapy-in-hearing-loss/2024-10-26T17:26:29+08:00https://flcube.com/shanghai-pharmaceuticals-and-hkstpc-launch-01labshong-kong-incubator/2024-10-26T17:24:29+08:00https://flcube.com/biosions-sirp%ce%b1-targeting-monoclonal-antibody-bsi-082-clears-us-fda-clinical-trial-hurdle/2024-10-26T17:19:50+08:00https://flcube.com/nmpa-proposes-streamlined-market-approval-process-for-domestically-produced-overseas-drugs/2024-10-26T14:23:10+08:00https://flcube.com/gsk-in-licenses-elegens-cell-free-dna-tech-to-advance-next-gen-gene-therapies-and-vaccines/2024-10-26T14:20:56+08:00https://flcube.com/nmpa-expands-generic-drug-catalog-with-74th-and-75th-batches-for-quality-consistency-evaluation/2024-10-26T14:18:31+08:00https://flcube.com/china-grand-pharmaceutical-gets-nmpa-green-light-for-mrna-cancer-vaccine-arc01-phase-i-study/2024-10-26T14:14:53+08:00https://flcube.com/boan-biotech-secures-fda-orphan-drug-designations-for-two-claudin18-2-targeting-candidates/2024-10-26T14:06:32+08:00https://flcube.com/shanghai-microport-initiates-pre-marketing-clinical-study-for-embolic-microspheres-in-liver-cancer-treatment/2024-10-26T14:03:49+08:00https://flcube.com/alphamab-and-3d-medicines-license-envafolimab-rights-to-glenmark-for-multiple-regions/2024-10-26T14:02:00+08:00https://flcube.com/lingyi-biotechnologys-gene-therapy-candidate-ly-m001-gets-fda-green-light-for-gauchers-disease/2024-10-26T13:57:51+08:00https://flcube.com/wuxi-biologics-launches-wuxiaadcc-plus-platform-for-non-fucosylated-antibody-development/2024-10-26T13:55:24+08:00https://flcube.com/phanes-therapeutics-first-in-class-bsab-pt217-accepted-for-review-by-chinas-cde/2024-10-26T13:53:09+08:00https://flcube.com/zhaoke-ophthalmology-secures-nmpa-approval-for-presbyopia-treatments-brimochol-pf-and-carbacholpf/2024-10-26T13:49:42+08:00https://flcube.com/harbour-biomed-gets-fda-green-light-for-phase-i-study-of-bsab-targeting-pd-l1-and-cd40/2024-10-26T13:46:00+08:00https://flcube.com/abbott-reports-mixed-2023-results-with-q4-growth-offsetting-full-year-decline/2024-10-26T13:42:55+08:00https://flcube.com/chongqing-zhifei-biologicals-influenza-vaccine-application-accepted-by-chinas-drug-evaluation-center/2024-10-26T13:22:19+08:00https://flcube.com/thedermas-series-a-round-to-fund-rd-and-commercialization-of-ahr-targeted-drugs/2024-10-26T13:01:11+08:00https://flcube.com/jiangxi-province-to-implement-direct-medical-insurance-fund-payments-for-nrdl-drugs-from-december-2024/2024-10-25T15:27:53+08:00https://flcube.com/boston-scientific-reports-19-5-yoy-increase-in-q3-net-sales-driven-by-new-product-launches-and-market-expansion/2024-10-25T15:15:24+08:00https://flcube.com/everest-medicines-velsipity-approved-for-use-in-select-hospitals-in-chinas-greater-bay-area/2024-10-25T14:57:19+08:00https://flcube.com/daiichi-sankyos-pexidartinib-poised-for-priority-review-in-china-for-tgct-treatment/2024-10-25T14:50:54+08:00https://flcube.com/abbvie-and-gedeon-richter-expand-partnership-to-develop-novel-neuropsychiatric-targets/2024-10-25T14:43:36+08:00https://flcube.com/asieris-pharmaceuticals-gets-fda-green-light-for-usp1-inhibitor-apl-2302-in-advanced-solid-tumors/2024-10-25T14:33:40+08:00https://flcube.com/henlius-biotech-commences-global-phase-iii-trial-for-serplulimab-in-first-line-metastatic-colorectal-cancer/2024-10-25T14:28:40+08:00https://flcube.com/immuneonco-biopharmaceuticals-initiates-phase-ib-study-for-dual-target-therapy-in-systemic-lupus-erythematosus/2024-10-25T14:22:47+08:00https://flcube.com/chinas-nhsa-sets-october-dates-for-national-reimbursement-drug-list-negotiations-and-price-bidding/2024-10-25T14:17:39+08:00https://flcube.com/sanofis-dupixent-demonstrates-positive-results-in-phase-iii-study-for-chronic-urticaria/2024-10-25T14:11:45+08:00https://flcube.com/3sbio-secures-exclusive-rights-to-commercialize-haihes-paclitaxel-oral-solution-in-china-and-hong-kong/2024-10-25T13:46:03+08:00https://flcube.com/chinas-nmpa-and-denmarks-medicines-agency-commit-to-enhanced-regulatory-cooperation/2024-10-25T13:38:57+08:00https://flcube.com/nucmito-and-amoytop-biotech-seal-deal-for-development-and-commercialization-of-nash-drug-candidate-in-greater-china/2024-10-25T13:28:34+08:00https://flcube.com/help-therapeutics-receives-fda-clearance-for-phase-i-clinical-trial-of-hicm-188-cell-therapy/2024-10-25T13:21:56+08:00https://flcube.com/wuxi-national-hi-tech-district-welcomes-synthetic-biology-industrial-park-and-east-chinas-first-rd-center/2024-10-25T12:02:29+08:00https://flcube.com/kingmed-diagnostics-and-megarobo-technologies-join-forces-to-pioneer-smart-medical-laboratories/2024-10-25T11:57:37+08:00https://flcube.com/henlius-biotech-ships-first-international-batch-of-hansizhuang-for-cancer-treatment-to-indonesia/2024-10-25T11:54:30+08:00https://flcube.com/shanghai-fosun-pharmaceutical-receives-nmpa-approval-for-phase-ii-study-of-fcn-338-for-light-chain-amyloidosis/2024-10-25T11:51:34+08:00https://flcube.com/gan-lee-pharmaceuticals-receives-bolivian-approval-for-insulin-aspart-expanding-access-to-rapid-acting-insulin/2024-10-25T11:45:59+08:00https://flcube.com/chinas-nhc-designates-100-areas-as-national-demonstration-zones-for-integrated-medical-and-elderly-care/2024-10-25T11:42:45+08:00https://flcube.com/roche-commences-phase-ii-trial-of-repare-therapeutics-atr-inhibitor-camonsertib-in-solid-tumors/2024-10-25T11:39:50+08:00https://flcube.com/roches-tecentriq-in-combination-with-exelixiss-cabometyx-meets-primary-endpoint-in-mcrpc-phase-iii-study/2024-10-25T11:36:34+08:00https://flcube.com/pfizers-nurtec-approved-by-chinas-nmpa-for-acute-treatment-of-migraines/2024-10-25T11:32:59+08:00https://flcube.com/novo-nordisks-rybelsus-approved-for-type-2-diabetes-in-china-setting-new-oral-treatment-standard/2024-10-25T11:30:11+08:00https://flcube.com/ocumension-therapeutics-zerviate-receives-marketing-approval-in-china-for-allergic-conjunctivitis-treatment/2024-10-25T09:48:53+08:00https://flcube.com/chinas-nmpa-releases-standards-for-brain-computer-interface-medical-devices/2024-10-25T09:47:32+08:00https://flcube.com/cspc-pharmaceutical-group-appoints-dr-liu-yongjun-as-group-ceo-and-global-rd-president/2024-10-25T09:46:13+08:00https://flcube.com/apeloa-pharmaceutical-invests-in-ji-xing-pharmaceuticals-series-d-financing-round/2024-10-25T09:45:43+08:00https://flcube.com/jicui-cell-therapy-forms-partnership-with-fosun-kite-to-advance-bispecific-car-t-cell-therapy-industrialization/2024-10-25T09:45:04+08:00https://flcube.com/lees-pharmaceuticals-zhaoke-ophthalmology-receives-nmpa-approval-for-generic-lumigan/2024-10-25T09:43:58+08:00https://flcube.com/beijings-apollobio-receives-nmpa-approval-for-hpv-therapeutic-vaccine-vgx-3100/2024-10-25T09:43:03+08:00https://flcube.com/jjs-rybrevant-secures-fda-approval-for-egfr-c-met-non-small-cell-lung-cancer-treatment/2024-10-25T09:42:30+08:00https://flcube.com/roches-xofluza-receives-fda-approval-for-reducing-influenza-transmission-in-phase-iii-study/2024-10-25T09:41:56+08:00https://flcube.com/aligos-therapeutics-alg-055009-achieves-positive-topline-results-in-phase-2a-herald-study-for-mash/2024-10-25T09:41:22+08:00https://flcube.com/astrazenecas-himalaya-trial-data-showcases-significant-survival-benefits-for-liver-cancer-treatment-at-esmo-2024/2024-10-25T09:40:43+08:00https://flcube.com/beijing-authorities-release-negative-list-for-data-export-in-key-industries/2024-10-25T09:35:30+08:00https://flcube.com/beijing-aims-to-establish-rare-disease-drug-security-pilot-zone-with-white-list-system/2024-10-25T09:35:00+08:00https://flcube.com/huadong-medicine-secures-exclusive-rights-to-janagliflozin-for-type-2-diabetes-treatment-in-china/2024-10-25T09:34:27+08:00https://flcube.com/tencents-we-doctor-partners-with-cha-on-national-digital-health-platform-and-academic-initiatives/2024-10-25T09:33:32+08:00https://flcube.com/fosun-pharmaceuticals-pd-1-inhibitor-hansizhuang-recommended-for-approval-by-emas-chmp/2024-10-25T09:32:37+08:00https://flcube.com/yantai-dongcheng-pharmaceuticals-18f-lnc1007-receives-clinical-clearance-for-solid-tumor-diagnostics/2024-10-25T09:32:01+08:00https://flcube.com/ocumension-therapeutics-ot-502-receives-nmpa-acceptance-for-post-cataract-inflammation-treatment/2024-10-25T09:31:19+08:00https://flcube.com/hybribios-chloroquine-phosphate-gel-cleared-for-clinical-trial-on-high-risk-hpv-infections/2024-10-25T09:30:42+08:00https://flcube.com/jacobio-pharmas-pan-kras-inhibitor-jab-23e73-clears-fda-hurdle-for-clinical-trials/2024-10-25T09:30:07+08:00https://flcube.com/sichuan-biokins-multi-specific-antibody-gnc-077-gets-nmpa-nod-for-advanced-solid-tumor-clinical-trial/2024-10-25T09:27:11+08:00https://flcube.com/novo-nordisks-obesity-drug-monlunabant-phase-iia-results-lead-to-share-price-drop/2024-10-25T09:26:08+08:00https://flcube.com/sanofis-sarclisa-secures-fda-approval-for-first-line-multiple-myeloma-treatment/2024-10-25T09:25:33+08:00https://flcube.com/global-researchers-call-for-the-revival-of-the-human-genome-project-to-advance-precision-medicine/2024-10-25T09:25:02+08:00https://flcube.com/sihuan-pharmaceutical-sees-aesthetics-and-biopharma-growth-amid-overall-revenue-dip/2024-10-25T09:24:27+08:00https://flcube.com/yunnan-province-increases-pediatric-medical-service-prices-for-children-under-6/2024-10-25T09:23:54+08:00https://flcube.com/frontera-therapeutics-receives-fda-approval-for-phase-ii-study-of-first-chinese-raav-gene-therapy/2024-10-25T09:22:57+08:00https://flcube.com/hainan-province-approves-heart-lung-walking-test-analysis-software-as-category-ii-device/2024-10-25T09:22:23+08:00https://flcube.com/haisco-pharmaceuticals-hsk21542-for-itching-in-dialysis-patients-receives-nmpa-review/2024-10-25T09:20:56+08:00https://flcube.com/allist-pharmaceuticals-egfr-inhibitor-ast2303-approved-for-clinical-trial-in-nsclc-by-nmpa/2024-10-25T00:15:38+08:00https://flcube.com/wuhan-yzy-biopharma-presents-m701-interim-results-at-2024-esmo-congress-for-nsclc-related-pleural-effusion/2024-10-25T00:15:02+08:00https://flcube.com/antengenes-xpovio-receives-nda-approval-in-thailand-for-multiple-myeloma-treatment/2024-10-25T00:14:28+08:00https://flcube.com/aimingmed-technologies-partners-with-rekeymed-to-advance-biotech-and-organoid-innovations/2024-10-25T00:13:19+08:00https://flcube.com/acotec-scientifics-heart-valve-balloon-dilatation-catheter-runflow-wins-nmpa-approval/2024-10-25T00:12:49+08:00https://flcube.com/cdes-bl-b01d1-on-track-for-breakthrough-therapy-designations-for-egfr-wild-type-and-mutant-nsclc/2024-10-25T00:12:19+08:00https://flcube.com/hbow-bios-first-in-class-tumor-imaging-drug-nc527-x-receives-nmpa-clinical-trial-approval/2024-10-25T00:11:47+08:00https://flcube.com/ucbs-bimzelx-gains-fda-approval-for-three-additional-autoimmune-indications/2024-10-25T00:11:16+08:00https://flcube.com/astrazeneca-launches-south-korea-innovation-program-with-focus-on-chinese-market-expansion/2024-10-25T00:10:37+08:00https://flcube.com/winner-medical-expands-global-footprint-with-acquisition-of-global-resources-international/2024-10-25T00:09:56+08:00https://flcube.com/huadong-medicines-v20-device-receives-nmpa-approval-for-market-launch/2024-10-25T00:09:27+08:00https://flcube.com/allist-pharmas-partner-abbisko-receives-nmpa-green-light-for-nsclc-drug-trial/2024-10-25T00:08:56+08:00https://flcube.com/junshi-biosciences-toripalimab-secures-ec-nod-for-two-cancer-indications/2024-10-25T00:08:24+08:00https://flcube.com/innocare-pharmas-h1-2024-revenue-boosted-by-orelabrutinib-anticipates-minjuvi-approval-in-2025/2024-10-25T00:06:14+08:00https://flcube.com/beijing-bohui-innovation-and-boaovax-end-collaboration-on-rabies-vaccine-development/2024-10-25T00:05:35+08:00https://flcube.com/elevation-oncologys-claudin-18-2-targeting-adc-earns-fda-fast-track-designation-for-gastric-cancer/2024-10-25T00:04:59+08:00https://flcube.com/nona-biosciences-partners-with-alkyon-therapeutics-to-develop-next-generation-immunotherapies/2024-10-25T00:04:32+08:00https://flcube.com/beijing-bohui-innovation-biotechnology-ends-rabies-vaccine-partnership-with-boaovax/2024-10-25T00:04:01+08:00https://flcube.com/amgens-tepezza-receives-approval-in-japan-for-treating-thyroid-eye-disease/2024-10-25T00:03:12+08:00https://flcube.com/tj-biopharma-and-sanofi-ink-deal-for-anti-cd73-antibody-uliledlimab-in-greater-china/2024-10-25T00:02:40+08:00https://flcube.com/shanghai-haihe-pharmaceuticals-oral-paclitaxel-rmx3001-wins-nmpa-nod-for-advanced-gastric-cancer/2024-10-25T00:02:07+08:00https://flcube.com/innovent-biologics-submits-market-approval-filing-for-picankibart-in-plaque-psoriasis-to-chinas-cde/2024-10-25T00:01:35+08:00https://flcube.com/beijing-expands-medical-insurance-coverage-to-include-anti-aquaporin-antibody-testing-and-advanced-heart-procedures/2024-10-25T00:00:52+08:00https://flcube.com/beijing-authorities-launch-plan-to-streamline-temporary-import-of-urgently-needed-medical-drugs-and-devices/2024-10-25T00:00:25+08:00https://flcube.com/shanghai-fosun-pharmaceutical-partners-with-state-owned-firms-to-boost-asean-drug-trade/2024-10-24T23:59:50+08:00https://flcube.com/belief-biomed-partners-with-bayers-askbio-to-explore-new-gene-therapies/2024-10-24T23:59:02+08:00https://flcube.com/sino-biopharmaceutical-receives-nmpa-approval-for-rivastigmine-patch-for-mild-to-moderate-alzheimers/2024-10-24T23:58:32+08:00https://flcube.com/cloudr-receives-nmpa-green-light-for-cloudt-01-a-groundbreaking-digital-diabetes-treatment/2024-10-24T23:57:07+08:00https://flcube.com/sansure-biotechs-hpv-detection-kit-receives-nmpa-approval-for-comprehensive-screening/2024-10-24T23:56:29+08:00https://flcube.com/johnson-johnson-reportedly-winding-down-cardiovascular-and-metabolic-pharma-unit/2024-10-24T23:55:10+08:00https://flcube.com/zelgen-biopharmaceuticals-receives-nmpa-approval-for-zg005-clinical-trial-in-advanced-solid-tumors/2024-10-24T23:54:38+08:00https://flcube.com/pfizer-partners-with-shanghai-pharmaceutical-for-long-term-vaccine-collaboration-in-china/2024-10-24T23:52:55+08:00https://flcube.com/shanghai-medical-procurement-platform-sets-price-cap-for-non-locally-supplied-drugs/2024-10-24T23:51:49+08:00https://flcube.com/chinas-pharmaceutical-industry-sees-mixed-results-in-h1-2024-capem-data-reveals/2024-10-24T23:51:15+08:00https://flcube.com/shanghai-junshi-biosciences-inks-licensing-deal-for-iama-001-nasal-spray-with-nanjing-jsiama/2024-10-24T23:50:33+08:00https://flcube.com/hunan-province-includes-fertility-treatments-in-medical-insurance-coverage-from-october-2024/2024-10-24T23:49:50+08:00https://flcube.com/fda-approves-cobenfy-as-novel-schizophrenia-treatment-with-first-in-decades-mechanism/2024-10-24T23:49:10+08:00https://flcube.com/apeloa-pharmaceutical-partners-with-biocre-tech-to-boost-pharmaceutical-innovation/2024-10-24T23:48:16+08:00https://flcube.com/jacobio-pharma-receives-rmb-172-million-milestone-payment-from-allist-pharmaceuticals/2024-10-24T23:47:45+08:00https://flcube.com/astrazenecas-tagrisso-secures-fda-approval-for-unresectable-stage-iii-egfrm-nsclc/2024-10-24T23:47:17+08:00https://flcube.com/jacobio-pharma-receives-nmpa-approval-for-pan-kras-inhibitor-jab-23e73-clinical-trial/2024-10-24T23:46:32+08:00https://flcube.com/china-unveils-medical-insurance-eligibility-management-system-for-designated-healthcare-personnel/2024-10-24T23:45:59+08:00https://flcube.com/china-sets-new-management-measures-for-investigator-initiated-trials-in-medical-institutions/2024-10-24T23:45:31+08:00https://flcube.com/3d-medicines-h124-financials-reflect-increased-comprehensive-loss-amid-revenue-decline/2024-10-24T23:44:56+08:00https://flcube.com/shanghai-fosun-pharmaceuticals-sbk010-stroke-treatment-accepted-for-nmpa-review/2024-10-24T23:44:26+08:00https://flcube.com/shanghai-fosun-pharmaceutical-gets-nmpa-clinical-clearance-for-lymphoma-drug-xs-04/2024-10-24T23:43:47+08:00https://flcube.com/shanghai-pharmaceuticals-partners-with-sibpt-to-boost-biopharmaceutical-rd-and-translation/2024-10-24T23:43:11+08:00https://flcube.com/hoya-surgical-optics-expands-in-china-with-new-artificial-intraocular-lens-facility/2024-10-24T23:42:36+08:00https://flcube.com/whittilong-pharma-secures-over-rmb-100-million-in-series-b-financing-for-modified-drug-development/2024-10-24T23:42:02+08:00https://flcube.com/abbvie-submits-first-bla-for-c-met-targeting-adc-telisotuzumab-vedotin-to-fda/2024-10-24T23:41:29+08:00https://flcube.com/study-predicts-2025-medicare-part-d-negotiation-candidates-with-novo-nordisks-semaglutide-leading-the-list/2024-10-24T23:39:04+08:00https://flcube.com/qilu-pharmaceuticals-ql1706-receives-nmpa-conditional-approval-for-cervical-cancer-treatment/2024-10-24T23:38:24+08:00https://flcube.com/mindray-bio-medical-partners-with-nanjing-drum-tower-hospital-to-boost-clinical-research/2024-10-24T23:37:55+08:00https://flcube.com/lenomed-medicals-touch-insulin-pump-receives-nmpa-approval-aids-chinas-diabetes-management/2024-10-24T23:37:23+08:00https://flcube.com/huadong-medicine-gets-nmpa-green-light-for-clinical-trials-of-roflumilast-cream/2024-10-24T23:36:44+08:00https://flcube.com/bayer-ag-launches-new-life-sciences-incubator-in-shanghai-to-boost-biotech-ecosystem/2024-10-24T23:36:13+08:00https://flcube.com/yabao-pharmaceuticals-sy-009-receives-nmpa-approval-for-phase-ii-clinical-trial-in-constipation/2024-10-24T23:34:34+08:00https://flcube.com/jjs-carvykti-shows-45-reduced-risk-of-death-in-multiple-myeloma-patients-landmark-trial-data-reveals/2024-10-24T23:34:05+08:00https://flcube.com/sichuan-biokins-partner-bristol-myers-squibb-gets-fda-nod-for-bispecific-adc-study/2024-10-24T23:32:39+08:00https://flcube.com/alphamab-oncology-strikes-licensing-deal-with-cspc-pharma-for-her2-targeted-adc-in-china/2024-10-24T23:32:11+08:00https://flcube.com/akeso-biopharmas-cadonilimab-secures-nmpa-approval-for-gastric-cancer-indication/2024-10-24T23:31:42+08:00https://flcube.com/cstone-pharmaceuticals-partner-hengrui-medicine-launches-phase-iii-trial-for-ctla-4-antibody-in-hcc/2024-10-24T23:30:45+08:00https://flcube.com/nmpa-clears-abbvies-abbv-706-for-clinical-trials-targeting-sclc-and-neuroendocrine-tumors/2024-10-24T23:29:35+08:00https://flcube.com/dizal-pharmaceuticals-surufatinib-earns-cde-consideration-for-breakthrough-therapy-in-egfr-exon20ins-nsclc/2024-10-24T23:28:38+08:00https://flcube.com/fr%ce%b1-adc-rina-s-by-genmab-enters-late-stage-clinical-trial-following-profoundbio-acquisition/2024-10-24T23:28:00+08:00https://flcube.com/akeso-biopharmas-pd-1-vegf-bispecific-antibody-study-completes-enrollment/2024-10-24T23:27:29+08:00https://flcube.com/innocare-pharmas-orelabrutinib-achieves-milestone-in-sle-clinical-trial-enrollment/2024-10-24T23:27:01+08:00https://flcube.com/unixell-advances-in-cell-therapy-with-cde-ind-acceptance/2024-10-24T23:24:48+08:00https://flcube.com/legend-biotech-corporation-to-establish-advanced-rd-center-in-philadelphia-for-next-generation-cell-therapies/2024-10-24T23:24:05+08:00https://flcube.com/chinas-cde-releases-draft-guidelines-for-biosimilar-drug-labeling/2024-10-24T23:23:40+08:00https://flcube.com/insilico-medicine-and-seto-biopartner-to-leverage-ai-in-synthetic-biology-and-drug-discovery/2024-10-24T23:23:14+08:00https://flcube.com/chinas-national-healthcare-security-administration-issues-draft-guidelines-for-long-term-care-insurance/2024-10-24T23:22:46+08:00https://flcube.com/tigermed-announces-acquisition-of-majority-stake-in-shanghai-guanhe-pharmaceutical-for-cny-140-million/2024-10-24T23:22:15+08:00https://flcube.com/wuxi-apptec-and-wuxi-biologics-weigh-asset-sales-in-us-and-europe-over-biosecure-act-concerns/2024-10-24T23:21:47+08:00https://flcube.com/genor-biopharma-to-acquire-eoc-pharma-group-in-a-merger-deal-eyeing-commercialization-synergies/2024-10-24T23:21:18+08:00https://flcube.com/chinas-cde-announces-care-plan-to-include-pfizers-marstaximab-for-rare-disease-drug-development/2024-10-24T23:20:34+08:00https://flcube.com/regor-therapeutics-strikes-deal-with-genentech-for-cdk-inhibitors-fetching-usd-850-million-upfront/2024-10-24T23:19:59+08:00https://flcube.com/cassava-sciences-to-pay-over-usd-40-million-to-settle-sec-charges-over-alzheimers-drug-claims/2024-10-24T22:25:03+08:00https://flcube.com/chinas-nmpa-introduces-12-measures-to-strengthen-drug-operation-administration/2024-10-24T22:23:36+08:00https://flcube.com/zai-lab-ltd-appoints-new-greater-china-cco-as-liang-yi-exits/2024-10-24T22:22:59+08:00https://flcube.com/genscript-biotech-corporation-reports-34-2-yoy-revenue-growth-in-2023-financial-results/2024-10-24T22:21:33+08:00https://flcube.com/chongqing-zhifei-biological-reports-38-3-yoy-revenue-growth-in-2023-financial-results/2024-10-24T22:19:49+08:00https://flcube.com/ipsens-somatuline-receives-first-prescription-in-china-for-gep-nets-treatment/2024-10-24T22:19:15+08:00https://flcube.com/genscripts-subsidiary-legend-biotech-expands-eu-approval-for-car-t-therapy-carvykti/2024-10-24T22:18:07+08:00https://flcube.com/kingmed-diagnostics-partners-with-genstar-biosolutions-to-develop-auto-antibody-immunofluorescence-ai-software/2024-10-24T22:17:30+08:00https://flcube.com/shenzhen-wingor-biotechnology-partners-with-guangzhou-institute-of-respiratory-health-for-msc-exos-research/2024-10-24T22:16:57+08:00https://flcube.com/canbridge-pharmaceuticals-can008-fails-to-meet-phase-ii-endpoints-in-glioblastoma-multiforme/2024-10-24T22:16:16+08:00https://flcube.com/zhejiang-dian-diagnostics-partners-with-henan-institute-to-open-neuroimmunity-research-center/2024-10-24T22:15:08+08:00https://flcube.com/sandozs-partner-samsung-bioepis-scores-ec-approval-for-stelara-biosimilar-pyzchiva/2024-10-24T22:12:49+08:00https://flcube.com/huadong-medicines-hdm1005-receives-us-fda-clinical-trial-approval-for-weight-management/2024-10-24T22:12:15+08:00https://flcube.com/akeso-biopharma-submits-snda-for-cadonilimab-in-cervical-cancer-to-chinas-cde/2024-10-24T22:11:40+08:00https://flcube.com/china-medical-system-holdings-desidustat-nda-accepted-for-review-by-chinas-nmpa/2024-10-24T22:10:59+08:00https://flcube.com/shanghai-henlius-biotech-achieves-first-patient-dosing-in-phase-i-trial-for-fibrosis-treatment-hlx6018/2024-10-24T22:09:34+08:00https://flcube.com/european-commission-approves-pfizers-antibiotic-emblaveo-for-multiple-indications/2024-10-24T22:08:21+08:00https://flcube.com/lepu-medical-technology-reports-2023-revenues-of-rmb-7-98-billion-marking-a-24-78-yoy-decrease/2024-10-24T22:07:25+08:00https://flcube.com/novartis-reports-11-yoy-sales-growth-in-q1-2024-led-by-entresto-and-cosentyx/2024-10-24T22:06:29+08:00https://flcube.com/chinas-csrc-unveils-16-measures-to-boost-capital-market-and-tech-enterprises/2024-10-24T22:05:11+08:00https://flcube.com/sanofis-rilzabrutinib-meets-primary-endpoint-in-phase-iii-itp-trial/2024-10-24T22:04:28+08:00https://flcube.com/china-unveils-16-measure-policy-to-support-overseas-investment-in-domestic-tech-firms/2024-10-24T22:03:50+08:00https://flcube.com/sichuan-kelun-pharmaceutical-reports-12-69-yoy-revenue-growth-in-2023-financial-results/2024-10-24T22:03:11+08:00https://flcube.com/jenscare-scientifics-lux-valve-fails-to-gain-approval-from-chinas-cdme/2024-10-24T22:00:50+08:00https://flcube.com/hubei-province-issues-anti-commercial-bribery-guidelines-for-medical-industry/2024-10-24T21:58:23+08:00https://flcube.com/novartiss-lutathera-secures-fda-approval-for-pediatric-gastroenteropancreatic-nets/2024-10-24T21:57:43+08:00https://flcube.com/microport-medbot-reports-384-2-yoy-revenue-increase-in-2023-driven-by-robotic-surgical-devices/2024-10-24T21:56:47+08:00https://flcube.com/apeloa-pharmaceutical-halts-phase-iii-trial-of-salfaprodil-for-acute-ischemic-stroke/2024-10-24T21:50:50+08:00https://flcube.com/tyk-medicines-files-for-ipo-on-hkse-amid-rising-losses-and-expanding-drug-pipeline/2024-10-24T21:48:55+08:00https://flcube.com/3d-medicines-partners-with-sino-cellbiomed-to-advance-tumor-immunotherapy-development/2024-10-24T21:25:07+08:00https://flcube.com/johnson-johnsons-rybrevant-and-lazertinib-filings-accepted-for-review-by-cde/2024-10-24T21:21:03+08:00https://flcube.com/shandong-boan-biotechnology-strikes-licensing-deal-with-joincare-for-long-acting-mab-ba2101/2024-10-24T20:46:18+08:00https://flcube.com/zhaoke-ophthalmology-strikes-distribution-deal-with-south-koreas-kwangdong-pharmaceutical-for-brimochol-pf/2024-10-24T20:38:29+08:00https://flcube.com/yantai-dongchengs-radiopharmaceutical-68galnc1007-gets-fda-nod-for-diagnostic-use-in-solid-tumors/2024-10-24T20:35:39+08:00https://flcube.com/joincare-pharmaceutical-partners-with-qyuns-therapeutics-for-exclusive-rights-to-qx008n-in-china-and-hong-kong/2024-10-24T20:33:16+08:00https://flcube.com/formosa-pharmaceuticals-strikes-licensing-deal-with-cristalia-for-ocular-surgery-pain-treatment-in-brazil/2024-10-24T20:31:25+08:00https://flcube.com/lonza-announces-factory-closures-in-the-us-and-china-amid-global-network-optimization/2024-10-24T20:29:01+08:00https://flcube.com/china-based-biotechs-respond-to-us-house-bill-limiting-federal-funding-for-concerning-companies/2024-10-24T20:27:00+08:00https://flcube.com/gilead-increases-stake-in-arcus-biosciences-and-invests-in-anti-tigit-program/2024-10-24T20:19:24+08:00https://flcube.com/takedas-gammagard-liquid-approved-by-fda-for-chronic-inflammatory-demyelinating-polyneuropathy/2024-10-24T20:15:33+08:00https://flcube.com/shaanxi-province-unveils-ambitious-three-year-plan-to-boost-traditional-chinese-medicine-industry/2024-10-24T20:13:09+08:00https://flcube.com/astrazenecas-enhertu-receives-priority-review-for-expanded-her2-positive-solid-tumor-indication/2024-10-24T20:09:19+08:00https://flcube.com/microport-scientific-corp-forecasts-31-34-revenue-growth-for-subsidiary-microport-endovascular-in-2023/2024-10-24T20:05:42+08:00https://flcube.com/sandt-secures-nearly-rmb-200-million-to-boost-x-ray-system-development-and-manufacturing/2024-10-24T20:02:27+08:00https://flcube.com/joincare-pharmaceutical-group-secures-usd-100-million-loan-from-ifc-for-expansion/2024-10-24T20:00:45+08:00https://flcube.com/south-korean-duo-gc-wellbeing-and-yooyoung-pharmaceutical-target-chinese-filler-market/2024-10-24T19:58:24+08:00https://flcube.com/eli-lillys-alzheimers-drug-kisunla-secures-marketing-approval-in-great-britain/2024-10-24T14:34:25+08:00https://flcube.com/sino-medical-sciences-technology-secures-marketing-approval-for-coronary-balloon-dilation-catheter-in-morocco/2024-10-24T14:27:09+08:00https://flcube.com/gan-lee-pharmaceuticals-initiates-phase-i-clinical-trial-for-biosimilar-secukinumab/2024-10-24T14:19:08+08:00https://flcube.com/lees-pharmaceuticals-subsidiary-reports-positive-results-from-phase-iii-myopia-treatment-study/2024-10-24T14:03:24+08:00https://flcube.com/nmpas-center-for-drug-evaluation-issues-new-guidelines-for-domestic-transfer-of-overseas-produced-vaccines/2024-10-24T13:55:26+08:00https://flcube.com/siemens-healthineers-ag-and-shandong-first-medical-universitys-college-of-radiology-collaborate-on-medical-imaging-metaverse/2024-10-24T13:43:57+08:00https://flcube.com/clinigen-expands-global-footprint-with-first-fully-owned-subsidiary-in-shanghais-free-trade-zone/2024-10-24T13:40:31+08:00https://flcube.com/wuxi-xdc-partners-with-multitude-therapeutics-and-signs-mou-with-shanghai-huilian-to-advance-adc-technologies/2024-10-24T13:32:12+08:00https://flcube.com/shanghai-administration-imposes-hefty-fine-on-hs-pharmaceutical-for-substandard-drugs/2024-10-24T13:28:10+08:00https://flcube.com/shanghai-junshi-biosciences-forecasts-6-02-revenue-growth-in-2023-driven-by-commercialized-products/2024-10-24T13:24:50+08:00https://flcube.com/regeneron-pharmaceuticals-acquires-2seventy-bio-to-boost-cell-therapy-capabilities/2024-10-24T13:21:47+08:00https://flcube.com/hunan-province-hospitals-commit-to-implementing-nationally-negotiated-drugs-in-policy-seminar/2024-10-24T13:18:00+08:00https://flcube.com/pfizer-reports-usd-58-5-billion-in-revenues-amid-post-pandemic-sales-shifts-and-oncology-pipeline-expansion/2024-10-24T13:15:13+08:00https://flcube.com/astellas-forges-partnership-with-mass-general-brigham-to-boost-oncology-and-rare-disease-research/2024-10-24T13:10:40+08:00https://flcube.com/shanghai-curegene-pharmaceutical-secures-usd-14-million-in-series-b-financing-to-advance-cardiovascular-treatments/2024-10-24T13:07:53+08:00https://flcube.com/mabwell-bioscience-extends-research-partnership-with-fudan-university-cancer-center/2024-10-24T12:58:40+08:00https://flcube.com/wuxi-biologics-achieves-full-scale-manufacturing-milestone-at-ireland-facility/2024-10-24T11:35:54+08:00https://flcube.com/hitgen-inc-and-bostal-drug-delivery-form-strategic-partnership-to-advance-nucleic-acid-drug-development/2024-10-24T11:33:05+08:00https://flcube.com/novartis-and-fudan-university-shanghai-cancer-center-renew-partnership-to-drive-precision-cancer-treatments/2024-10-24T11:28:46+08:00https://flcube.com/rebecca-tech-secures-usd-10-million-in-series-a-funding-to-expand-micro-rf-technology-globally/2024-10-24T11:25:56+08:00https://flcube.com/acotec-scientifics-peridge-catheter-receives-nmpa-nod-for-hemodialysis-lesion-treatment/2024-10-24T11:18:08+08:00https://flcube.com/beijing-tiantan-biological-halts-phase-iii-clinical-trial-for-cmv-immunoglobulin-citing-strategic-reasons/2024-10-24T11:14:57+08:00https://flcube.com/wuxi-xdc-forecasts-over-100-revenue-growth-for-2023-on-strength-of-adc-industry/2024-10-24T11:12:32+08:00https://flcube.com/gsk-posts-5-yoy-growth-in-2023-financials-vaccines-business-drives-expansion/2024-10-24T11:08:29+08:00https://flcube.com/novartis-sees-robust-growth-in-innovative-medicines-with-2023-financials-reflecting-a-shift-toward-rd-focus/2024-10-24T10:56:28+08:00https://flcube.com/gileads-kite-subsidiary-reduces-car-t-cell-therapy-turnaround-time-with-fda-approval/2024-10-24T10:53:57+08:00https://flcube.com/junde-pharmaceuticals-licenses-weight-reducing-capsule-jtx-102-to-changchun-genescience/2024-10-24T10:49:33+08:00https://flcube.com/manhattan-biosolutions-strikes-agreement-with-biocytogen-for-access-to-novel-tumor-antigens/2024-10-24T10:46:57+08:00https://flcube.com/smartnuclide-biopharmaceutical-partners-with-gosun-pharmaceuticals-for-rhtsh-market-promotion-in-china/2024-10-24T10:25:25+08:00https://flcube.com/mindrank-ltd-partners-with-henlius-biotech-to-pioneer-ai-powered-drug-therapies/2024-10-24T09:59:25+08:00https://flcube.com/sandoz-launches-biosimilar-natalizumab-in-germany-challenging-biogens-tysabri/2024-10-24T09:55:53+08:00https://flcube.com/teva-pharmaceuticals-initiates-spin-off-of-tapi-unit-targeting-2025-for-completion/2024-10-24T09:51:10+08:00https://flcube.com/merck-kgaas-tepmetko-launches-in-china-expanding-access-to-met-inhibitor-for-lung-cancer-patients/2024-10-24T09:48:24+08:00https://flcube.com/takeda-secures-rights-to-protagonist-therapeutics-rusfertide-in-landmark-deal/2024-10-24T09:41:21+08:00https://flcube.com/shanghai-junshi-biosciences-toripalimab-aims-for-singapore-approval-in-nasopharyngeal-carcinoma/2024-10-24T09:37:17+08:00https://flcube.com/novo-nordisk-delivers-strong-2023-results-with-record-breaking-sales/2024-10-24T09:33:48+08:00https://flcube.com/sanofi-reports-full-year-revenue-growth-driven-by-dupixent-and-vaccines-eyes-biopharma-focus/2024-10-24T09:25:41+08:00https://flcube.com/takeda-reports-flat-9-month-revenue-growth-amid-pipeline-optimization-efforts/2024-10-24T09:22:02+08:00https://flcube.com/sanofi-secures-rights-to-gravitons-rock2-inhibitor-candidates-in-strategic-biotechnology-investment/2024-10-24T09:16:28+08:00https://flcube.com/chinas-nhc-unveils-2024-goals-for-medical-quality-and-safety-improvement/2024-10-24T09:05:16+08:00https://flcube.com/betta-pharmaceuticals-bpi-16350-combo-therapy-shows-improved-pfs-in-breast-cancer-trial/2024-10-24T00:26:53+08:00https://flcube.com/insilico-medicine-partners-with-invox-pharma-to-boost-ai-driven-drug-discovery/2024-10-24T00:24:56+08:00https://flcube.com/novartis-becomes-first-mnc-to-publicly-adjust-china-crdmo-partnerships-in-response-to-biosecure-act/2024-10-24T00:23:15+08:00https://flcube.com/gan-lee-pharmaceuticals-reports-52-31-yoy-revenue-growth-in-2023-driven-by-insulin-sales/2024-10-24T00:22:27+08:00https://flcube.com/roches-q1-2024-turnover-rises-2-yoy-driven-by-new-medicines-and-diagnostics/2024-10-24T00:21:28+08:00https://flcube.com/novartis-receives-positive-interim-results-for-antimalarial-coartem-in-infants/2024-10-24T00:19:27+08:00https://flcube.com/sanofi-reports-6-7-yoy-sales-growth-in-q1-2024-driven-by-dupixent-and-new-product-launches/2024-10-24T00:18:36+08:00https://flcube.com/us-fda-greenlights-henlius-biotechs-hanquyou-as-biosimilar-to-roches-herceptin/2024-10-24T00:17:24+08:00https://flcube.com/chinas-nhc-to-assume-management-of-human-genetic-resources-from-may-2024/2024-10-24T00:15:22+08:00https://flcube.com/huadong-medicines-lidocaine-containing-hyaluronic-acid-gel-accepted-for-nmpa-review/2024-10-24T00:14:47+08:00https://flcube.com/jw-therapeutics-reports-19-3-yoy-revenue-growth-in-2023-driven-by-car-t-therapy-carteyva/2024-10-24T00:11:29+08:00https://flcube.com/clover-biopharmaceuticals-reports-first-commercial-sales-and-narrows-annual-loss-in-2023/2024-10-24T00:10:31+08:00https://flcube.com/wuhan-bio-raid-biotechnology-secures-nmpa-approval-for-first-in-class-cd99-targeted-car-t-therapy/2024-10-24T00:09:45+08:00https://flcube.com/allgens-medical-technology-to-acquire-german-dental-implant-maker-humantech-dental-for-eur-3-25-million/2024-10-24T00:09:13+08:00https://flcube.com/microport-cardioflow-medtechs-vitaflow-liberty-receives-ce-mark-for-european-expansion/2024-10-24T00:08:13+08:00https://flcube.com/astrazeneca-reports-19-yoy-revenue-growth-in-q1-2024-driven-by-oncology-and-ri/2024-10-24T00:06:59+08:00https://flcube.com/takeda-exits-biotechnology-innovation-organization-as-big-pharma-reevaluates-industry-groups/2024-10-24T00:05:33+08:00https://flcube.com/abelzeta-pharmas-car-t-therapy-c-car031-receives-implicit-approval-for-clinical-study-in-china/2024-10-24T00:03:47+08:00https://flcube.com/neusoft-medical-systems-partners-with-west-china-hospital-to-boost-indigenous-medical-tech-innovation/2024-10-24T00:02:58+08:00https://flcube.com/abbvies-rinvoq-outperforms-sanofis-dupixent-in-moderate-to-severe-atopic-dermatitis-trial/2024-10-24T00:01:38+08:00https://flcube.com/united-imaging-healthcare-reports-23-52-yoy-revenue-growth-in-2023-driven-by-strong-product-launches-and-partnerships/2024-10-24T00:00:27+08:00https://flcube.com/mindray-bio-medical-electronics-reports-15-04-yoy-revenue-growth-in-2023-financial-results/2024-10-23T23:59:21+08:00https://flcube.com/novartiss-iptacopan-fabhalta-receives-marketing-approval-in-china-for-pnh-treatment/2024-10-23T23:58:12+08:00https://flcube.com/china-launches-unannounced-inspections-on-medical-insurance-funds-targets-fraud-and-mismanagement/2024-10-23T23:56:50+08:00https://flcube.com/hutchmeds-partner-takeda-gets-chmp-nod-for-fruquintinib-as-crc-treatment-in-europe/2024-10-23T23:56:06+08:00https://flcube.com/bio-thera-solutions-bat1806-receives-positive-chmp-recommendation-for-eu-approval/2024-10-23T23:53:14+08:00https://flcube.com/pfizers-gene-therapy-beqvez-wins-fda-nod-for-moderate-to-severe-hemophilia-b/2024-10-23T23:50:33+08:00https://flcube.com/abbvie-reports-54-3-billion-in-2023-revenues-amid-humira-erosion-and-segment-variability/2024-10-23T23:46:45+08:00https://flcube.com/biotech-pharmaceutical-secures-approval-for-nimotuzumab-in-head-and-neck-cancer-treatment/2024-10-23T23:38:51+08:00https://flcube.com/china-reports-over-4-8-million-new-cancer-cases-in-2022-amid-rising-incidence-and-mortality-rates/2024-10-23T23:32:13+08:00https://flcube.com/johnson-johnsons-kenvue-partners-with-tencent-for-integrated-health-services-in-china/2024-10-23T23:30:03+08:00https://flcube.com/inmagene-biopharmaceuticals-secures-exclusive-license-for-hutchmeds-drug-candidates-img-007-and-img-004/2024-10-23T23:24:59+08:00https://flcube.com/luye-pharmas-paliperidone-palmitate-nda-avoids-patent-lawsuit-clears-path-for-fda-approval/2024-10-23T23:21:57+08:00https://flcube.com/matridx-bio-secures-series-c-funding-to-advance-infectious-pathogens-diagnostics/2024-10-23T23:19:33+08:00https://flcube.com/china-medical-system-reclaims-rights-to-velphoro-from-winhealth-in-greater-china/2024-10-23T23:17:28+08:00https://flcube.com/sichuans-ancocare-gets-fda-green-light-for-phase-i-iii-study-of-oncolytic-virus-in-neuroblastoma/2024-10-23T23:15:07+08:00https://flcube.com/siemens-healthineers-posts-5-7-q1-2024-sales-growth-exceeds-pre-pandemic-levels/2024-10-23T23:08:31+08:00https://flcube.com/roche-posts-modest-2023-growth-amid-shifts-in-demand-for-covid-related-products/2024-10-23T23:06:20+08:00https://flcube.com/cspc-pharmaceuticals-rhtnk-tpa-gets-nmpa-approval-for-acute-ischemic-stroke-treatment/2024-10-23T23:02:34+08:00https://flcube.com/roches-faricimab-shows-sustained-vision-benefits-in-phase-iii-study-for-retinal-vein-occlusion/2024-10-23T21:56:19+08:00https://flcube.com/cde-reports-35-84-increase-in-drug-filings-for-2023-with-focus-on-innovation-and-rare-diseases/2024-10-23T21:53:13+08:00https://flcube.com/jjs-gene-therapy-for-x-linked-retinitis-pigmentosa-receives-cde-nod-for-breakthrough-designation/2024-10-23T21:51:17+08:00https://flcube.com/german-tech-giant-merck-launches-digital-hub-in-singapore-to-boost-healthcare-and-semiconductor-research/2024-10-23T21:47:49+08:00https://flcube.com/johnson-johnsons-talquetamab-and-daiichi-sankyos-enhertu-eye-priority-review-in-china/2024-10-23T21:44:44+08:00https://flcube.com/biogen-discontinues-aduhelm-development-redirects-focus-to-other-alzheimers-therapies/2024-10-23T21:40:14+08:00https://flcube.com/beckton-dickinsons-q1-results-affected-by-volume-based-procurement-life-sciences-growth/2024-10-23T21:37:11+08:00https://flcube.com/baidu-health-partners-with-souyao-to-boost-offline-pharmacy-services-in-china/2024-10-23T21:30:14+08:00https://flcube.com/keymed-biosciences-stapokibart-meets-primary-endpoint-in-phase-iii-seasonal-allergic-rhinitis-study/2024-10-23T18:47:53+08:00https://flcube.com/yantai-dongcheng-pharmaceutical-receives-nmpa-approval-for-advanced-solid-tumor-therapy/2024-10-23T18:37:52+08:00https://flcube.com/carsgen-therapeutics-submits-capa-report-to-us-fda-following-clinical-hold/2024-10-23T18:36:59+08:00https://flcube.com/chengdu-kanghong-pharmaceutical-gets-us-fda-nod-for-clinical-trial-of-kh658-for-wet-amd/2024-10-23T18:35:33+08:00https://flcube.com/astellas-pharma-inc-reports-revenue-growth-in-fy2023-driven-by-xtandi-and-padcev-sales/2024-10-23T18:31:21+08:00https://flcube.com/remegens-q1-2024-revenues-surge-96-41-yoy-rd-spending-outpaces-income/2024-10-23T18:28:54+08:00https://flcube.com/chinas-national-drug-alliance-procurement-office-announces-insulin-vbp-re-tender-results/2024-10-23T18:27:50+08:00https://flcube.com/daiichi-sankyo-reports-25-3-revenue-growth-in-fy2023-boosted-by-enhertu-and-lixiana-sales/2024-10-23T18:26:50+08:00https://flcube.com/bristol-myers-squibb-prepares-contingency-plans-in-response-to-the-biosecure-act/2024-10-23T18:26:01+08:00https://flcube.com/eoc-pharmas-entinostat-secures-chinese-approval-for-breast-cancer-treatment/2024-10-23T18:25:12+08:00https://flcube.com/wuxi-apptecs-q1-2024-revenues-affected-by-covid-19-project-exclusion/2024-10-23T18:24:19+08:00https://flcube.com/chinas-q1-2024-pharma-trade-registers-6-3-growth-amid-global-recovery/2024-10-23T18:22:22+08:00https://flcube.com/sino-biological-inc-to-acquire-canadian-bioactive-enzyme-manufacturer-signalchem-biotech/2024-10-23T18:21:46+08:00https://flcube.com/u-s-judge-dismisses-johnson-johnson-and-bristol-myers-squibb-lawsuits-against-drug-pricing-provisions-in-inflation-reduction-act/2024-10-23T18:20:33+08:00https://flcube.com/german-study-highlights-potential-of-amgens-blinatumomab-in-treating-rheumatoid-arthritis/2024-10-23T18:19:20+08:00https://flcube.com/zhejiang-huahai-pharmaceutical-wins-ind-approval-for-antibody-drug-conjugate-from-chinas-nmpa/2024-10-23T18:18:25+08:00https://flcube.com/cutia-therapeutics-submits-new-drug-application-for-androgenic-alopecia-treatment-in-hong-kong/2024-10-23T18:17:21+08:00https://flcube.com/bristol-myers-squibbs-camzyos-approved-by-chinas-nmpa-for-hypertrophic-cardiomyopathy-treatment/2024-10-23T18:16:17+08:00https://flcube.com/keymed-biosciences-il-4r%ce%b1-monoclonal-antibody-for-allergic-rhinitis-accepted-by-china-nmpa/2024-10-23T18:14:57+08:00https://flcube.com/gba-center-of-nmpa-launches-filing-guidance-for-pharmaceutical-enterprises/2024-10-23T18:13:44+08:00https://flcube.com/hainan-poly-pharms-manufacturing-units-get-gmp-nod-from-saudi-food-and-drug-authority/2024-10-23T18:13:07+08:00https://flcube.com/siemens-healthineers-ag-partners-with-haidian-district-government-to-boost-medical-innovation-in-beijing/2024-10-23T18:12:04+08:00https://flcube.com/jacobio-pharmas-glecirasib-shows-promise-in-phase-ii-study-for-nsclc-presented-at-asco/2024-10-23T18:09:13+08:00https://flcube.com/zhejiang-hisun-pharmaceuticals-ex-president-li-yan-investigated-for-graft/2024-10-23T18:08:16+08:00https://flcube.com/shenzhen-hepalink-logs-5-55-q1-revenue-growth-and-133-net-profit-increase/2024-10-23T18:07:21+08:00https://flcube.com/well-lead-medicals-stone-removal-sheath-gains-karl-storz-as-us-sole-agent/2024-10-23T18:06:17+08:00https://flcube.com/hansoh-pharmaceutical-secures-exclusive-rights-to-qyuns-therapeutics-qx004n-in-greater-china/2024-10-23T18:05:22+08:00https://flcube.com/united-imagings-umr-jupiter-5t-becomes-first-ultra-high-frequency-mri-system-to-gain-fda-approval/2024-10-23T18:03:27+08:00https://flcube.com/wondfo-biotechs-welllife-test-kit-receives-fda-nod-for-home-use-in-the-us/2024-10-23T18:02:28+08:00https://flcube.com/everest-medicines-nefecon-secures-market-approval-for-igan-treatment-in-hong-kong/2024-10-23T18:01:34+08:00https://flcube.com/us-legislature-reviews-biosecurity-bill-to-sever-biotech-industry-ties-with-chinese-companies/2024-10-23T17:59:12+08:00https://flcube.com/pfizers-q1-2024-results-highlight-robust-portfolio-growth-and-profitability/2024-10-23T17:57:42+08:00https://flcube.com/eyepoint-pharmaceuticals-durvayu-fails-to-meet-primary-endpoint-in-npdr-trial/2024-10-23T17:56:48+08:00https://flcube.com/pfizer-appoints-citigroups-andrew-baum-as-executive-vice-president-for-strategy-and-innovation/2024-10-23T17:55:49+08:00https://flcube.com/eli-lilly-co-raises-full-year-guidance-on-strength-of-q1-2024-results-and-production-expansion/2024-10-23T17:54:30+08:00https://flcube.com/gsks-q1-2024-results-beat-forecasts-with-10-yoy-revenue-increase-upgrades-full-year-outlook/2024-10-23T17:53:40+08:00https://flcube.com/cde-seeks-public-comment-on-latest-generic-chemical-reference-preparations/2024-10-23T17:52:00+08:00https://flcube.com/chinas-cde-gives-tacit-approval-to-keymed-biosciences-alzheimers-drug-cm383-for-clinical-trials/2024-10-23T17:49:54+08:00https://flcube.com/jacobio-pharma-applies-for-approval-of-kras-g12c-inhibitor-gecirasib-in-china/2024-10-23T17:49:19+08:00https://flcube.com/henlius-her2-dual-targeted-therapy-gets-green-light-for-global-phase-iii-trial-by-fda/2024-10-23T17:48:30+08:00https://flcube.com/bio-surveys-members-on-china-cdmo-dependence-amid-biosecurity-bill-deliberations/2024-10-23T17:47:30+08:00https://flcube.com/tonghua-dongbao-pharmaceuticals-commences-phase-iia-trial-for-dual-targeted-gout-drug-candidate/2024-10-23T17:45:31+08:00https://flcube.com/betta-pharmaceuticals-files-for-market-approval-of-cdk4-6-inhibitor-bpi-16350-in-china/2024-10-23T17:43:51+08:00https://flcube.com/lei-haichao-takes-over-as-party-secretary-of-chinas-national-health-commission/2024-10-23T17:35:27+08:00https://flcube.com/meruss-zenocutuzumab-receives-priority-review-status-from-fda-for-lung-and-pancreatic-cancer-indications/2024-10-23T17:34:51+08:00https://flcube.com/china-upgrades-midazolam-to-category-i-psychotropic-drug-list-in-regulatory-rescheduling/2024-10-23T17:33:40+08:00https://flcube.com/sichuan-biokins-egfr-her3-adc-expands-phase-ii-clinical-program-with-nmpa-approval/2024-10-23T17:33:07+08:00https://flcube.com/yantai-dongcheng-pharmaceuticals-radiopharmaceutical-18f-lnc1007-cleared-for-australian-phase-i-trial/2024-10-23T17:32:07+08:00https://flcube.com/innovent-biologics-cldn18-2-adc-ibi343-receives-breakthrough-designation-in-china/2024-10-23T17:31:03+08:00https://flcube.com/mabwell-biosciences-9mw2821-earns-orphan-drug-status-from-fda-for-esophageal-cancer/2024-10-23T17:30:08+08:00https://flcube.com/ono-pharmaceutical-secures-deal-to-acquire-deciphera-pharmaceuticals-for-usd-2-4-billion/2024-10-23T17:22:02+08:00https://flcube.com/leo-pharmas-enstilar-outperforms-daivobet-in-phase-iii-psoriasis-trial-in-china/2024-10-23T17:19:42+08:00https://flcube.com/xi-and-macron-discuss-enhanced-market-access-for-foreign-investors-focus-on-life-sciences/2024-10-23T17:18:49+08:00https://flcube.com/medtronics-rdn-system-symplicity-spyral-earns-first-ever-nmpa-approval/2024-10-23T17:18:06+08:00https://flcube.com/citi-pharma-ltd-and-hangzhou-newsea-technology-form-jv-to-boost-api-production/2024-10-23T17:10:55+08:00https://flcube.com/andon-healths-triplex-virus-test-kit-receives-us-fda-emergency-use-authorization/2024-10-23T17:10:13+08:00https://flcube.com/wanbangde-pharmaceuticals-huperzine-a-earns-fda-rare-pediatric-disease-designation-for-hie-treatment/2024-10-23T17:00:49+08:00https://flcube.com/everest-medicines-velsipity-for-uc-receives-first-asian-approval-in-macau/2024-10-23T16:59:40+08:00https://flcube.com/siemens-healthineers-ag-forges-expanded-partnership-with-xian-daixing-hospital/2024-10-23T16:58:29+08:00https://flcube.com/astrazeneca-hong-kong-launches-hrdetect-program-to-offer-free-genetic-testing-for-cancer-patients/2024-10-23T16:57:17+08:00https://flcube.com/siemens-healthineers-reports-3-yoy-growth-in-q2-2024-fiscal-report-amidst-challenging-comparison/2024-10-23T16:55:21+08:00https://flcube.com/jjs-erleada-plus-adt-shows-0-biochemical-recurrence-rate-in-high-risk-prostate-cancer-trial/2024-10-23T16:52:59+08:00https://flcube.com/tonghua-dongbao-pharmaceuticals-inks-licensing-deal-for-semaglutide-in-china/2024-10-23T16:52:00+08:00https://flcube.com/pfizer-pauses-dosing-in-dmd-gene-therapy-trial-following-participants-sudden-death/2024-10-23T16:50:59+08:00https://flcube.com/boehringer-ingelheims-anti-sema3a-bi-764524-shows-promise-in-diabetic-macular-ischemia-trial/2024-10-23T16:50:02+08:00https://flcube.com/profluents-neural-network-model-designs-high-efficiency-crispr-gene-editing-system/2024-10-23T16:49:24+08:00https://flcube.com/abbisko-and-allist-pharmaceuticals-initiate-phase-ii-trial-for-nsclc-drug-combination/2024-10-23T16:48:43+08:00https://flcube.com/blue-sail-medicals-new-catheter-receives-nmpa-approval-for-complex-coronary-lesion-treatment/2024-10-23T16:47:13+08:00https://flcube.com/innovent-biologics-mazdutide-shows-superiority-in-type-2-diabetes-phase-iii-trial/2024-10-23T16:46:12+08:00https://flcube.com/organons-q1-2024-revenues-rise-7-yoy-womens-health-and-biosimilars-lead-the-way/2024-10-23T16:44:58+08:00https://flcube.com/brii-biosciences-brii-835-aims-for-breakthrough-therapy-status-in-china-for-chronic-hepatitis-b/2024-10-23T16:42:44+08:00https://flcube.com/zai-labs-q1-2024-revenue-rises-43-yoy-on-strong-product-launch-and-nrdl-inclusion/2024-10-23T16:40:40+08:00https://flcube.com/novo-nordisks-q1-2024-global-sales-surge-24-yoy-on-strength-of-glp-1-therapies/2024-10-23T16:39:16+08:00https://flcube.com/astellas-invests-usd-90-million-in-new-us-facility-to-boost-research-and-commercialization/2024-10-23T16:38:09+08:00https://flcube.com/cancer-diagnostics-firm-mirxes-aims-for-usd-100-million-in-hong-kong-ipo/2024-10-23T16:36:45+08:00https://flcube.com/microport-medbots-toumai-robot-gets-eu-green-light-for-broad-surgical-applications/2024-10-23T16:33:57+08:00https://flcube.com/jiangsu-qyuns-therapeutics-gets-nmpa-green-light-for-csu-treatment-qx013n/2024-10-23T16:32:36+08:00https://flcube.com/sandoz-q1-2024-results-highlight-6-growth-led-by-biosimilars-and-european-strength/2024-10-23T16:31:34+08:00https://flcube.com/bio-thera-solutions-pd-1-and-adc-combo-gets-nmpa-approval-for-clinical-trial-in-solid-tumors/2024-10-23T16:29:39+08:00https://flcube.com/sichuan-biokin-pharmaceutical-advances-bl-b16d1-to-clinical-trial-for-advanced-solid-tumors/2024-10-23T16:28:19+08:00https://flcube.com/gsk-shakes-up-leadership-with-promotion-of-cecilia-qi-and-appointment-of-sherman-yu/2024-10-23T16:26:50+08:00https://flcube.com/novartis-shakes-up-executive-suite-with-appointments-and-transitions/2024-10-23T16:24:47+08:00https://flcube.com/novo-nordisks-mim8-for-haemophilia-a-exceeds-endpoints-in-late-stage-trial/2024-10-23T16:24:03+08:00https://flcube.com/sunshine-guojian-pharma-reports-q3-revenue-growth-and-advances-in-clinical-trials/2024-10-23T15:20:20+08:00https://flcube.com/lindis-biotechs-catumaxomab-receives-positive-opinion-from-emas-comp-for-malignant-ascites-treatment/2024-10-23T15:05:27+08:00https://flcube.com/chinas-nmpa-launches-pilot-program-for-phased-manufacturing-of-biological-products/2024-10-23T14:53:45+08:00https://flcube.com/beijing-biostar-technologies-goes-public-in-hong-kong-to-fund-cancer-drug-development/2024-10-23T14:46:28+08:00https://flcube.com/china-grand-pharmaceutical-receives-nmpa-approval-for-innovative-adjustable-thrombectomy-stent/2024-10-23T14:38:14+08:00https://flcube.com/grifols-partners-with-barda-to-develop-treatment-for-sulfur-mustard-ocular-injury/2024-10-23T14:33:11+08:00https://flcube.com/walvax-biotechnologys-weuphoria-vaccine-approved-in-oman-for-pediatric-pneumococcal-infections/2024-10-23T14:17:07+08:00https://flcube.com/german-endoscope-maker-karl-storz-secures-marketing-approval-for-disposable-ureteroscope-in-china/2024-10-23T14:11:45+08:00https://flcube.com/lenz-therapeutics-presbyopia-therapy-lnz100-accepted-for-fda-review/2024-10-23T14:04:41+08:00https://flcube.com/hong-kong-sar-and-nmpa-renew-agreements-to-boost-drug-and-medical-device-regulation/2024-10-23T13:44:25+08:00https://flcube.com/china-grants-marketing-nod-to-ferring-pharmaceuticals-rekovelle-for-assisted-reproduction/2024-10-23T13:43:45+08:00https://flcube.com/biontech-secures-global-rights-to-biotheus-inc-s-pre-clinical-bispecific-antibody/2024-10-23T13:42:45+08:00https://flcube.com/westgene-biopharmas-groundbreaking-mrna-vaccine-for-eb-virus-tumors-gets-fda-green-light/2024-10-23T13:39:57+08:00https://flcube.com/takedas-fiscal-2023-revenues-grow-1-5-ceo-weber-forecasts-2025-profitability-after-2024-dip/2024-10-23T13:39:15+08:00https://flcube.com/china-unveils-sweeping-2024-legislative-plan-with-healthcare-and-pharma-at-forefront/2024-10-23T13:36:00+08:00https://flcube.com/sanofi-secures-novavax-vaccine-tech-in-a-deal-valued-at-up-to-usd-1-2-billion/2024-10-23T13:35:17+08:00https://flcube.com/novo-nordisk-partners-with-flagship-pioneering-for-development-of-novel-obesity-treatments/2024-10-23T13:32:53+08:00https://flcube.com/dscilab-mrna-pharma-startup-bags-rmb-100-million-in-angel-financing-led-by-fosun-health/2024-10-23T13:31:17+08:00https://flcube.com/jiangsu-bioperfectus-dengue-detection-kit-gains-nmpa-approval-for-commercialization/2024-10-23T13:30:16+08:00https://flcube.com/vazyme-biotech-and-sph-kdl-health-join-forces-to-promote-alzheimers-blood-tests/2024-10-23T13:29:03+08:00https://flcube.com/macera-therapeutics-and-innorna-co-ltd-collaborate-on-car-m-mrna-lnp-technology/2024-10-23T13:27:56+08:00https://flcube.com/qilu-pharmaceutical-achieves-first-approval-for-generic-bendamustine-in-china/2024-10-23T13:27:14+08:00https://flcube.com/jacobio-pharmas-kras-g12c-inhibitor-gains-nmpa-approval-for-phase-iii-crc-study/2024-10-23T13:24:39+08:00https://flcube.com/biosecure-act-advances-in-us-aiming-to-curb-ties-with-chinese-bioscience-firms/2024-10-23T13:23:26+08:00https://flcube.com/ribobay-pharma-and-general-biol-to-commence-gmp-grade-oligonucleotide-manufacturing-services/2024-10-23T13:20:08+08:00https://flcube.com/eisais-fycompa-gains-new-indication-for-generalized-tonic-clonic-seizures-in-china/2024-10-23T13:19:24+08:00https://flcube.com/bio-survey-highlights-extensive-dependence-on-chinese-cdmos-in-life-sciences/2024-10-23T13:16:25+08:00https://flcube.com/fda-reviews-bms-opdivo-subcutaneous-formulation-for-broad-indications/2024-10-23T13:15:44+08:00https://flcube.com/chinas-nmpa-revamps-medical-device-classification-rules-to-improve-regulatory-efficiency/2024-10-23T13:06:39+08:00https://flcube.com/novartis-inks-deal-to-acquire-mariana-oncology-bolstering-radioligand-therapy-portfolio/2024-10-23T13:05:54+08:00https://flcube.com/nmpa-updates-in-vitro-diagnostic-reagents-classification-list-for-enhanced-regulatory-oversigh/2024-10-23T13:04:50+08:00https://flcube.com/shenzhen-hepalinks-enoxaparin-sodium-gets-green-light-in-singapore/2024-10-23T13:03:47+08:00https://flcube.com/subtle-medical-inc-closes-usd-10-million-series-b-round-to-accelerate-global-expansion/2024-10-23T12:59:22+08:00https://flcube.com/huadong-medicines-egfr-inhibitor-mefatinib-for-nsclc-accepted-by-nmpa-for-review/2024-10-23T12:58:40+08:00https://flcube.com/mabwells-9mw2821-adc-for-triple-negative-breast-cancer-accepted-for-review-by-nmpa/2024-10-23T12:57:35+08:00https://flcube.com/nmpa-accepts-jiangsu-yahong-meditechs-application-for-cervical-hsil-treatment-cevira/2024-10-23T12:56:32+08:00https://flcube.com/zai-labs-ros1-inhibitor-augtyro-earns-nmpa-nod-for-advanced-nsclc-treatment/2024-10-23T12:54:39+08:00https://flcube.com/hutchmeds-hmpl-306-advances-to-phase-iii-trial-in-r-r-aml-patients/2024-10-23T12:53:18+08:00https://flcube.com/brii-biosciences-hbv-drug-candidates-receive-nmpas-breakthrough-therapy-designations/2024-10-23T12:51:37+08:00https://flcube.com/healingovation-raises-over-rmb-60-million-in-pre-series-a-round-for-aquablation-surgical-robot/2024-10-23T12:49:50+08:00https://flcube.com/takeda-strikes-deal-with-ac-immune-for-global-rights-to-alzheimers-immunotherapies/2024-10-23T12:43:03+08:00https://flcube.com/nmpa-seeks-public-comment-on-draft-proposal-for-drug-re-registration-procedures/2024-10-23T12:42:01+08:00https://flcube.com/abbvie-and-gilgamesh-pharmaceuticals-join-forces-to-develop-psychiatric-disorder-therapies/2024-10-23T12:40:19+08:00https://flcube.com/novo-nordisks-bispecific-antibody-mim8-achieves-milestone-in-haemophilia-a-trial/2024-10-23T12:37:14+08:00https://flcube.com/bayers-q1-2024-report-shows-slight-dip-in-sales-amid-pharmaceutical-units-growth/2024-10-23T12:36:18+08:00https://flcube.com/remegens-telitacicept-achieves-full-enrollment-in-phase-iii-primary-sjogrens-syndrome-trial/2024-10-23T12:35:13+08:00https://flcube.com/nmpa-releases-80th-batch-of-reference-drugs-for-generic-quality-evaluation/2024-10-23T12:32:17+08:00https://flcube.com/chinas-cde-issues-draft-guidelines-for-patient-centric-rare-disease-drug-rd/2024-10-23T12:30:00+08:00https://flcube.com/nmpa-reports-record-61-innovative-medical-device-approvals-in-2023/2024-10-23T10:51:28+08:00https://flcube.com/novartis-to-acquire-morphosys-for-e2-7-billion-in-strategic-oncology-expansion/2024-10-23T10:48:10+08:00https://flcube.com/bayer-partners-with-tetrascience-to-enhance-data-management-in-product-development/2024-10-23T10:43:21+08:00https://flcube.com/zhejiang-anglikang-enters-rd-cooperation-agreement-with-affinity-biopharmaceutical/2024-10-23T10:39:05+08:00https://flcube.com/novo-holdings-to-acquire-catalent-for-16-5-billion-in-strategic-move-to-enhance-biopharmaceutical-capacity/2024-10-23T10:35:50+08:00https://flcube.com/peijia-medicals-taurus-atlas-pro-balloon-dilation-catheter-approved-by-nmpa-for-pulmonary-valve-procedures/2024-10-23T10:28:39+08:00https://flcube.com/microport-crm-receives-nmpa-approval-for-next-generation-mri-safe-implantable-cardiac-pacing-system/2024-10-23T10:25:45+08:00https://flcube.com/jiangsu-wuzhong-pharmaceutical-partners-with-sph-kdl-health-to-boost-aesthetics-product-aesthefill/2024-10-23T10:22:32+08:00https://flcube.com/luye-pharma-grants-myung-in-pharm-rights-to-rivastigmine-patch-for-alzheimers-treatment-in-south-korea/2024-10-23T10:13:46+08:00https://flcube.com/abbisko-therapeutics-secures-70-million-upfront-payment-in-licensing-deal-with-merck-kgaa/2024-10-23T10:10:58+08:00https://flcube.com/joincare-pharmaceuticals-gets-green-light-for-semaglutide-biosimilar-clinical-trial/2024-10-23T10:08:39+08:00https://flcube.com/astellas-pharma-inc-reports-2-1-yoy-growth-in-q1-q3-fiscal-2023-revenues-2/2024-10-23T10:06:06+08:00https://flcube.com/gileads-2023-flat-sales-reflect-stagnation-and-covid-19-demand-decline/2024-10-23T10:02:32+08:00https://flcube.com/astellas-pharma-inc-reports-2-1-yoy-growth-in-q1-q3-fiscal-2023-revenues/2024-10-23T09:59:18+08:00https://flcube.com/gileads-2023-stagnation-foresees-flat-2024-sales-as-veklury-revenues-dwindle/2024-10-23T09:56:14+08:00https://flcube.com/amgens-q4-2023-results-showcase-9-yoy-growth-18-drugs-hit-record-sales/2024-10-23T09:53:26+08:00https://flcube.com/medical-institutions-directed-to-adhere-to-six-should-dos-and-six-prohibited-behaviors-for-academic-lectures/2024-10-23T09:50:49+08:00https://flcube.com/china-proposes-market-oriented-pricing-for-innovative-drugs-to-boost-high-quality-development/2024-10-23T09:48:26+08:00https://flcube.com/eli-lillys-2023-revenue-soars-on-metabolism-drugs-anticipates-further-growth-in-2024/2024-10-23T09:46:38+08:00https://flcube.com/innovent-biologics-posts-65-yoy-growth-in-q4-2023-with-over-rmb-1-6-billion-in-sales/2024-10-23T09:40:44+08:00https://flcube.com/shanghai-procurement-platform-offers-price-cut-leeway-to-escape-high-priced-drugs-tag/2024-10-23T09:37:47+08:00https://flcube.com/organon-reports-q4-2023-revenue-growth-driven-by-womens-health-and-biosimilars/2024-10-22T23:59:43+08:00https://flcube.com/i-mab-to-become-u-s-based-biotech-divesting-all-china-assets-for-up-to-80-million/2024-10-22T23:56:51+08:00https://flcube.com/abbvie-expands-licensing-agreement-for-innovative-scar-t-platform-with-scripps-research/2024-10-22T23:54:28+08:00https://flcube.com/astrazeneca-announces-300-million-investment-in-next-gen-cell-therapies-manufacturing-in-the-u-s/2024-10-22T23:52:22+08:00https://flcube.com/fda-grants-priority-review-for-gsks-arexvy-to-expand-rsv-vaccine-age-range-to-50-59/2024-10-22T23:49:22+08:00https://flcube.com/cms-secures-nmpa-approval-for-clinical-trials-of-tyk2-inhibitor-cms-d001-and-gnrh-antagonist-cms-d002/2024-10-22T23:46:46+08:00https://flcube.com/chinagene-secures-cde-approval-for-zvs101e-gene-therapy-targeting-retinitis-pigmentosa/2024-10-22T23:42:09+08:00https://flcube.com/yantai-dongcheng-acquires-full-rights-to-alfatide-ii-targeting-diagnostic-and-therapeutic-applications/2024-10-22T23:39:29+08:00https://flcube.com/nanjing-zenshines-zx-7101a-nda-accepted-by-nmpa-for-uncomplicated-influenza-treatment/2024-10-22T23:36:56+08:00https://flcube.com/roches-piasky-crovalimab-secures-nmpa-approval-for-untreated-paroxysmal-nocturnal-hemoglobinuria/2024-10-22T23:34:58+08:00https://flcube.com/roche-secures-nmpa-approval-for-rozlytrek-to-treat-pediatric-ntrk-fusion-positive-tumors/2024-10-22T23:32:49+08:00https://flcube.com/akeso-biopharma-to-acquire-35-stake-in-ad-pharmaceuticals-for-rmb-267-million/2024-10-22T23:30:32+08:00https://flcube.com/astrazeneca-reports-6-revenue-growth-in-2023-driven-by-oncology-and-diabetes-drug-sales/2024-10-22T23:28:06+08:00https://flcube.com/novartis-begins-review-of-70-stake-in-indian-unit-strategic-options-under-consideration/2024-10-22T23:25:47+08:00https://flcube.com/boao-yiling-life-care-center-launches-innovative-dental-technologies-under-pilot-medical-policy/2024-10-22T23:24:00+08:00https://flcube.com/brii-biosciences-acquires-vbi-vaccines-intellectual-property-and-manufacturing-rights-in-strategic-deal/2024-10-22T23:22:19+08:00https://flcube.com/lianbio-to-wind-down-operations-amid-market-challenges-announces-special-dividend/2024-10-22T23:20:00+08:00https://flcube.com/nmpa-launches-pilot-program-to-streamline-supplementary-drug-approval-process/2024-10-22T23:16:49+08:00https://flcube.com/roches-xolair-gains-fda-approval-to-combat-ige-mediated-food-allergies-in-patients-aged-1-and-up/2024-10-22T23:13:13+08:00https://flcube.com/fda-approves-takedas-eohilia-as-first-oral-therapy-for-eosinophilic-esophagitis-in-patients-aged-11-and-up/2024-10-22T23:08:21+08:00https://flcube.com/astellas-pharma-partners-with-kelonia-therapeutics-to-advance-car-t-cell-therapies/2024-10-22T23:05:28+08:00https://flcube.com/denali-therapeutics-faces-setback-as-als-trial-fails-to-meet-primary-endpoint/2024-10-22T23:03:19+08:00https://flcube.com/chinas-nmpa-releases-77th-batch-of-reference-drugs-for-generic-quality-evaluation/2024-10-22T23:00:30+08:00https://flcube.com/gsks-avodart-receives-nmpa-approval-to-resume-sales-in-china-from-september/2024-10-22T22:58:42+08:00https://flcube.com/national-health-commission-notification-signals-new-poliovirus-containment-measures/2024-10-22T22:57:01+08:00https://flcube.com/chinas-nhc-approves-2023-large-medical-equipment-configuration-licenses-targets-cancer-treatment/2024-10-22T22:55:36+08:00https://flcube.com/hainan-poly-pharm-wins-fda-nod-for-generic-version-of-ucbs-vimpat/2024-10-22T22:53:56+08:00https://flcube.com/us-lawmakers-call-for-sanctions-against-wuxi-apptec-and-wuxi-biologics-over-national-security-concerns/2024-10-22T22:51:52+08:00https://flcube.com/mabwell-bioscience-receives-fda-green-light-for-b7-h3-targeting-adc-7mw3711/2024-10-22T22:48:38+08:00https://flcube.com/bms-and-sichuan-biokin-commence-joint-development-of-egfr-her3-targeted-adc/2024-10-22T22:46:35+08:00https://flcube.com/everest-medicines-terminates-agreement-with-providence-therapeutics-retains-mrna-rights/2024-10-22T22:43:36+08:00https://flcube.com/jacobio-pharma-gets-cde-green-light-for-phase-iii-study-combining-gleevec-inhibitors-in-nsclc/2024-10-22T22:41:04+08:00https://flcube.com/neurophth-biotechnology-completes-enrollment-and-dosing-in-us-clinical-study-for-nd4-lhon-gene-therapy/2024-10-22T22:39:03+08:00https://flcube.com/biocytogen-pharmaceuticals-inks-antibody-evaluation-deal-with-gilead-sciences/2024-10-22T22:36:48+08:00https://flcube.com/phanes-therapeutics-pt886-receives-cde-approval-for-clinical-trials-in-advanced-solid-tumors/2024-10-22T22:32:06+08:00https://flcube.com/immunotech-biopharm-gets-nmpa-green-light-for-clinical-study-of-at19-injection-for-b-all/2024-10-22T22:30:18+08:00https://flcube.com/beijing-tianjin-and-hebei-release-draft-proposal-for-updated-drug-clinical-trial-inspection-standards/2024-10-22T22:28:09+08:00https://flcube.com/astrazenecas-tagrisso-wins-expanded-fda-approval-for-egfr-mutated-nsclc/2024-10-22T22:24:48+08:00https://flcube.com/innovent-biologics-ibi311-achieves-primary-endpoint-in-phase-iii-study-for-thyroid-eye-disease/2024-10-22T22:15:52+08:00https://flcube.com/chinas-cde-issues-guiding-principles-for-adc-research-and-evaluation/2024-10-22T22:13:17+08:00https://flcube.com/gsk-and-peers-respond-to-ftc-criticism-withdraw-patent-listings-from-us-orange-book/2024-10-22T22:11:43+08:00https://flcube.com/novo-nordisks-wegovy-shows-durable-weight-loss-and-heart-health-in-extended-trials/2024-10-22T18:44:25+08:00https://flcube.com/china-launches-nationwide-unannounced-inspections-of-medical-insurance-funds/2024-10-22T18:43:06+08:00https://flcube.com/viiv-healthcares-hiv-prep-therapy-approved-by-chinas-nmpa-offers-alternative-to-daily-medication/2024-10-22T18:41:20+08:00https://flcube.com/zai-lab-advances-vygart-hytrulo-for-cidp-with-sbla-filing-in-china/2024-10-22T18:38:59+08:00https://flcube.com/fosun-pharmaceutical-advances-lasofocine-clinical-trials-for-breast-cancer-after-nmpa-nod/2024-10-22T18:37:34+08:00https://flcube.com/genmab-ceo-cites-chinas-biotech-as-a-mind-boggling-source-of-innovation/2024-10-22T18:35:39+08:00https://flcube.com/us-readies-hefty-tariffs-on-chinese-medical-equipment-and-other-imports/2024-10-22T18:34:37+08:00https://flcube.com/elite-suzhou-analytical-instruments-boosts-liquid-chromatography-push-with-series-a-round/2024-10-22T18:33:58+08:00https://flcube.com/everest-medicines-commences-commercial-sales-of-nefecon-in-china-post-launch/2024-10-22T18:32:54+08:00https://flcube.com/eli-lilly-co-expands-clinical-collaboration-with-shanghai-east-hospital-in-china/2024-10-22T18:31:43+08:00https://flcube.com/vision-medicals-raises-hundreds-of-millions-in-series-d-round-to-advance-molecular-diagnostics/2024-10-22T18:29:23+08:00https://flcube.com/ge-healthcare-partners-with-shanghai-pudong-for-usd-52-5-million-medical-tech-investment/2024-10-22T18:28:47+08:00https://flcube.com/insilico-medicines-ism8207-enters-phase-i-clinical-trial-for-lymphoma-and-solid-tumors/2024-10-22T18:27:45+08:00https://flcube.com/olymvax-biopharmaceuticals-gets-green-light-for-tetravalent-influenza-vaccine-clinical-trial/2024-10-22T18:26:19+08:00https://flcube.com/lifetech-scientifics-ibs-stent-demonstrates-non-inferiority-in-phase-ii-trial/2024-10-22T18:25:08+08:00https://flcube.com/sunho-biologics-lists-on-hkex-with-hkd-461-million-biotech-ipo/2024-10-22T18:24:15+08:00https://flcube.com/astrazeneca-and-benevolentai-reach-milestone-in-heart-failure-target-validation/2024-10-22T18:22:29+08:00https://flcube.com/novo-holdings-gains-controlling-interest-in-biopharma-equipment-supplier-single-use-support/2024-10-22T18:20:23+08:00https://flcube.com/landmark-biosecure-act-passes-us-house-committee-with-40-1-vote-eyes-2024-enactment/2024-10-22T18:19:21+08:00https://flcube.com/roche-marks-30-years-in-china-with-commitment-to-boost-investments-and-local-manufacturing/2024-10-22T18:16:30+08:00https://flcube.com/chunlizhengdas-handheld-orthopedic-robot-approved-by-chinas-nmpa/2024-10-22T18:15:03+08:00https://flcube.com/merck-kgaa-subsidiary-teams-up-with-aulos-bioscience-to-test-pd-l1-and-anti-il-2-combination/2024-10-22T18:13:54+08:00https://flcube.com/bayers-225ac-psma-trillium-therapy-begins-early-stage-clinical-trial-for-mcrpc/2024-10-22T18:13:03+08:00https://flcube.com/huaixi-medical-and-beijing-humadx-tech-join-forces-to-boost-in-vitro-diagnostics/2024-10-22T18:11:53+08:00https://flcube.com/chinas-health-commission-boosts-efforts-to-monitor-and-respond-to-drug-shortages/2024-10-22T18:10:46+08:00https://flcube.com/jj-acquires-immune-mediated-diseases-specialist-proteologix-in-a-deal-worth-up-to-usd-850-million/2024-10-22T18:10:07+08:00https://flcube.com/sol-gel-technologies-partners-with-shenzhen-beimei-for-twyneo-commercialization-in-china/2024-10-22T18:07:48+08:00https://flcube.com/shanghai-unicar-therapys-innovative-car-t-therapy-targets-breakthrough-designation-with-il-6-silencing/2024-10-22T18:06:32+08:00https://flcube.com/hutchmeds-sovleplenib-phase-iii-results-to-be-showcased-at-eha-2024/2024-10-22T18:05:56+08:00https://flcube.com/north-china-pharmaceuticals-ormutivimab-approved-for-pediatric-use-in-china/2024-10-22T18:04:10+08:00https://flcube.com/eisai-to-support-grassroots-healthcare-in-china-with-significant-pariet-donation/2024-10-22T18:03:11+08:00https://flcube.com/hutchmed-chairman-simon-to-steps-down-dr-dan-eldar-appointed-successor/2024-10-22T18:01:45+08:00https://flcube.com/roches-ct-388-shows-significant-weight-loss-in-phase-i-clinical-trial-for-obesity/2024-10-22T17:58:35+08:00https://flcube.com/cspc-pharmaceuticals-%ce%b2klotho-monoclonal-antibody-jmt202-receives-clinical-trial-approval-from-nmpa/2024-10-22T17:57:29+08:00https://flcube.com/siemens-healthineers-and-ruijin-hospital-collaborate-to-build-medical-digital-human-metaverse/2024-10-22T17:56:35+08:00https://flcube.com/immuneonco-biopharmaceuticals-cd47-inhibitor-receives-nmpa-go-ahead-for-phase-iii-trial/2024-10-22T17:55:58+08:00https://flcube.com/biotherus-inc-advances-pm8002-bispecific-antibody-to-phase-iii-for-triple-negative-breast-cancer/2024-10-22T17:54:17+08:00https://flcube.com/porton-biologics-and-safe-collaborate-to-accelerate-pharmaceutical-rd-services/2024-10-22T17:53:42+08:00https://flcube.com/zhejiang-huahai-pharmaceutical-co-ltd-plans-capital-raise-for-digital-manufacturing-expansion/2024-10-22T17:53:05+08:00https://flcube.com/medtronics-advanced-mazor-x-spinal-surgery-robot-receives-chinese-market-clearance/2024-10-22T17:51:43+08:00https://flcube.com/fosun-pharma-nods-to-fosun-health-spin-off-ipo-venue-and-requirements-under-review/2024-10-22T17:50:50+08:00https://flcube.com/pharmaron-to-sell-proteologix-stake-in-upcoming-johnson-johnson-acquisition/2024-10-22T17:49:17+08:00https://flcube.com/eli-lillys-weekly-insulin-efsitora-alfa-matches-daily-basal-insulins-in-reducing-a1c-levels/2024-10-22T17:47:38+08:00https://flcube.com/fda-gives-accelerated-nod-to-amgens-imdelltra-in-small-cell-lung-cancer/2024-10-22T17:46:38+08:00https://flcube.com/zai-lab-and-innoviva-win-china-approval-for-sul-dur-to-treat-hospital-acquired-pneumonia/2024-10-22T17:45:18+08:00https://flcube.com/union-hospital-teams-up-with-baidu-health-for-ai-enhanced-outpatient-services/2024-10-22T17:43:57+08:00https://flcube.com/innovent-biologics-ibi311-new-drug-application-accepted-for-review-by-chinas-cde/2024-10-22T17:43:21+08:00https://flcube.com/pharmaron-and-astrazeneca-enter-sweeping-partnership-to-span-drug-development-services/2024-10-22T17:41:24+08:00https://flcube.com/china-and-south-korea-reinforce-ties-with-renewed-mou-on-pharmaceuticals-and-cosmetics-regulation/2024-10-22T17:39:17+08:00https://flcube.com/hymson-lasers-mid-infrared-femtosecond-laser-technology-makes-medical-industry-inroads/2024-10-22T17:37:39+08:00https://flcube.com/bgi-genomics-delays-market-filing-for-brca1-2-detection-kit-due-to-incomplete-data/2024-10-22T17:36:43+08:00https://flcube.com/astrazeneca-commits-1-5-billion-to-build-singapore-based-adc-manufacturing-facility/2024-10-22T17:35:11+08:00https://flcube.com/gileads-seladelpar-shows-interim-benefits-in-pbc-related-itch-clinical-trial/2024-10-22T17:34:14+08:00https://flcube.com/chinas-cde-reports-record-high-in-clinical-trials-for-innovative-drugs-in-2023/2024-10-22T17:33:19+08:00https://flcube.com/3686/2024-10-22T17:32:44+08:00https://flcube.com/eli-lillys-tirzepatide-earns-china-approval-for-type-2-diabetes-treatment/2024-10-22T17:27:42+08:00https://flcube.com/sanofi-leads-pharma-industry-with-ai-collaboration-with-formation-bio-and-openai/2024-10-22T17:26:47+08:00https://flcube.com/astellas-pharma-considers-joint-cell-therapy-platform-with-yaskawa-electric/2024-10-22T17:25:53+08:00https://flcube.com/gsk-confronted-with-whistleblower-allegations-over-zantac-and-ndma-link/2024-10-22T17:24:29+08:00https://flcube.com/henlius-biotech-and-palleon-pharmaceuticals-modify-licensing-agreement-for-bifunctional-antibody/2024-10-22T17:21:55+08:00https://flcube.com/astrazenecas-wainzua-earns-chmp-nod-for-hattr-pn-treatment-in-the-eu/2024-10-22T15:53:31+08:00https://flcube.com/novo-nordisks-semaglutide-shows-14-reduction-in-cardiovascular-events-in-landmark-soul-trial/2024-10-22T15:48:14+08:00https://flcube.com/thermo-fishers-oncomine-dx-target-test-gets-fda-green-light-as-companion-diagnostic-for-serviers-voranigo/2024-10-22T15:42:27+08:00https://flcube.com/gsk-and-cambridge-university-forge-50-million-partnership-to-tackle-immune-diseases/2024-10-22T15:31:37+08:00https://flcube.com/astrazenecas-saphnelo-approved-for-use-in-guangdong-under-hong-kong-macau-drug-access-policy/2024-10-22T14:03:01+08:00https://flcube.com/inventisbio-acquires-immuno-oncology-assets-from-lyvgen-biopharma-in-rmb1-5-million-deal/2024-10-22T13:55:49+08:00https://flcube.com/beigenes-tevimbra-receives-chmp-recommendation-for-expanded-use-in-g-gej-and-escc-cancers-in-eu/2024-10-22T13:48:31+08:00https://flcube.com/olymvax-bio-receives-nmpa-approval-for-clinical-study-of-trivalent-influenza-vaccine/2024-10-22T13:42:57+08:00https://flcube.com/sino-biopharmaceuticals-anlotinib-receives-ninth-indication-approval-from-chinas-cde-for-soft-tissue-sarcoma/2024-10-22T13:28:25+08:00https://flcube.com/genscript-dissolves-merger-with-car-t-specialist-legend-biotech-reclassifies-as-associated-company/2024-10-22T13:19:58+08:00https://flcube.com/chinas-nmpa-greenlights-pilot-plan-for-phased-manufacturing-of-biological-products/2024-10-22T13:12:37+08:00https://flcube.com/otsuka-holdings-weighs-sale-of-stake-in-medical-device-maker-microport-scientific/2024-10-22T13:08:10+08:00https://flcube.com/astrazeneca-secures-shareholder-approval-for-1-billion-acquisition-of-gracell-biotechnologies/2024-10-22T11:18:22+08:00https://flcube.com/fda-issues-warning-letter-to-sichuan-deebio-for-cgmp-violations-in-api-manufacturing/2024-10-22T11:14:10+08:00https://flcube.com/bayer-advances-bay3018250-into-phase-ii-trial-following-successful-phase-i-completion/2024-10-22T11:12:12+08:00https://flcube.com/wuxi-atus-philadelphia-facility-approved-for-amtagvi-production-following-fda-nod/2024-10-22T11:01:06+08:00https://flcube.com/hitgens-vernalis-partners-with-hox-therapeutics-to-develop-novel-cancer-inhibitors/2024-10-22T10:55:18+08:00https://flcube.com/immune-onc-therapeutics-partners-with-roche-for-phase-ib-ii-study-of-io-108-in-liver-cancer/2024-10-22T10:48:42+08:00https://flcube.com/innovent-biologics-partners-with-immvirx-to-launch-clinical-study-combining-tyvyt-and-ivx037/2024-10-22T10:44:39+08:00https://flcube.com/biogen-appoints-ding-weibo-as-head-of-asia-pacific-region-succeeding-francis-wan/2024-10-22T10:41:49+08:00https://flcube.com/shenzhen-eureka-biotechnology-secures-rmb-300-million-in-series-b-funding-for-cgt-expansion/2024-10-22T10:38:40+08:00https://flcube.com/dongcheng-pharma-moves-to-enhance-portfolio-with-acquisition-of-rongcheng-medicals-gsa-injection/2024-10-22T10:33:57+08:00https://flcube.com/pfizers-velsipity-approved-by-european-commission-for-moderately-to-severely-active-ulcerative-colitis/2024-10-22T10:30:19+08:00https://flcube.com/fda-authorizes-biweekly-dosing-for-jjs-tecvayli-in-multiple-myeloma-treatment/2024-10-22T10:27:47+08:00https://flcube.com/abbvie-ceo-rick-gonzalez-to-retire-succeeded-by-robert-a-michael/2024-10-22T10:24:55+08:00https://flcube.com/immune-onc-therapeutics-io-202-earns-orphan-drug-designation-for-cmml-from-us-fda/2024-10-22T10:18:44+08:00https://flcube.com/innovent-biologics-tyvyt-receives-marketing-approval-for-multiple-indications-in-macau/2024-10-22T10:16:40+08:00https://flcube.com/cde-opens-consultation-on-79th-batch-of-generic-drug-reference-preparations/2024-10-22T10:07:25+08:00https://flcube.com/zhongsheng-pharmaceutical-initiates-phase-ii-trials-for-polypeptide-drug-ray1225-in-diabetes-and-obesity/2024-10-22T10:05:29+08:00https://flcube.com/polpharma-biologics-biosimilar-candidate-pb016-shows-comparable-profiles-to-takedas-entyvio/2024-10-22T09:59:49+08:00https://flcube.com/jiangsu-hengrui-receives-nmpa-approval-for-adjuvant-therapy-clinical-study-of-adebrelimab-in-nsclc/2024-10-22T09:56:51+08:00https://flcube.com/biocity-biopharma-achieves-full-enrollment-in-phase-ii-study-of-sc0062-for-iga-nephropathy/2024-10-22T09:54:15+08:00https://flcube.com/livzon-pharmaceutical-gets-cde-green-light-for-jp-1366-reflux-esophagitis-clinical-study/2024-10-22T09:52:02+08:00https://flcube.com/hinova-pharmaceuticals-hp537-receives-cde-approval-for-clinical-study-in-hematologic-malignancies/2024-10-22T09:49:39+08:00https://flcube.com/rossum-robots-intelligent-surgical-robot-for-trauma-and-spinal-surgery-clears-nmpa-approval/2024-10-22T09:44:44+08:00https://flcube.com/astrazenecas-tagrisso-meets-pfs-endpoint-in-late-stage-nsclc-trial-and-expands-fda-approval/2024-10-22T09:35:35+08:00https://flcube.com/simcere-pharmaceuticals-oncology-unit-raises-rmb-970-million-to-advance-cancer-drug-development/2024-10-21T23:50:03+08:00https://flcube.com/astrazeneca-launches-phase-i-trial-for-sirna-therapy-in-collaboration-with-silence-therapeutics/2024-10-21T23:43:32+08:00https://flcube.com/b-one-ortho-partners-with-think-surgical-to-expand-mobio-knee-system-in-u-s-market/2024-10-21T23:40:45+08:00https://flcube.com/cardioacc-initiates-regulatory-study-for-groundbreaking-7-5f-intracardiac-ultrasound-system/2024-10-21T23:38:47+08:00https://flcube.com/jiangsu-nhwa-secures-exclusive-rights-to-tevas-austedo-in-china-with-30-million-deal/2024-10-21T23:37:02+08:00https://flcube.com/guangdong-province-releases-new-batch-of-urgently-needed-drugs-and-medical-devices-for-greater-bay-area/2024-10-21T23:33:28+08:00https://flcube.com/tencent-hands-over-two-former-csig-employees-to-authorities-on-embezzlement-allegations/2024-10-21T23:31:45+08:00https://flcube.com/sanofis-dupixent-receives-fda-priority-review-for-copd-indication-extension/2024-10-21T23:28:39+08:00https://flcube.com/fujian-province-issues-provisional-regulations-for-managing-medical-representative-visits/2024-10-21T23:22:30+08:00https://flcube.com/genscripts-subsidiary-legend-biotech-gets-chmp-nod-for-carvykti-label-expansion-in-multiple-myeloma/2024-10-21T23:18:27+08:00https://flcube.com/takedas-recombinant-pig-fviii-drug-for-acquired-hemophilia-a-approved-in-china/2024-10-21T23:09:45+08:00https://flcube.com/mabwell-bioscience-cancels-licensing-agreements-with-yangtze-river-pharma-for-two-drug-candidates/2024-10-21T23:07:21+08:00https://flcube.com/mabwell-biosciences-nectin-4-targeting-adc-earns-fda-fast-track-designation-for-esophageal-cancer/2024-10-21T22:59:46+08:00https://flcube.com/harbour-biomed-partners-with-boostimmune-to-develop-novel-adc-therapies/2024-10-21T22:55:17+08:00https://flcube.com/chinas-nmpa-updates-rules-for-administrative-penalty-discretions-in-drug-supervision/2024-10-21T22:52:46+08:00https://flcube.com/astrazenecas-fasenra-matches-nucala-in-egpa-trial-and-shows-steroid-reduction-benefits/2024-10-21T22:50:56+08:00https://flcube.com/shanghai-fosun-pharmaceutical-partners-with-nanning-city-to-broaden-collaboration-in-biopharma-and-beyond/2024-10-21T22:46:06+08:00https://flcube.com/everest-medicines-gets-cde-approval-for-global-phase-iib-study-of-zetomipzomib-in-lupus-nephritis/2024-10-21T22:42:42+08:00https://flcube.com/beigene-reports-record-revenues-and-rapid-growth-in-q4-and-full-year-2023-with-continued-expansion/2024-10-21T22:37:08+08:00https://flcube.com/novo-nordisk-partners-with-neomorph-to-target-undruggable-diseases-with-molecular-glue-degraders/2024-10-21T22:33:52+08:00https://flcube.com/astrazeneca-expands-global-footprint-with-shanghai-strategic-center/2024-10-21T22:30:19+08:00https://flcube.com/china-invalidates-heart-failure-patent-for-dapagliflozin-maintains-protection-for-kidney-disease-use/2024-10-21T18:43:22+08:00https://flcube.com/asymchem-laboratories-enters-european-market-with-pfizers-uk-api-plant-and-rd-lab-purchase/2024-10-21T18:42:34+08:00https://flcube.com/shanghai-fosun-pharmas-fcn-159-receives-priority-review-for-pediatric-neurofibromatosis-treatment/2024-10-21T18:40:49+08:00https://flcube.com/jacobio-pharmas-gecirasib-gets-priority-review-for-nsclc-treatment-by-chinas-nmpa/2024-10-21T18:39:42+08:00https://flcube.com/alphamab-oncologys-jskn016-begins-phase-i-clinical-trial-for-solid-tumor-treatment/2024-10-21T18:38:39+08:00https://flcube.com/ai-in-pharma-mindrank-ltd-joins-forces-with-zhejiang-hisun-pharmaceutical-for-drug-rd/2024-10-21T18:37:20+08:00https://flcube.com/sichuan-biokins-bl-b01d1-advances-to-phase-iii-for-hr-her2-breast-cancer/2024-10-21T18:35:37+08:00https://flcube.com/astrazeneca-sets-sights-on-80-billion-revenue-target-and-20-new-molecular-entities-by-2030/2024-10-21T18:32:31+08:00https://flcube.com/milliporesigma-avoids-prosecution-in-biochemical-diversion-case-a-doj-first/2024-10-21T18:30:07+08:00https://flcube.com/johnson-johnsons-akeega-approved-in-china-as-first-dual-action-tablet-for-mcrpc/2024-10-21T16:34:27+08:00https://flcube.com/everest-medicines-nefecon-approved-in-taiwan-for-primary-igan-treatment/2024-10-21T16:27:50+08:00https://flcube.com/tianjin-municipality-unveils-plan-to-boost-synthetic-biology-and-biomanufacturing-innovation/2024-10-21T14:23:38+08:00https://flcube.com/novo-nordisks-alhemo-receives-chmp-recommendation-for-haemophilia-prophylaxis-in-europe/2024-10-21T14:18:11+08:00https://flcube.com/novartiss-kisqali-receives-positive-chmp-opinion-for-early-breast-cancer-treatment-in-the-eu/2024-10-21T14:09:16+08:00https://flcube.com/kanghong-pharmaceuticals-nash-drug-kh629-approved-for-clinical-trials-in-china/2024-10-21T14:00:46+08:00https://flcube.com/huadong-medicine-gets-green-light-for-hpk1-protac-drug-hdm2006-in-advanced-solid-tumors/2024-10-21T13:46:57+08:00https://flcube.com/chinas-nhsa-concludes-pre-negotiation-talks-for-national-reimbursement-drug-list/2024-10-21T13:41:42+08:00https://flcube.com/astellas-pharmas-vyloy-receives-fda-approval-for-gastric-cancer-treatment-in-cldn18-2-positive-tumors/2024-10-21T13:35:46+08:00https://flcube.com/microport-sorim-crms-platinium-series-icd-receives-nmpa-approval-a-first-for-china/2024-10-21T13:04:32+08:00https://flcube.com/jacobio-pharmas-g12c-inhibitor-gecirasib-earns-orphan-drug-designation-in-europe-for-pancreatic-cancer/2024-10-21T12:59:04+08:00https://flcube.com/microport-neurotechs-numen-silk-receives-fda-approval-for-embolization-treatment/2024-10-21T12:52:26+08:00https://flcube.com/porton-pharma-solutions-invests-e50-million-in-slovenian-rd-expansion/2024-10-21T12:44:58+08:00https://flcube.com/fda-alert-chinese-syringe-maker-jiangsu-shenli-initiates-voluntary-recall/2024-10-21T11:52:41+08:00https://flcube.com/amoy-diagnostics-teams-up-with-boehringer-ingelheim-for-cdx-developmen/2024-10-21T11:51:25+08:00https://flcube.com/fosun-diagnostics-and-jointown-medical-ink-partnership-to-boost-medical-supply-chain/2024-10-21T11:48:46+08:00https://flcube.com/astrazeneca-partners-with-nona-biosciences-in-multimillion-dollar-monoclonal-antibody-agreement/2024-10-21T11:45:56+08:00https://flcube.com/nk-celltechs-nk-cell-therapy-gets-green-light-from-chinas-nmpa-for-solid-tumor-treatment/2024-10-21T11:40:19+08:00https://flcube.com/simcere-pharmaceuticals-quviviq-secures-hong-kong-marketing-approval-for-insomnia-treatment/2024-10-21T11:39:11+08:00https://flcube.com/jiuzhou-pharmaceutical-expands-global-footprint-with-9-5-million-german-cro-subsidiary/2024-10-21T11:24:08+08:00https://flcube.com/chinas-nmpa-and-nhc-tighten-control-on-psychotropic-substances-with-new-regulations/2024-10-21T11:21:50+08:00https://flcube.com/alvotech-and-dr-reddys-partner-to-challenge-amgens-denosumab-with-biosimilar-avt03/2024-10-21T11:17:18+08:00https://flcube.com/eli-lilly-partners-with-aktis-oncology-to-advance-cancer-radiopharmaceuticals/2024-10-21T11:14:14+08:00https://flcube.com/boehringer-ingelheim-and-peking-university-deepen-partnership-with-joint-drug-research-lab/2024-10-21T11:13:03+08:00https://flcube.com/sino-biopharmaceuticals-benmelstobart-shows-positive-results-in-rcc-combination-therapy-study/2024-10-21T11:03:29+08:00https://flcube.com/keymed-biosciences-stapokibart-earns-priority-review-for-chronic-sinusitis-treatment-in-china/2024-10-21T11:02:20+08:00https://flcube.com/chinas-tigermed-taps-veeva-systems-for-advanced-electronic-data-acquisition/2024-10-21T11:01:03+08:00https://flcube.com/gan-lee-pharmaceuticals-gains-marketing-approval-for-insulin-glargine-in-mexico/2024-10-21T10:59:15+08:00https://flcube.com/guangzhou-boosts-innovative-drug-development-with-new-hsa-initiatives/2024-10-21T10:58:08+08:00https://flcube.com/remegens-disitamab-vedotin-on-track-for-breakthrough-designation-in-muscle-invasive-bladder-cancer/2024-10-21T10:57:09+08:00https://flcube.com/roches-genentech-gets-green-light-for-vixarelimab-uc-clinical-trial-in-china/2024-10-21T10:56:04+08:00https://flcube.com/degron-therapeutics-partners-with-takeda-for-molecular-glue-degraders-development/2024-10-21T10:54:57+08:00https://flcube.com/sandoz-receives-european-commission-approval-for-biosimilars-wyost-and-jubbonti/2024-10-21T10:40:38+08:00https://flcube.com/jjs-tremfya-meets-primary-endpoints-in-phase-iii-crohns-disease-trial/2024-10-21T10:33:41+08:00https://flcube.com/akeso-biopharmas-ivonescimab-approved-for-nsclc-treatment-in-china/2024-10-21T10:31:44+08:00https://flcube.com/beijings-cipher-gene-secures-rmb-100-million-in-series-c-financing-to-expand-precision-medicine-services/2024-10-21T10:30:30+08:00https://flcube.com/chinas-nhsa-aims-to-boost-medical-insurance-reform-with-sanming-model/2024-10-21T10:29:30+08:00https://flcube.com/cstone-pharmaceuticals-expands-european-reach-with-ewopharma-partnership-for-sugemalimab/2024-10-21T10:28:53+08:00https://flcube.com/shanghai-fosun-pharmas-fcn-159-file-for-dendritic-and-histiocytic-tumors-accepted-by-chinas-nmpa/2024-10-21T10:26:30+08:00https://flcube.com/accuredit-therapeutics-publishes-positive-data-for-gene-edited-drug-art001-in-amyloidosis-treatment/2024-10-21T10:23:53+08:00https://flcube.com/novartis-atrasentan-shows-significant-reduction-in-proteinuria-in-iga-nephropathy-trial/2024-10-21T10:22:56+08:00https://flcube.com/abbisko-therapeutics-reports-positive-phase-i-results-for-absk061-in-solid-tumors-at-esmo-tat-2024/2024-10-21T10:20:08+08:00https://flcube.com/cutia-therapeutics-cu-20401-shows-promising-safety-and-efficacy-in-phase-i-abdominal-fat-reduction-study/2024-10-21T10:16:55+08:00https://flcube.com/shandong-buchang-pharmaceuticals-gets-nmpa-greenlight-for-phase-i-study-of-bc001-in-solid-tumors/2024-10-21T10:13:59+08:00https://flcube.com/bayers-bay-2927088-receives-fda-breakthrough-therapy-designation-for-her2-mutated-nsclc/2024-10-21T10:08:54+08:00https://flcube.com/haisco-pharmaceutical-gets-nmpa-greenlight-for-hsk39775-solid-tumor-drug-candidate/2024-10-21T10:06:13+08:00https://flcube.com/gileads-biktarvy-receives-fda-approval-for-expanded-hiv-treatment-indication/2024-10-21T10:03:49+08:00https://flcube.com/zai-lab-ltd-reports-31-yoy-growth-in-product-revenues-and-strategic-pipeline-expansion/2024-10-21T10:01:09+08:00https://flcube.com/takeda-partners-with-biological-e-to-boost-production-of-dengue-vaccine-qdenga/2024-10-21T09:57:52+08:00https://flcube.com/fda-withdraws-approval-for-multiple-myeloma-drug-pepaxto-over-safety-and-efficacy-concerns/2024-10-21T09:55:22+08:00https://flcube.com/jenscare-scientific-achieves-milestone-with-first-lux-valve-plus-implantation-in-brazil/2024-10-21T09:46:02+08:00https://flcube.com/viatris-secures-late-stage-programs-from-idorsia-with-potential-for-future-asset-additions/2024-10-21T09:43:33+08:00https://flcube.com/microport-cardioflow-forecasts-31-36-yoy-sales-growth-for-2023-driven-by-tavi-product-expansion/2024-10-21T09:39:47+08:00https://flcube.com/hutchmeds-2023-financials-show-102-yoy-revenue-growth-and-robust-collaboration-with-takeda/2024-10-21T09:34:59+08:00https://flcube.com/angitia-bio-secures-usd-40-million-in-series-b-financing-to-advance-musculoskeletal-disorder-therapies/2024-10-21T09:31:50+08:00https://flcube.com/bms-taps-into-circular-rna-potential-with-shanghai-circode-bio-agreement/2024-10-21T09:29:19+08:00https://flcube.com/abbvie-partners-with-ose-immunotherapeutics-to-develop-first-in-class-immunotherapy-ose-230/2024-10-21T09:24:05+08:00https://flcube.com/astrazenecas-azd0486-receives-nmpa-greenlight-for-clinical-study-in-b-cell-leukemia/2024-10-21T09:20:24+08:00https://flcube.com/viatris-eyes-growth-after-concluding-initial-phase-of-strategy-with-2023-sales-at-15-4-billion/2024-10-21T09:18:03+08:00https://flcube.com/bmss-azacitidine-first-oral-aml-therapy-reaches-gba-patients-via-special-policy/2024-10-21T09:15:16+08:00https://flcube.com/bidens-executive-order-may-restrict-data-access-for-china-based-life-science-firms-in-the-us/2024-10-21T00:02:32+08:00https://flcube.com/maruho-expands-into-china-with-new-wholly-owned-subsidiary-in-beijing/2024-10-20T23:59:56+08:00https://flcube.com/haihe-pharmaceuticals-licenses-glumetinib-to-taiho-for-exclusive-development-in-japan-and-asia/2024-10-20T23:55:03+08:00https://flcube.com/canbridge-pharmaceuticals-partners-with-peking-union-medical-college-to-advance-rare-disease-research/2024-10-20T23:52:25+08:00https://flcube.com/fosun-pharmaceutical-secures-nmpa-approval-for-phase-ii-study-of-fcn-338-and-fcn-647-in-chronic-lymphocytic-leukemia/2024-10-20T23:49:31+08:00https://flcube.com/shanghai-pharmaceuticals-meditrust-health-teams-up-with-eisai-to-enhance-alzheimers-prevention-and-treatment/2024-10-20T23:46:39+08:00https://flcube.com/cde-streamlines-patent-dispute-resolution-for-generic-drug-filings-with-new-online-submission-process/2024-10-20T23:40:15+08:00https://flcube.com/innovent-biologics-launches-phase-i-study-for-ibi3002-a-bispecific-antibody-targeting-asthma/2024-10-20T23:35:40+08:00https://flcube.com/cde-grants-priority-review-to-jiu-ans-adrenaline-and-anhearts-taletrectinib-two-others-earn-breakthrough-therapy-designation/2024-10-20T23:33:09+08:00https://flcube.com/sandoz-agrees-to-265-million-settlement-in-u-s-generic-drug-antitrust-case/2024-10-20T23:29:29+08:00https://flcube.com/huadong-medicines-maili-extreme-achieves-clinical-study-milestone-for-chin-retraction-treatment/2024-10-20T23:26:28+08:00https://flcube.com/arsmo-plastic-aesthetic-hospital-introduces-liquid-pcl-implant-gouri-in-hainan/2024-10-20T23:23:57+08:00https://flcube.com/carsgen-therapeutics-bcma-targeted-car-t-cell-therapy-approved-by-chinas-nmpa/2024-10-20T23:21:29+08:00https://flcube.com/mercks-mavenclad-demonstrates-lasting-efficacy-in-rms-patients-new-data-show/2024-10-20T23:10:57+08:00https://flcube.com/alzecure-pharmas-alzheimers-drug-candidate-acd856-receives-global-patent-awards/2024-10-20T23:08:09+08:00https://flcube.com/sino-biocan-secures-series-b-funding-to-boost-cell-and-gene-therapy-production-platforms/2024-10-20T23:06:11+08:00https://flcube.com/aim-vaccine-advances-pneumococcal-vaccine-and-initiates-phase-ii-meningococcal-study/2024-10-20T23:03:53+08:00https://flcube.com/hainan-poly-pharm-secures-tentative-fda-approval-for-generic-version-of-ucbs-briviact/2024-10-20T22:59:27+08:00https://flcube.com/bmss-yervoy-opdivo-combo-on-track-for-breakthrough-therapy-designation-in-china-for-crc/2024-10-20T22:56:53+08:00https://flcube.com/beijing-tinavi-medical-technologies-to-form-radiotherapy-equipment-jv-with-im-inno-and-celestial-oncology/2024-10-20T22:53:17+08:00https://flcube.com/pfizers-rsv-vaccine-demonstrates-durable-efficacy-with-abrysvo-phase-iii-results/2024-10-20T22:44:20+08:00https://flcube.com/shanghai-fosun-pharmas-gck-01-car-nk-cell-therapy-gets-tacit-clinical-approval-from-chinas-cde/2024-10-20T22:40:23+08:00https://flcube.com/jjs-rybrevant-secures-full-fda-approval-for-nsclc-with-egfr-exon-20-insertions/2024-10-20T22:37:10+08:00https://flcube.com/astellas-launches-late-stage-trial-in-japan-for-nonhormonal-menopause-treatment/2024-10-20T22:34:55+08:00https://flcube.com/hebei-province-proposes-measures-for-internet-medical-services-and-insurance-management/2024-10-20T22:32:30+08:00https://flcube.com/eli-lilly-invests-5-3-billion-to-expand-manufacturing-capacity-for-incretin-receptor-agonists/2024-10-20T18:30:39+08:00https://flcube.com/boston-scientific-gets-nmpa-approval-for-agent-dcb-first-of-its-kind-for-coronary-isr-treatment/2024-10-20T18:29:48+08:00https://flcube.com/bio-thera-solutions-receives-nmpa-approval-for-bat6005-and-bat1308-combination-therapy-trial/2024-10-20T18:28:53+08:00https://flcube.com/bayers-consumer-health-division-to-invest-83-million-in-new-supply-center-in-china/2024-10-20T18:28:00+08:00https://flcube.com/henlius-biotechs-denosumab-biosimilar-secures-ema-review-for-european-market-entry/2024-10-20T18:26:00+08:00https://flcube.com/novartis-fabhalta-shows-promise-in-late-stage-c3-glomerulopathy-trial/2024-10-20T18:23:10+08:00https://flcube.com/chinese-biopharma-companies-set-to-showcase-oncology-pipelines-at-asco-2024/2024-10-20T18:22:20+08:00https://flcube.com/medilink-therapeutics-partners-with-biontech-to-develop-adc-products-using-tmalin-technology/2024-10-20T18:19:04+08:00https://flcube.com/yantai-dongcheng-pharmaceutical-receives-nmpa-approval-for-sstr2-targeted-radioactive-drug/2024-10-20T18:17:59+08:00https://flcube.com/beijing-unveils-action-plan-to-boost-pharmaceutical-and-health-industry-by-2026/2024-10-20T18:16:55+08:00https://flcube.com/3403/2024-10-20T18:16:12+08:00https://flcube.com/rarestone-groups-pitolisant-secures-nmpa-approval-to-treat-narcolepsy-in-children-and-adolescents/2024-10-20T18:14:14+08:00https://flcube.com/blue-sail-medical-receives-nmpa-approval-for-disposable-coronary-intravascular-impact-waveguide/2024-10-20T18:13:31+08:00https://flcube.com/innovent-biologics-picankibart-achieves-positive-results-in-phase-iii-psoriasis-trial/2024-10-20T18:12:19+08:00https://flcube.com/hotgen-biotech-receives-fda-clearance-to-initiate-clinical-trials-for-sgc001/2024-10-20T18:11:16+08:00https://flcube.com/henlius-biotechs-biosimilar-rituximab-receives-first-overseas-marketing-approval-from-peru/2024-10-20T18:10:16+08:00https://flcube.com/hinova-pharmaceuticals-to-present-hp518-data-at-asco-marking-first-in-human-trial-milestone/2024-10-20T18:08:33+08:00https://flcube.com/boan-biotechs-dulaglutide-biosimilar-accepted-for-review-by-chinas-cde/2024-10-20T18:07:24+08:00https://flcube.com/innovent-biologics-picankibart-achieves-positive-results-in-phase-iii-psoriasis-trial-2/2024-10-20T18:06:25+08:00https://flcube.com/hotgen-biotech-receives-fda-approval-to-begin-clinical-trials-for-acute-myocardial-infarction-drug/2024-10-20T18:05:30+08:00https://flcube.com/henlius-biotechs-biosimilar-rituximab-receives-first-overseas-marketing-approval-from-peru-2/2024-10-20T18:04:38+08:00https://flcube.com/hinova-pharmaceuticals-to-present-phase-i-data-for-protac-drug-hp518-at-asco-2024/2024-10-20T18:03:21+08:00https://flcube.com/boan-biotechs-dulaglutide-biosimilar-accepted-for-review-by-chinas-cde-2/2024-10-20T18:02:04+08:00https://flcube.com/china-unveils-comprehensive-plan-to-tackle-unhealthy-practices-in-pharma-and-healthcare/2024-10-20T17:59:22+08:00https://flcube.com/3sbio-secures-license-for-semaglutide-biosimilar-from-hybio-pharmaceutical/2024-10-20T17:58:49+08:00https://flcube.com/alphamab-oncologys-kn046-misses-primary-endpoint-in-phase-iii-pancreatic-cancer-study/2024-10-20T17:57:34+08:00https://flcube.com/asahi-kasei-moves-to-fully-acquire-swedish-rare-disease-biopharma-calliditas-in-all-cash-deal/2024-10-20T17:56:30+08:00https://flcube.com/roche-extends-long-standing-partnership-with-hitachi-high-tech-to-innovate-diagnostic-solutions/2024-10-20T17:54:05+08:00https://flcube.com/bio-thera-solutions-partners-with-stada-for-european-commercialization-of-golimumab-biosimilar/2024-10-20T17:51:58+08:00https://flcube.com/sanofi-partners-with-bluecrux-to-enhance-supply-chain-with-ai-technologies/2024-10-20T17:49:15+08:00https://flcube.com/gilead-partners-with-cartography-biosciences-to-develop-therapies-for-triple-negative-breast-cancer/2024-10-20T15:18:16+08:00https://flcube.com/sino-medical-sciences-innovative-drug-coated-stent-system-accepted-for-nmpa-review/2024-10-20T15:17:22+08:00https://flcube.com/ivd-medical-holding-ltd-enters-non-binding-mou-with-chinese-chemiluminescence-ivd-company-for-potential-collaboration/2024-10-20T15:12:17+08:00https://flcube.com/full-life-technologies-receives-fda-green-light-for-%c2%b2%c2%b2%e2%81%b5ac-fl-020-clinical-study-in-mcrpc/2024-10-20T15:09:52+08:00https://flcube.com/amgens-bkemv-becomes-first-biosimilar-to-challenge-astrazenecas-soliris-with-fda-approval/2024-10-20T15:09:07+08:00https://flcube.com/fosun-pharma-rumored-to-fully-acquire-subsidiary-henlius-pharmaceutical-shares-suspended/2024-10-20T15:07:44+08:00https://flcube.com/zelgen-biopharmaceuticals-gets-nmpa-approval-for-jacktinib-vitiligo-trial-in-adolescents-and-adults/2024-10-20T15:04:45+08:00https://flcube.com/wanbangdes-huperzine-a-earns-orphan-drug-status-from-fda-for-treating-neonatal-brain-injury/2024-10-20T15:03:43+08:00https://flcube.com/jiangsu-qyuns-therapeutics-initiates-phase-iii-trial-for-skin-disease-candidate-qx005n/2024-10-20T15:01:42+08:00https://flcube.com/johnson-johnson-to-acquire-atopic-dermatitis-therapy-nm26-in-1-25-billion-deal/2024-10-20T15:00:36+08:00https://flcube.com/shanghai-research-team-achieves-global-first-in-treating-type-2-diabetes-with-stem-cell-therapy/2024-10-20T14:59:38+08:00https://flcube.com/merck-kgaa-launches-construction-on-largest-asia-pacific-investment-with-south-korean-bioprocessing-plant/2024-10-20T14:59:02+08:00https://flcube.com/lucy-therapeutics-boosts-cns-disease-research-with-usd-12-5-million-in-additional-financing/2024-10-20T14:56:49+08:00https://flcube.com/akeso-inc-s-ivonescimab-shows-positive-interim-analysis-in-phase-iii-nsclc-study/2024-10-20T14:55:33+08:00https://flcube.com/jw-therapeutics-presents-positive-clinical-data-for-carteyva-in-sle-at-eular-2024/2024-10-20T14:54:42+08:00https://flcube.com/parexel-partners-with-ruijin-hospital-hainan-subsidiary-to-enhance-real-world-evidence-in-drug-development/2024-10-20T14:52:43+08:00https://flcube.com/burning-rock-expands-companion-diagnostics-partnership-with-bayer-for-precision-oncology-in-china/2024-10-20T14:51:53+08:00https://flcube.com/astellas-pharmas-vyloy-receives-fda-approval-for-cldn18-2-positive-gastric-cancer-treatment/2024-10-20T14:38:45+08:00https://flcube.com/sandoz-achieves-fda-milestone-with-approval-of-first-us-denosumab-biosimilars/2024-10-20T13:53:10+08:00https://flcube.com/chinas-government-work-report-highlights-biomedicine-innovation-and-healthcare-reforms/2024-10-20T13:52:11+08:00https://flcube.com/ema-reviews-datopotamab-deruxtecan-filings-from-astrazeneca-and-daiichi-sankyo-for-oncology-indications/2024-10-20T13:50:29+08:00https://flcube.com/pfizers-cibinqo-secures-nmpa-approval-for-expanded-use-in-atopic-dermatitis/2024-10-20T13:47:41+08:00https://flcube.com/china-aims-to-insure-80-of-newborns-with-basic-medical-insurance-by-2024/2024-10-20T13:45:36+08:00https://flcube.com/novartis-gene-therapy-zolgensma-shows-continued-benefits-in-broader-sma-patient-group/2024-10-20T13:43:48+08:00https://flcube.com/bitterroot-bio-and-biotheus-inc-join-forces-to-develop-therapies-for-cardiovascular-diseases/2024-10-20T13:41:32+08:00https://flcube.com/luye-pharma-initiates-phase-iii-clinical-trial-for-irinotecan-liposome-injection-in-small-cell-lung-cancer/2024-10-20T13:39:45+08:00https://flcube.com/henlius-biotech-forecasts-first-ever-profit-in-2023-driven-by-sales-growth-and-efficient-management/2024-10-20T13:37:15+08:00https://flcube.com/nuance-pharma-wins-arbitration-rescinds-licensing-deal-with-antibe-therapeutics/2024-10-20T13:34:07+08:00https://flcube.com/aosaikangs-marketing-approval-filing-for-delafloxacin-accepted-by-chinas-nmpa/2024-10-20T13:31:34+08:00https://flcube.com/vivolight-medical-secures-over-rmb-100-million-in-strategic-financing-to-boost-global-expansion/2024-10-20T13:29:44+08:00https://flcube.com/huadong-medicines-arcalyst-filing-for-recurrent-pericarditis-accepted-by-chinas-nmpa/2024-10-20T13:27:47+08:00https://flcube.com/sino-medical-sciences-receives-hong-kong-approval-for-ht-supreme-drug-eluting-stent-system/2024-10-20T13:22:28+08:00https://flcube.com/hitgen-secures-cde-approval-for-lipisense-ind-filing-advancing-development-for-dyslipidemia-treatment/2024-10-20T13:18:29+08:00https://flcube.com/viiv-healthcare-presents-phase-i-data-for-ultra-long-acting-cabotegravir-in-hiv-treatment-and-prevention/2024-10-20T13:15:13+08:00https://flcube.com/merck-teams-up-with-c4-therapeutics-for-targeted-protein-degraders-in-oncology/2024-10-20T13:11:43+08:00https://flcube.com/innovent-biologics-taletrectinib-receives-second-nda-acceptance-in-china-for-ros1-positive-nsclc/2024-10-20T13:07:08+08:00https://flcube.com/apeloa-pharmaceutical-and-zhenge-biotech-join-forces-to-create-comprehensive-adc-platform/2024-10-20T12:34:56+08:00https://flcube.com/lundbeck-a-s-posts-8-2-yoy-revenue-growth-in-2023-with-strong-performance-across-key-therapies/2024-10-20T12:25:54+08:00https://flcube.com/formosa-pharmaceuticals-secures-fda-nod-for-new-steroidal-eye-drug-set-to-launch-via-eyenovia/2024-10-20T12:23:43+08:00https://flcube.com/mgi-tech-lands-eurofins-genomics-deal-for-t20-ultra-high-throughput-sequencer-in-europe/2024-10-20T12:21:09+08:00https://flcube.com/bayer-posts-1-2-yoy-sales-decline-in-2023-with-pharmaceuticals-and-consumer-health-segment-updates/2024-10-20T12:18:57+08:00https://flcube.com/novo-nordisks-ozempic-meets-phase-iii-endpoints-in-type-2-diabetes-and-chronic-kidney-disease-study/2024-10-20T12:15:45+08:00https://flcube.com/hybio-pharmaceutical-gets-fda-nod-for-liraglutide-raw-materials-with-dmf-adequacy-letter/2024-10-20T12:08:43+08:00https://flcube.com/bio-thera-solutions-receives-nmpa-approval-for-three-cancer-treatments-including-a-novel-adc/2024-10-20T12:03:34+08:00https://flcube.com/everest-medicines-to-establish-integrated-kidney-disease-diagnosis-and-treatment-ecosystem/2024-10-20T12:01:15+08:00https://flcube.com/boehringer-ingelheims-spevigo-receives-nmpa-approval-for-gpp-treatment-in-china/2024-10-20T11:59:03+08:00https://flcube.com/zylox-tonbridge-medical-technology-secures-licensing-deal-with-avinger-to-boost-device-portfolio/2024-10-20T11:57:20+08:00https://flcube.com/luye-pharma-launches-small-cell-lung-cancer-treatment-zepzelca-in-hong-kong-and-macau/2024-10-20T11:53:01+08:00https://flcube.com/proviva-therapeutics-secures-18-million-in-series-a-financing-to-advance-ptx-912/2024-10-20T11:50:43+08:00https://flcube.com/us-senate-committee-backs-bill-to-restrict-chinese-biotechnology-firms-access-to-american-genetic-data/2024-10-20T11:49:00+08:00https://flcube.com/carsgen-launches-bcma-targeted-car-t-therapy-in-china-with-high-price-point/2024-10-20T11:45:19+08:00https://flcube.com/xian-janssens-tremfya-heads-for-priority-review-in-china-for-crohns-disease-treatment/2024-10-20T11:41:48+08:00https://flcube.com/ema-reviews-jjs-darzalex-subcutaneous-formulation-for-newly-diagnosed-multiple-myeloma/2024-10-20T11:39:50+08:00https://flcube.com/gilead-and-merus-form-strategic-oncology-alliance-to-develop-trispecific-t-cell-engagers/2024-10-20T11:35:03+08:00https://flcube.com/henlius-biotechs-her2-targeting-biosimilar-secures-thai-and-philippine-approvals/2024-10-20T11:30:26+08:00https://flcube.com/lees-pharmaceutical-secures-malaysian-distribution-for-generic-glaucoma-treatment/2024-10-20T11:26:20+08:00https://flcube.com/mercks-2023-annual-report-a-mixed-bag-amid-global-challenges/2024-10-20T11:20:56+08:00https://flcube.com/gsk-reports-us-adult-non-flu-vaccination-rates-recover-post-pandemic/2024-10-20T11:16:40+08:00https://flcube.com/visen-pharmaceuticals-transcon-hgh-accepted-for-review-by-chinas-nmpa/2024-10-20T11:08:00+08:00https://flcube.com/shandong-luoxin-pharmaceutical-partners-with-xbiome-to-access-microbiome-transplantation-technology/2024-10-20T11:05:21+08:00https://flcube.com/shanghai-fosun-pharma-gets-nmpa-green-light-for-universal-nk-cell-therapy-gck-01-clinical-study/2024-10-20T11:00:12+08:00https://flcube.com/novo-nordisks-anti-obesity-drug-wegovy-eyed-for-china-launch-in-2024/2024-10-20T10:56:14+08:00https://flcube.com/china-grand-pharmaceutical-receives-fda-approval-for-post-surgical-ophthalmic-drug-gpn00833/2024-10-20T10:53:55+08:00https://flcube.com/shanghai-fosun-pharma-gets-nmpa-green-light-for-xs-02-solid-tumor-clinical-study/2024-10-20T10:51:19+08:00https://flcube.com/tuv-partners-with-lancy-co-ltds-bravou-to-enhance-medical-aesthetics-services-in-china/2024-10-19T23:58:41+08:00https://flcube.com/eli-lilly-launches-new-formula-of-taltz-in-china-with-reduced-injection-site-pain/2024-10-19T23:57:05+08:00https://flcube.com/cstone-pharmaceuticals-sugemalimab-receives-positive-chmp-opinion-for-nsclc-treatment-in-europe/2024-10-19T23:53:07+08:00https://flcube.com/immuneonco-receives-nmpa-approval-for-phase-iii-clinical-trial-of-timdarpacept-in-cmml/2024-10-19T23:52:11+08:00https://flcube.com/simcere-pharmas-anti-insomnia-drug-daridorexant-meets-primary-endpoint-in-phase-iii-clinical-trial/2024-10-19T23:50:54+08:00https://flcube.com/gileads-trodelvy-misses-overall-survival-endpoint-in-late-stage-urothelial-cancer-study/2024-10-19T23:47:59+08:00https://flcube.com/andon-healths-covid-19-trio-test-kit-and-otc-antigen-test-win-fda-approval/2024-10-19T23:45:19+08:00https://flcube.com/innovent-biologics-presents-clinical-data-for-pipeline-candidates-at-asco-2024/2024-10-19T23:43:56+08:00https://flcube.com/chinas-nhsa-launches-new-procedures-for-drug-catalogue-attribution-identification/2024-10-19T23:42:43+08:00https://flcube.com/nmpa-announces-digitalization-of-medical-device-regulatory-documents/2024-10-19T23:41:40+08:00https://flcube.com/jacobio-pharmas-kras-g12c-inhibitor-combo-shows-promising-results-in-nsclc-at-asco-2024/2024-10-19T23:30:24+08:00https://flcube.com/ascentage-pharmas-apg-2449-shows-positive-results-in-ros1-and-alk-positive-nsclc-at-asco-2024/2024-10-19T23:29:27+08:00https://flcube.com/simcere-pharmas-suvemcitug-shows-positive-results-in-platinum-resistant-ovarian-cancer-study/2024-10-19T23:28:12+08:00https://flcube.com/simcere-pharmaceuticals-suvemcitug-files-for-approval-in-china-for-recurrent-ovarian-cancer/2024-10-19T23:27:38+08:00https://flcube.com/astellas-resubmits-fda-application-for-vyloy-as-treatment-for-cldn18-2-positive-cancer/2024-10-19T23:24:47+08:00https://flcube.com/simcere-secures-fda-approval-for-clinical-study-of-trispecific-antibody-sim0500-in-multiple-myeloma/2024-10-19T23:14:03+08:00https://flcube.com/everest-medicines-velsipity-nda-accepted-in-macau-poised-for-first-asian-approval/2024-10-19T23:11:19+08:00https://flcube.com/sichuan-biokin-and-bristol-myers-squibb-activate-800-million-adc-licensing-deal/2024-10-19T23:06:30+08:00https://flcube.com/cloudr-launches-dapagliflozin-generic-version-of-astrazenecas-forxiga-after-nmpa-approval/2024-10-19T23:00:37+08:00https://flcube.com/hangzhou-kang-mings-cloudr-posts-strong-financial-growth-with-diversified-solutions-and-p2m-strategy/2024-10-19T22:58:04+08:00https://flcube.com/eli-lilly-delays-donanemab-action-date-as-fda-calls-for-advisory-committee-review/2024-10-19T22:50:18+08:00https://flcube.com/china-cracks-down-on-medical-insurance-fraud-with-new-guidelines-and-increased-prosecutions/2024-10-19T22:47:51+08:00https://flcube.com/fda-approves-wegovy-for-cardiovascular-risk-reduction-in-obese-patients-first-of-its-kind/2024-10-19T22:46:04+08:00https://flcube.com/amgen-reports-positive-results-for-otezla-in-pediatric-psoriasis-trial/2024-10-19T22:41:36+08:00https://flcube.com/sinocelltech-gains-nmpa-approval-for-clinical-study-of-sctb35-in-b-cell-non-hodgkins-lymphoma/2024-10-19T22:33:40+08:00https://flcube.com/huadong-medicine-secures-nmpa-approval-for-hdm1005-targeting-type-2-diabetes-and-obesity/2024-10-19T22:31:39+08:00https://flcube.com/innovent-and-hutchmeds-combination-therapy-set-for-priority-review-in-china-for-advanced-endometrial-cancer/2024-10-19T22:28:43+08:00https://flcube.com/sanofis-amlitelimab-shows-promising-phase-iib-results-in-atopic-dermatitis-potential-for-12-week-dosing/2024-10-19T22:24:48+08:00https://flcube.com/jiangsu-qyuns-therapeutics-eyes-hk-ipo-to-raise-up-to-hkd-243-million-for-autoimmune-pipeline/2024-10-19T21:42:29+08:00https://flcube.com/legend-biotech-reports-q4-and-full-year-2023-financials-with-focus-on-carvykti-milestones/2024-10-19T21:39:42+08:00https://flcube.com/gilead-nears-completion-of-cymabay-acquisition-after-waiting-period-expires/2024-10-19T21:36:59+08:00https://flcube.com/jjs-tremfya-files-for-ulcerative-colitis-indication-with-fda-building-on-positive-late-stage-data/2024-10-19T21:34:26+08:00https://flcube.com/pfizers-adcetris-combo-shows-improved-survival-in-relapsed-refractory-dlbcl-late-stage-trial/2024-10-19T21:32:50+08:00https://flcube.com/innovent-biologics-allegedly-closes-us-research-facility-shifts-focus-to-china/2024-10-19T21:24:06+08:00https://flcube.com/vectorbuilder-partners-with-minaris-regenerative-medicine-to-enhance-gene-therapy-solutions/2024-10-19T21:21:57+08:00https://flcube.com/bio-thera-solutions-gets-green-light-for-phase-ib-ii-study-of-adc-bat8008-in-advanced-solid-tumors/2024-10-19T21:19:54+08:00https://flcube.com/betta-pharmaceuticals-ensartinib-accepted-for-fda-review-for-first-line-alk-nsclc-treatment/2024-10-19T21:17:39+08:00https://flcube.com/innocare-pharma-receives-ind-approval-in-china-for-bcl2-inhibitor-combo-therapy/2024-10-19T21:11:20+08:00https://flcube.com/simcere-pharmaceutical-gets-nmpa-approval-for-clinical-study-of-trispecific-antibody-sim0500/2024-10-19T21:08:41+08:00https://flcube.com/fosun-pharmaceutical-gets-nmpa-green-light-for-phase-i-study-of-fibrosis-drug-hlx6018/2024-10-19T21:06:48+08:00https://flcube.com/nmpa-releases-78th-batch-of-reference-drugs-for-generic-quality-consistency-evaluation/2024-10-19T21:04:34+08:00https://flcube.com/chinas-nhc-outlines-cross-departmental-law-enforcement-to-strengthen-medical-supervision/2024-10-19T21:02:22+08:00https://flcube.com/kanghong-pharmaceuticals-nash-drug-kh629-receives-clinical-trial-implicit-approval-in-china/2024-10-19T19:10:20+08:00https://flcube.com/pfizers-lorbrena-outperforms-xalkori-in-5-year-alk-positive-nsclc-follow-up/2024-10-19T15:16:52+08:00https://flcube.com/genscript-shares-slide-on-us-congressional-request-for-fbi-investigation/2024-10-19T15:15:46+08:00https://flcube.com/chinas-nhsa-and-mof-plan-expansion-of-long-term-care-insurance-system-pilot-program/2024-10-19T15:11:33+08:00https://flcube.com/changchun-genescience-to-distribute-twi-pharmas-megestrol-in-china-and-southeast-asia/2024-10-19T15:10:59+08:00https://flcube.com/gilead-and-arcus-biosciences-report-positive-interim-phase-ii-data-for-domvanalimab-combo-in-gi-cancers/2024-10-19T15:10:13+08:00https://flcube.com/cspc-pharmaceutical-secures-nmpa-nod-for-generic-version-of-astrazenecas-lynparza/2024-10-19T15:07:15+08:00https://flcube.com/varian-medical-gets-china-approval-for-fourth-generation-halcyon-radiotherapy-system/2024-10-19T15:03:10+08:00https://flcube.com/legend-biotechs-carvykti-shows-durable-responses-in-multiple-myeloma-patients-post-asct/2024-10-19T15:01:09+08:00https://flcube.com/allergan-aesthetics-botox-secures-new-indication-for-masseter-muscle-protrusion-in-china/2024-10-19T15:00:14+08:00https://flcube.com/jiangsu-aidea-pharmaceutical-gets-green-light-from-nmpa-for-ainuovirine-apis/2024-10-19T14:57:45+08:00https://flcube.com/akeso-expands-licensing-deal-with-summit-therapeutics-for-ivonescimab-bispecific-antibody/2024-10-19T14:56:46+08:00https://flcube.com/zylox-tonbridge-medical-technology-earns-nmpa-approval-for-first-vascular-stapler-in-china/2024-10-19T14:55:13+08:00https://flcube.com/eli-lilly-acquires-quralis-unc13a-targeting-compounds-for-neurodegenerative-diseases/2024-10-19T14:53:44+08:00https://flcube.com/zhaoke-ophthalmology-partners-with-chinas-eye-valley-to-establish-ophthalmic-research-institute/2024-10-19T14:52:30+08:00https://flcube.com/micurx-pharmaceuticals-mrx-8-achieves-positive-results-in-phase-i-clinical-study/2024-10-19T14:50:59+08:00https://flcube.com/astrazenecas-tagrisso-achieves-milestone-progression-free-survival-in-late-stage-lung-cancer-study/2024-10-19T14:49:54+08:00https://flcube.com/gilead-and-arcus-biosciences-report-positive-combination-therapy-results-in-mcrc-trial/2024-10-19T14:48:50+08:00https://flcube.com/chinas-nhc-mandates-urban-hospitals-to-aid-county-level-medical-institutions/2024-10-19T14:47:07+08:00https://flcube.com/boe-backed-genewise-bio-secures-rmb-100-million-in-series-a-financing-for-molecular-diagnostics/2024-10-19T14:45:35+08:00https://flcube.com/sanofi-receives-nmpa-approval-for-phase-iii-clinical-trial-of-rsv-vaccine-sp0125/2024-10-19T14:44:35+08:00https://flcube.com/olymvax-bio-receives-ethical-approval-for-oral-helicobacter-pylori-vaccine-trial-in-australia/2024-10-19T14:43:20+08:00https://flcube.com/obio-technology-partners-with-shenzhen-innovation-immunotechnology-for-tcr-t-cell-therapy-development/2024-10-19T14:41:39+08:00https://flcube.com/aim-vaccine-submits-pre-ind-applications-for-mrna-vaccines-targeting-rsv-and-herpes-zoster-to-nmpa/2024-10-19T14:40:27+08:00https://flcube.com/shenzhen-light-and-biotechnology-partners-with-shenzhen-increcare-biotech-in-ivd-sector/2024-10-19T14:39:21+08:00https://flcube.com/innocares-tafasitamab-lenalidomide-combo-on-track-for-priority-review-in-china-for-dlbcl-treatment/2024-10-19T14:37:28+08:00https://flcube.com/abelzeta-and-astrazenecas-c-car031-shows-promising-results-in-hcc-treatment/2024-10-19T14:35:57+08:00https://flcube.com/chinas-nhc-launches-health-literacy-plan-to-shift-focus-to-preventative-healthcare/2024-10-19T14:33:12+08:00https://flcube.com/cloudbreak-pharma-files-for-hong-kong-ipo-with-focus-on-ophthalmic-innovations/2024-10-19T14:31:26+08:00https://flcube.com/jjs-tecvayli-shows-promising-response-rates-in-multiple-myeloma-trial/2024-10-19T14:29:22+08:00https://flcube.com/wuxi-biologics-expands-manufacturing-capacity-with-new-bioreactors-at-hangzhou-facility/2024-10-19T14:28:19+08:00https://flcube.com/rightongene-bio-receives-nmpa-approval-for-bcr-abl-p210-fusion-gene-detection-kit/2024-10-19T14:26:59+08:00https://flcube.com/3sbio-secures-exclusive-licensing-agreement-for-seven-drug-candidates-from-subsidiary/2024-10-19T14:25:38+08:00https://flcube.com/sino-biopharmaceutical-presents-fs222-phase-i-results-at-asco-annual-meeting/2024-10-19T14:22:56+08:00https://flcube.com/alphamab-oncology-partners-with-arrivent-biopharma-for-global-adc-development-and-commercialization/2024-10-19T14:21:23+08:00https://flcube.com/akeso-biopharma-launches-phase-ib-ii-trial-for-cadonilimab-and-ak112-in-pancreatic-cancer/2024-10-19T13:30:00+08:00https://flcube.com/fda-extends-review-of-amgens-lumakras-for-kras-g12c-mcrc-treatment-to-january-2025/2024-10-19T13:02:27+08:00https://flcube.com/pfizer-partners-with-triana-biomedicines-to-develop-molecular-glue-degraders-for-oncology-and-other-diseases/2024-10-19T12:59:47+08:00https://flcube.com/shenzhen-chipscreen-advances-cs231295-for-cancer-treatment-as-ind-accepted-by-nmpa/2024-10-19T12:43:01+08:00https://flcube.com/cnipa-invalidates-novo-nordisks-victoza-patent-opening-door-for-chinese-biosimilars/2024-10-18T23:28:27+08:00https://flcube.com/cnipa-invalidates-abbvie-patents-setting-new-precedent-for-pharmaceutical-disclosure/2024-10-18T23:25:29+08:00https://flcube.com/innovent-biologics-denies-lab-closure-confirms-relocation-to-california/2024-10-18T23:19:31+08:00https://flcube.com/novartis-acquires-ifm-due-for-90-million-expanding-sting-inhibitor-pipeline/2024-10-18T23:17:15+08:00https://flcube.com/bio-reverses-support-for-wuxi-apptec-amid-security-concerns-plans-legislative-shift/2024-10-18T23:14:57+08:00https://flcube.com/european-commission-approves-pfizers-prevenar-20-for-pediatric-use/2024-10-18T23:12:07+08:00https://flcube.com/shanghai-bdgene-partners-with-sph-rd-to-advance-gene-therapy-development/2024-10-18T23:07:20+08:00https://flcube.com/allist-pharmaceuticals-secures-nmpa-approval-for-phase-i-study-of-ast2169-liposome-in-kras-g12d-tumors/2024-10-18T23:03:43+08:00https://flcube.com/biogeometry-and-sanyou-biopharmaceuticals-forge-ai-partnership-for-antibody-drug-discovery/2024-10-18T23:01:23+08:00https://flcube.com/sichuan-biokin-gains-nmpa-approval-for-phase-i-study-of-bl-m05d1-in-advanced-solid-tumors/2024-10-18T22:59:07+08:00https://flcube.com/genor-biopharma-secures-nmpa-review-for-lerociclib-in-advanced-breast-cancer-indication/2024-10-18T22:56:33+08:00https://flcube.com/fosun-pharma-launches-rmb-5-billion-fund-to-boost-biopharmaceutical-investments-in-shenzhen/2024-10-18T22:54:29+08:00https://flcube.com/shanghai-unveils-17-measures-to-enhance-medical-administration-business-environment/2024-10-18T22:51:45+08:00https://flcube.com/shanghai-henlius-initiates-phase-i-trial-for-hlx42-an-innovative-adc-targeting-egfr/2024-10-18T22:49:42+08:00https://flcube.com/astrazeneca-acquires-amolyt-pharma-for-800-million-to-bolster-rare-disease-pipeline/2024-10-18T22:46:45+08:00https://flcube.com/kechow-pharma-secures-conditional-approval-for-hl-085-a-first-of-its-kind-mek-inhibitor-for-advanced-melanoma/2024-10-18T22:43:29+08:00https://flcube.com/boehringer-ingelheim-jj-and-novo-holdings-invest-in-asgard-therapeutics-for-cancer-immunotherapy/2024-10-18T22:37:50+08:00https://flcube.com/pfizers-sugemalimab-secures-nmpa-approval-for-gastric-and-gastroesophageal-junction-adenocarcinoma/2024-10-18T22:35:12+08:00https://flcube.com/madrigal-pharmaceuticals-rezdiffra-earns-fda-accelerated-approval-for-nash-in-adults/2024-10-18T22:32:19+08:00https://flcube.com/swire-pacific-to-deepen-healthcare-investment-focus-in-china-and-indonesia/2024-10-18T22:29:26+08:00https://flcube.com/boehringer-ingelheim-partners-with-sosei-group-to-develop-gpr52-agonists-for-schizophrenia/2024-10-18T22:25:05+08:00https://flcube.com/hansoh-pharmaceutical-secures-global-rights-to-biotheus-bsab-hs-20117-pm1080/2024-10-18T22:19:40+08:00https://flcube.com/legend-biotechs-carvykti-earns-fda-committees-unanimous-recommendation-for-expanded-use-2/2024-10-18T22:17:40+08:00https://flcube.com/legend-biotechs-carvykti-earns-fda-committees-unanimous-recommendation-for-expanded-use/2024-10-18T22:14:31+08:00https://flcube.com/microenergy-medical-technology-secures-pre-series-a-funding-to-advance-medical-devices/2024-10-18T22:11:41+08:00https://flcube.com/getein-biotech-partners-with-dymind-biotechnology-to-advance-ivd-market-presence/2024-10-18T22:09:18+08:00https://flcube.com/sino-biopharmaceutical-advances-lanifibranor-and-tqa2225-into-late-stage-clinical-trials-for-mash/2024-10-18T21:58:25+08:00https://flcube.com/mabwells-nectin-4-targeting-adc-9mw2821-shows-promise-in-cervical-cancer-clinical-study/2024-10-18T21:54:45+08:00https://flcube.com/everest-medicines-stakeholders-pledge-six-month-hold-amid-confidence-in-long-term-growth/2024-10-18T21:51:34+08:00https://flcube.com/novo-nordisks-wegovy-leads-in-total-us-prescriptions-for-weight-loss-market/2024-10-18T21:49:13+08:00https://flcube.com/hutchmed-initiates-phase-i-clinical-trial-for-hmpl-506-in-hematologic-malignancies/2024-10-18T18:14:45+08:00https://flcube.com/luye-pharma-submits-market-approval-application-for-rivastigmine-patch-in-japan/2024-10-18T18:13:11+08:00https://flcube.com/fosun-pharmas-fcn-159-receives-priority-review-status-from-nmpa-for-pediatric-neurofibromatosis/2024-10-18T18:11:59+08:00https://flcube.com/qilu-pharmaceuticals-generic-pomalidomide-wins-nmpa-nod-for-multiple-myeloma-treatment/2024-10-18T18:10:14+08:00https://flcube.com/microport-endovascular-medtech-secures-nmpa-approval-for-vena-cava-filter/2024-10-18T18:09:24+08:00https://flcube.com/sansure-biotechs-hbv-rna-detection-kit-receives-nmpa-marketing-approval/2024-10-18T18:08:04+08:00https://flcube.com/sinovac-biotech-commits-usd-100-million-investment-in-brazil-for-vaccine-research-and-collaboration/2024-10-18T18:07:00+08:00https://flcube.com/china-unveils-ambitious-2024-medical-reforms-with-increased-investment-and-policy-reforms/2024-10-18T18:05:48+08:00https://flcube.com/jj-loses-us-court-case-over-asbestos-in-cosmetic-products-ordered-to-pay-260-million/2024-10-18T18:02:15+08:00https://flcube.com/four-more-chinese-provinces-include-art-in-medical-insurance-payment-system/2024-10-18T18:01:16+08:00https://flcube.com/gsk-finalizes-acquisition-of-oligonucleotide-specialist-elsie-biotechnologies-for-up-to-50-million/2024-10-18T18:00:29+08:00https://flcube.com/abbvies-telisotuzumab-vedotin-earns-breakthrough-therapy-designation-in-china-for-c-met-positive-nsclc/2024-10-18T17:58:13+08:00https://flcube.com/gileads-bulevirtide-pegifn-combo-achieves-high-hdv-remission-rates-in-phase-iib-trial/2024-10-18T17:57:04+08:00https://flcube.com/astrazeneca-files-for-market-approval-of-tremelimumab-in-china-for-hepatocellular-carcinoma/2024-10-18T15:26:10+08:00https://flcube.com/astrazenecas-akt-inhibitor-truqap-approved-in-japan-for-hr-her2-breast-cancer/2024-10-18T15:22:34+08:00https://flcube.com/zhejiang-dian-diagnostics-partners-with-haihe-laboratory-to-advance-hematology-diagnostics/2024-10-18T15:12:44+08:00https://flcube.com/microport-cardioflows-heart-valve-balloon-dilatation-catheter-alwide-plus-gains-mexican-approval/2024-10-18T15:03:35+08:00https://flcube.com/changshan-biochemical-pharmaceutical-wins-marketing-approval-for-enoxaparin-in-niger/2024-10-18T14:54:58+08:00https://flcube.com/huahai-pharmaceutical-gets-fda-nod-for-generic-empagliflozin-and-metformin-anda/2024-10-18T14:47:34+08:00https://flcube.com/sanofi-invests-eur-300-million-in-joint-venture-with-orano-med-for-next-generation-radioligand-therapies/2024-10-18T14:29:53+08:00https://flcube.com/antengenes-xpovio-secures-expanded-access-in-south-korea-for-multiple-myeloma-treatment/2024-10-18T14:18:49+08:00https://flcube.com/abbvies-vyalev-wins-fda-approval-as-first-subcutaneous-levodopa-therapy-for-advanced-parkinsons/2024-10-18T14:14:11+08:00https://flcube.com/chengdu-drafts-comprehensive-policy-to-stimulate-biomedical-industry-growth/2024-10-18T14:08:47+08:00https://flcube.com/chongqing-zhifei-biologicals-ec-injection-receives-market-approval-in-indonesia/2024-10-18T14:00:46+08:00https://flcube.com/tencent-invests-usd-30-million-in-early-cancer-detection-firm-insighta-backed-by-prenetics/2024-10-18T13:52:30+08:00https://flcube.com/lanova-medicines-secures-rmb-300-million-in-series-c1-financing-to-advance-cancer-therapy-pipeline/2024-10-18T13:42:02+08:00https://flcube.com/abbott-laboratories-posts-9-4-q3-sales-growth-driven-by-medical-devices-and-pharmaceuticals/2024-10-18T13:33:53+08:00https://flcube.com/chengdu-baiyu-pharmaceutical-strikes-licensing-deal-with-novartis-for-unannounced-anti-tumor-asset/2024-10-18T13:28:43+08:00https://flcube.com/merck-boosts-global-distribution-capabilities-with-e180-million-expansion-of-german-center/2024-10-18T13:07:26+08:00https://flcube.com/jiangxi-fushines-subsidiary-linkchem-eyes-hong-kong-ipo-amid-strong-revenue-growth/2024-10-18T13:05:24+08:00https://flcube.com/chinas-nmpa-issues-new-supervision-measures-for-medical-device-clinical-trials-starting-october-2024/2024-10-18T13:03:33+08:00https://flcube.com/ai-powered-biotech-insilico-medicine-initiates-phase-i-clinical-trial-for-inflammatory-bowel-disease-drug/2024-10-18T13:02:53+08:00https://flcube.com/brii-biosciences-brii-179-shows-promise-in-phase-ii-trials-for-chronic-hepatitis-b-at-easl-2024/2024-10-18T13:02:04+08:00https://flcube.com/shanghai-turtle-technology-partners-with-focusgen-biotech-to-advance-tumor-liquid-biopsy-innovations/2024-10-18T13:00:27+08:00https://flcube.com/shanghai-pharmaceuticals-halts-development-of-b001-and-i022-for-selected-indications/2024-10-18T12:59:28+08:00https://flcube.com/china-medical-system-secures-exclusive-rights-to-baiyiyuan-biotechs-implant-in-greater-china/2024-10-18T12:57:43+08:00https://flcube.com/ascletis-pharmas-asc41-shows-promise-in-phase-ii-study-for-metabolic-dysfunction-associated-steatohepatitis/2024-10-18T12:55:19+08:00https://flcube.com/biosions-bosakitug-shows-positive-results-in-atopic-dermatitis-phase-ii-poc-study/2024-10-18T12:49:49+08:00https://flcube.com/novartiss-tabrecta-earns-nmpa-nod-for-met-positive-advanced-nsclc-in-china/2024-10-18T12:37:43+08:00https://flcube.com/recorna-and-starna-therapeutics-join-forces-to-advance-rna-gene-editing-in-lung-diseases/2024-10-18T12:36:38+08:00https://flcube.com/chinas-nmpa-unveils-three-year-smart-supervision-plan-for-blood-product-industry/2024-10-18T12:35:41+08:00https://flcube.com/innocare-pharmas-tyk2-inhibitor-icp-332-receives-fda-ind-approval-for-atopic-dermatitis/2024-10-18T12:34:54+08:00https://flcube.com/chinas-cde-opens-consultation-on-83rd-batch-of-generic-chemical-reference-preparations/2024-10-18T12:32:45+08:00https://flcube.com/bayers-her2-targeting-drug-bay-2927088-earns-breakthrough-designation-in-china/2024-10-18T12:32:02+08:00https://flcube.com/johnson-johnson-to-acquire-biotechnology-firm-yellow-jersey-for-1-25-billion/2024-10-18T12:30:19+08:00https://flcube.com/kyowa-kirin-to-invest-530-million-in-us-biologics-factory-for-rare-disease-therapies/2024-10-18T12:29:16+08:00https://flcube.com/ascentage-pharma-gets-green-light-for-global-phase-iii-trial-of-olverembatinib-in-sdh-deficient-gist/2024-10-18T12:28:06+08:00https://flcube.com/sansure-biotechs-tuberculosis-detection-kit-gains-ce-ivdr-certification-for-eu-market/2024-10-18T12:27:04+08:00https://flcube.com/sino-biopharmaceuticals-kras-inhibitor-garsorasib-earns-breakthrough-designation-in-china/2024-10-18T12:24:02+08:00https://flcube.com/cgps-gpn00884-myopia-drug-enters-phase-i-clinical-trial-with-first-patient-dosed/2024-10-18T12:22:28+08:00https://flcube.com/sinomab-biosciences-sm17-atopic-dermatitis-drug-reaches-first-patient-milestone-in-phase-ib-trial/2024-10-18T12:20:57+08:00https://flcube.com/junshi-biosciences-toripalimab-bevacizumab-combo-meets-primary-endpoints-in-hcc-phase-iii-trial/2024-10-18T12:19:53+08:00https://flcube.com/luye-pharmas-paliperidone-palmitate-injection-wins-nmpa-nod-for-schizophrenia-treatment/2024-10-18T12:18:01+08:00https://flcube.com/zai-labs-global-rd-leadership-transition-dr-harald-reinhart-to-retire-dr-rafael-amado-expands-role/2024-10-18T12:16:18+08:00https://flcube.com/sperogenix-launches-early-access-program-for-dmd-therapy-agamgree-in-hainan/2024-10-18T12:13:59+08:00https://flcube.com/kyowa-kirins-evocalcet-wins-nmpa-nod-for-chronic-kidney-disease-treatment/2024-10-18T12:12:16+08:00https://flcube.com/junshi-biosciences-toripalimab-scores-new-indication-for-first-line-es-sclc-treatment-in-china/2024-10-18T12:10:41+08:00https://flcube.com/abbvie-calico-partnership-advances-with-fda-approval-for-fosigotifator-trial-in-rare-brain-disorder/2024-10-18T12:08:24+08:00https://flcube.com/eli-lillys-tirzepatide-hits-primary-endpoint-in-mash-trial-outperforming-placebo/2024-10-18T12:07:20+08:00https://flcube.com/pfizer-forges-partnership-with-flagship-pioneering-for-novel-obesity-treatments/2024-10-18T12:06:20+08:00https://flcube.com/accuray-wins-chinese-nod-for-precision-treatment-planning-system-boosting-regional-expansion/2024-10-18T12:05:26+08:00https://flcube.com/haisco-pharmaceuticals-braf-inhibitor-hsk42360-gains-nmpa-approval-for-clinical-trials/2024-10-18T12:04:09+08:00https://flcube.com/wuxi-apptec-and-wuxi-bio-shares-rally-as-us-biosecure-act-excluded-from-defense-bill/2024-10-18T12:02:51+08:00https://flcube.com/joincare-pharmaceutical-receives-nmpa-approval-for-generic-seretide/2024-10-18T12:01:01+08:00https://flcube.com/zelgen-biopharmaceuticals-jacktinib-meets-primary-endpoint-in-severe-alopecia-areata-trial/2024-10-18T11:59:58+08:00https://flcube.com/wuxi-apptec-posts-modest-revenue-growth-despite-regulatory-hurdles/2024-10-18T11:30:09+08:00https://flcube.com/astrazenecas-lynparza-imfinzi-combo-shows-promising-results-in-endometrial-cancer-study/2024-10-18T11:13:03+08:00https://flcube.com/chinas-national-joint-procurement-office-sets-march-2024-for-insulin-contracts-renewal/2024-10-18T11:10:30+08:00https://flcube.com/teruisi-pharmas-trs005-receives-support-for-breakthrough-designation-in-china-for-cd20-positive-lymphoma/2024-10-18T11:04:26+08:00https://flcube.com/pfizers-elrexfio-anticipated-for-priority-review-in-china-for-relapsed-refractory-multiple-myeloma/2024-10-18T11:00:57+08:00https://flcube.com/cde-seeks-public-feedback-on-latest-batch-of-generic-drug-reference-preparations/2024-10-18T10:58:16+08:00https://flcube.com/astrazeneca-caps-monthly-costs-for-us-patients-with-asthma-and-copd-inhalers/2024-10-18T10:55:51+08:00https://flcube.com/jiangsu-yahong-meditech-to-present-phase-iii-results-for-cervical-cancer-treatment-at-sgo-annual-meeting/2024-10-18T10:53:21+08:00https://flcube.com/sino-medical-sciences-secures-south-korean-approvals-for-three-cardiovascular-devices/2024-10-18T10:47:54+08:00https://flcube.com/bio-thera-solutions-and-steincares-ink-licensing-deal-for-latam-biosimilar-distribution/2024-10-18T10:44:44+08:00https://flcube.com/cy-pharmaceutical-teams-up-with-gigaceuticals-to-form-ai-driven-drug-development-jv/2024-10-18T10:42:07+08:00https://flcube.com/gsks-jemperli-shows-survival-benefits-in-phase-iii-endometrial-cancer-study/2024-10-18T10:39:23+08:00https://flcube.com/akeso-biopharma-reports-record-revenue-and-first-profit-driven-by-innovative-drugs/2024-10-18T10:36:26+08:00https://flcube.com/zuellig-pharma-expands-commercialization-deal-for-karo-healthcares-lamisil-in-asian-markets/2024-10-18T10:30:18+08:00https://flcube.com/cspc-pharmaceutical-gets-nmpa-greenlight-for-syh2039-clinical-study-in-advanced-malignant-tumors/2024-10-18T10:28:11+08:00https://flcube.com/novo-nordisk-invests-rmb-4-billion-to-expand-sterile-manufacturing-in-tianjin/2024-10-18T10:25:07+08:00https://flcube.com/suzhou-porton-biologics-partners-with-kunshi-biotech-to-advance-third-generation-car-m-therapy/2024-10-18T10:22:54+08:00https://flcube.com/china-expands-medical-service-pricing-reform-with-three-additional-pilot-provinces/2024-10-18T10:19:09+08:00https://flcube.com/swiss-pharma-firm-carbogen-amcis-receives-brazils-anvisa-gmp-certification-for-shanghai-site/2024-10-18T10:17:26+08:00https://flcube.com/everest-medicines-strengthens-leadership-with-appointments-of-sandra-zeng-and-rico-liang/2024-10-18T10:14:59+08:00https://flcube.com/wuxi-xdc-breaks-ground-on-state-of-the-art-manufacturing-base-in-singapore-to-boost-adc-production/2024-10-18T10:12:25+08:00https://flcube.com/wuxi-bio-reports-2023-revenue-growth-amid-covid-19-business-loss-and-geopolitical-tensions/2024-10-18T10:09:35+08:00https://flcube.com/shanghai-winpu-technology-and-silver-mars-merge-under-yinke-holding-to-accelerate-healthcare-innovation/2024-10-18T10:06:54+08:00https://flcube.com/everest-medicines-nefegan-approved-by-singapore-hsa-for-primary-igan-treatment/2024-10-18T10:04:35+08:00https://flcube.com/shanghai-pharmaceuticals-appoints-new-chairman-amid-leadership-shake-up/2024-10-18T10:01:56+08:00https://flcube.com/china-grand-pharmaceutical-reports-robust-2023-revenues-and-pipeline-advancements/2024-10-18T09:53:52+08:00https://flcube.com/china-medical-system-gets-green-light-for-phase-iii-clinical-trial-of-opzelura-in-atopic-dermatitis/2024-10-18T09:37:36+08:00https://flcube.com/boehringer-ingelheims-survodutide-earns-breakthrough-designation-for-mash-treatment-in-china/2024-10-18T00:35:53+08:00https://flcube.com/eli-lillys-baqsimi-gains-nmpa-approval-for-diabetes-hypoglycemia-treatment/2024-10-18T00:34:25+08:00https://flcube.com/nhsa-seeks-public-input-on-national-reimbursement-drug-list-adjustments/2024-10-18T00:33:36+08:00https://flcube.com/amgens-prolia-secures-nmpa-approval-for-treating-glucocorticoid-induced-osteoporosis-in-high-risk-patients/2024-10-18T00:32:58+08:00https://flcube.com/astrazenecas-farxiga-receives-fda-approval-for-pediatric-type-2-diabetes-treatment/2024-10-18T00:31:42+08:00https://flcube.com/pfizers-gene-therapy-for-duchenne-muscular-dystrophy-misses-late-stage-trial-endpoints/2024-10-18T00:30:49+08:00https://flcube.com/gsk-partners-with-ochre-bio-to-access-liver-data-for-hepatology-therapy-development/2024-10-18T00:29:52+08:00https://flcube.com/apeloa-pharmaceutical-partners-with-beijing-highthink-for-cro-services-on-semaglutide-generic/2024-10-18T00:28:52+08:00https://flcube.com/zhejiang-dian-diagnostics-partners-with-quest-diagnostics-to-advance-alzheimers-disease-blood-tests/2024-10-18T00:27:18+08:00https://flcube.com/cellbri-bio-secures-nearly-rmb-200-million-in-series-b-financing-to-boost-cgt-commercialization/2024-10-18T00:26:22+08:00https://flcube.com/ronovo-surgical-secures-over-rmb-300-million-in-series-b-to-globalize-surgical-robot/2024-10-18T00:25:46+08:00https://flcube.com/innovent-biologics-ibi363-shows-promising-results-in-phase-ia-ib-trial-for-advanced-solid-tumors/2024-10-18T00:25:08+08:00https://flcube.com/cstone-pharmaceuticals-gets-nmpa-green-light-for-local-production-of-gavreto/2024-10-18T00:24:14+08:00https://flcube.com/abbvie-strikes-deal-with-futuregen-for-global-rights-to-next-gen-tl1a-antibody-fg-m701/2024-10-18T00:20:30+08:00https://flcube.com/remegens-disitamab-vedotin-shows-positive-results-in-phase-iii-trial-for-her2-positive-breast-cancer/2024-10-18T00:19:36+08:00https://flcube.com/carsgen-therapeutics-saikaize-and-ct071-show-strong-results-in-eha-clinical-trials/2024-10-18T00:18:24+08:00https://flcube.com/takeda-secures-global-rights-to-ascentage-pharmas-olverembatinib-outside-of-china-and-select-territories/2024-10-18T00:10:41+08:00https://flcube.com/neusoft-intelliray-secures-over-rmb-100-million-in-series-c-funding-round/2024-10-18T00:09:07+08:00https://flcube.com/catug-biotechnology-secures-nearly-rmb-100-million-in-latest-financing-round-to-expand-globally/2024-10-18T00:08:18+08:00https://flcube.com/amgens-blincyto-secures-new-indication-approval-for-b-all-consolidation-treatment-in-the-us/2024-10-18T00:03:30+08:00https://flcube.com/takedas-soticlestat-misses-primary-endpoints-in-phase-iii-epilepsy-trials/2024-10-18T00:01:54+08:00https://flcube.com/biontech-and-medilinks-her3-adc-bnt326-faces-partial-clinical-hold-in-the-us/2024-10-17T23:59:52+08:00https://flcube.com/sinovac-partners-with-brazils-fiocruz-to-boost-vaccine-research-and-development/2024-10-17T23:58:37+08:00https://flcube.com/walvax-biotechnology-halts-covid-19-vaccine-clinical-trials-citing-low-benefits/2024-10-17T23:55:54+08:00https://flcube.com/shenzhen-chipscreen-biosciences-receives-nmpa-approval-for-chiauranib-phase-ii-trial-in-pancreatic-cancer/2024-10-17T23:53:57+08:00https://flcube.com/wuxis-binhu-district-partners-with-fresenius-kabi-to-boost-healthcare-services/2024-10-17T23:52:50+08:00https://flcube.com/shineco-partners-with-tuling-vision-to-develop-intelligent-healthcare-solutions/2024-10-17T23:52:05+08:00https://flcube.com/remegens-telitacicept-receives-nmpa-approval-for-clinical-trial-in-igg4-related-diseases/2024-10-17T23:46:56+08:00https://flcube.com/microport-endovasculars-vewatch-filter-gets-nmpa-green-light-for-pulmonary-embolism-prevention/2024-10-17T23:44:27+08:00https://flcube.com/baidu-health-partners-with-yibang-to-enhance-operations-for-brick-and-mortar-pharmacies/2024-10-17T23:33:14+08:00https://flcube.com/edan-instruments-partners-with-global-health-labs-to-develop-ai-enhanced-handheld-ultrasound/2024-10-17T23:30:15+08:00https://flcube.com/takeda-gains-mhlw-approval-for-adzynma-targeting-rare-blood-disorder-cttp/2024-10-17T23:26:34+08:00https://flcube.com/takedas-strategic-shift-china-becomes-integral-to-global-rd-pipeline/2024-10-17T23:25:53+08:00https://flcube.com/fda-grants-accelerated-approval-for-takedas-iclusig-in-newly-diagnosed-ph-all/2024-10-17T23:25:19+08:00https://flcube.com/china-unveils-action-plan-to-boost-foreign-investment-and-open-economy-further/2024-10-17T23:21:52+08:00https://flcube.com/simcere-pharmaceutical-reports-4-5-revenue-growth-in-2023-amid-shifts-in-profitability/2024-10-17T23:19:01+08:00https://flcube.com/bayer-and-thermo-fisher-partner-to-develop-rapid-companion-diagnostics-for-precision-oncology/2024-10-17T23:08:02+08:00https://flcube.com/cair-launches-cares-copilot-1-0-a-revolutionary-ai-chatbot-for-medical-diagnosis-and-treatment/2024-10-17T22:30:13+08:00https://flcube.com/viva-biotech-secures-licensing-deal-with-lonza-for-advanced-bispecific-antibody-technology/2024-10-17T22:26:56+08:00https://flcube.com/antengenes-atg-022-advances-to-dose-expansion-phase-in-phase-ii-clinch-study-for-solid-tumors/2024-10-17T22:09:34+08:00https://flcube.com/cspc-pharmaceutical-secures-nmpa-approval-for-clinical-study-of-sys6023-in-advanced-solid-tumors/2024-10-17T22:07:09+08:00https://flcube.com/3sbio-reports-13-8-revenue-growth-in-2023-driven-by-strong-sales-of-core-biologics/2024-10-17T22:04:41+08:00https://flcube.com/innovent-biologics-reports-36-2-revenue-growth-in-2023-highlights-robust-product-sales/2024-10-17T22:02:10+08:00https://flcube.com/sino-biological-partners-with-rapid-novor-to-market-mab-sequencing-services-across-asia/2024-10-17T21:59:19+08:00https://flcube.com/lynk-pharmaceuticals-doses-first-patient-in-phase-iii-trial-for-atopic-dermatitis-treatment/2024-10-17T21:53:56+08:00https://flcube.com/hutchmed-launches-phase-ii-iii-study-for-sovleplenib-in-autoimmune-hemolytic-anemia/2024-10-17T21:50:40+08:00https://flcube.com/neuexcell-therapeutics-doses-first-patient-in-groundbreaking-clinical-trial-for-neurod1-gene-therapy/2024-10-17T21:47:35+08:00https://flcube.com/astra-biotech-raises-tens-of-millions-in-pre-series-b-funding-to-expand-diagnostic-capabilities/2024-10-17T21:43:45+08:00https://flcube.com/horimed-secures-tens-of-millions-in-financing-to-advance-oct-imaging-technologies/2024-10-17T21:41:39+08:00https://flcube.com/beijing-varnotech-biopharm-secures-rmb-600-million-in-series-b-funding-for-vaccine-development/2024-10-17T21:39:48+08:00https://flcube.com/porespect-secures-tens-of-millions-in-angel-funding-led-by-forcefield-ventures/2024-10-17T21:37:01+08:00https://flcube.com/intuitive-surgicals-ion-robotic-system-gains-regulatory-approval-in-china/2024-10-17T21:34:46+08:00https://flcube.com/bayer-eliminates-c-level-roles-in-restructuring-efforts-to-boost-profitability/2024-10-17T21:26:38+08:00https://flcube.com/sandoz-expands-antibiotics-production-with-new-austrian-factory/2024-10-17T21:22:03+08:00https://flcube.com/shanghai-institutes-biosimilar-rituximab-approved-by-nmpa-for-lymphoma-treatments/2024-10-17T21:10:32+08:00https://flcube.com/ema-panel-backs-novartiss-fabhalta-for-pnh-treatment-awaits-ec-decision/2024-10-17T21:08:10+08:00https://flcube.com/sumitomo-pharmas-china-ceo-highlights-strategic-importance-of-local-market/2024-10-17T20:53:53+08:00https://flcube.com/roche-invests-eur-90-million-in-new-gene-therapy-center-in-germany/2024-10-17T20:50:26+08:00https://flcube.com/sanofi-projects-eur-13-billion-in-dupixent-sales-for-2024-despite-q1-challenges/2024-10-17T20:47:59+08:00https://flcube.com/fibrogens-roxadustat-approved-in-macau-for-chronic-kidney-disease-related-anemia/2024-10-17T20:45:28+08:00https://flcube.com/chinas-commerce-minister-meets-with-global-pharma-leaders-to-discuss-innovation-cooperation/2024-10-17T20:43:26+08:00https://flcube.com/yifan-pharmaceuticals-f-627-approved-by-european-commission-for-marketing-in-eu/2024-10-17T20:41:53+08:00https://flcube.com/obio-technology-partners-with-saierxin-bio-to-support-treg-cell-therapy-development/2024-10-17T20:39:53+08:00https://flcube.com/grand-pharma-receives-nmpa-approval-for-global-phase-iii-study-of-rdc-itm-11-in-gep-nets/2024-10-17T20:37:45+08:00https://flcube.com/jenscare-scientific-completes-enrollment-in-clinical-study-for-mitral-valve-repair-system/2024-10-17T20:35:24+08:00https://flcube.com/golden-leaf-med-tec-secures-series-d-funding-to-advance-hypertension-and-diabetes-treatments/2024-10-17T20:30:11+08:00https://flcube.com/joincare-pharmaceuticals-secures-rights-to-bayers-respiratory-drug-in-china/2024-10-17T20:28:01+08:00https://flcube.com/aribio-expands-alzheimers-drug-ar1001-licensing-deal-with-samjin-to-include-china/2024-10-17T20:25:49+08:00https://flcube.com/nanjing-sanhomes-oritinib-wins-nmpa-approval-for-egfr-t790m-positive-nsclc/2024-10-17T18:44:00+08:00https://flcube.com/astrazeneca-restructures-county-oncology-team-to-enhance-vertical-alignment/2024-10-17T18:43:16+08:00https://flcube.com/ascentage-pharma-presents-positive-clinical-results-for-olverembatinib-and-lisaftoclax-at-eha-meeting/2024-10-17T18:41:59+08:00https://flcube.com/guangdong-pharmaceutical-association-expands-off-label-drug-use-catalogue-for-2024/2024-10-17T18:39:40+08:00https://flcube.com/gansu-province-introduces-measures-for-management-of-pharmaceutical-personnel/2024-10-17T18:39:01+08:00https://flcube.com/roche-secures-rna-exon-editing-tech-for-neurological-diseases-with-ascidian-deal/2024-10-17T18:38:22+08:00https://flcube.com/astrazenecas-akt-inhibitor-truqap-misses-primary-endpoints-in-phase-iii-tnbc-trial/2024-10-17T18:34:51+08:00https://flcube.com/china-medical-systems-methylthioninium-tablets-get-nmpa-green-light-for-colonoscopy-use/2024-10-17T18:33:42+08:00https://flcube.com/day-one-biopharmaceuticals-expands-pipeline-with-mabcare-therapeutics-licensing-deal/2024-10-17T18:32:35+08:00https://flcube.com/clover-biopharmaceuticals-rsv-vaccine-candidate-shows-promising-results-in-elderly/2024-10-17T18:31:21+08:00https://flcube.com/sanofi-partners-with-belharra-therapeutics-to-tap-into-chemoproteomics-for-immunology-targets/2024-10-17T18:30:20+08:00https://flcube.com/suzhou-zelgens-recombinant-human-thyroid-stimulating-hormone-accepted-for-nmpa-review/2024-10-17T18:28:32+08:00https://flcube.com/kanghong-pharmaceuticals-lumitin-approved-in-myanmar-for-neovascular-amd-treatment/2024-10-17T18:27:25+08:00https://flcube.com/hybribio-ltd-secures-nmpa-approval-for-%ce%b1-thalassemia-genotyping-detection-kit/2024-10-17T18:25:50+08:00https://flcube.com/3sbio-secures-long-term-financing-from-ifc-for-manufacturing-and-global-expansion/2024-10-17T18:24:38+08:00https://flcube.com/nmpa-releases-81st-batch-of-reference-drugs-for-generic-quality-consistency-evaluation/2024-10-17T18:21:58+08:00https://flcube.com/astrazenecas-gracell-biotechnologies-to-expand-cell-therapy-manufacturing-in-china/2024-10-17T18:21:15+08:00https://flcube.com/abbvies-skyrizi-secures-fda-approval-for-ulcerative-colitis-expands-treatment-portfolio/2024-10-17T18:18:18+08:00https://flcube.com/xencor-reclaims-rights-to-plamotamab-after-janssen-halts-development/2024-10-17T18:17:07+08:00https://flcube.com/keymed-biosciences-cm313-shows-promise-in-treating-immune-thrombocytopenia-nejm-study-says/2024-10-17T18:15:30+08:00https://flcube.com/jiuzhou-pharmaceutical-shuts-down-two-subsidiaries-to-streamline-operations/2024-10-17T18:13:44+08:00https://flcube.com/shanghai-fosun-pharmaceutical-sells-stake-in-gland-pharma-for-usd-211-million/2024-10-17T18:12:33+08:00https://flcube.com/dizal-pharmaceuticals-golidocitinib-wins-nmpa-approval-for-relapsed-refractory-ptcl/2024-10-17T18:10:19+08:00https://flcube.com/china-expands-controlled-substances-catalogue-to-include-three-additional-substances/2024-10-17T18:09:02+08:00https://flcube.com/novartis-moves-toward-full-ownership-of-morphosys-with-shareholder-squeeze-out/2024-10-17T18:08:13+08:00https://flcube.com/fudan-zhangjiang-bio-pharmaceutical-advances-aminolevulinic-acid-study-for-glioma-visualization/2024-10-17T18:04:48+08:00https://flcube.com/luye-pharmas-once-weekly-parkinsons-disease-treatment-receives-nmpa-approval/2024-10-17T18:01:48+08:00https://flcube.com/shanghai-fudan-zhangjiang-and-hanhui-pharmaceutical-end-marketing-deal-for-libaoduo/2024-10-17T17:59:06+08:00https://flcube.com/dk-medical-technology-secures-hundreds-of-millions-in-series-e-financing-for-expansion/2024-10-17T17:55:39+08:00https://flcube.com/tonghua-dongbao-pharmaceuticals-thdbh120-receives-nmpa-approval-for-phase-ii-clinical-trial/2024-10-17T17:55:02+08:00https://flcube.com/zhangzhou-pien-tze-huangs-pzh2113-receives-nmpa-clinical-trial-approval-for-lymphoma-treatment/2024-10-17T17:53:16+08:00https://flcube.com/shineco-inc-acquires-80-stake-in-internetmedical-care-platform-meitong-tech-for-usd-20-million/2024-10-17T17:51:49+08:00https://flcube.com/ascentage-pharmas-thdbh120-receives-nmpa-approval-for-phase-ib-clinical-trial/2024-10-17T17:50:20+08:00https://flcube.com/qilu-pharmaceuticals-generic-version-of-vyndaqel-receives-nmpa-marketing-approval/2024-10-17T17:46:48+08:00https://flcube.com/metis-therapeutics-secures-usd-100-million-in-series-c-financing-to-advance-ai-drug-delivery/2024-10-17T17:45:38+08:00https://flcube.com/inkon-life-technology-partners-with-united-imaging-to-establish-advanced-medical-centers-and-digital-platform/2024-10-17T17:44:13+08:00https://flcube.com/hefei-airport-port-designated-as-drug-import-port-by-chinese-authorities/2024-10-17T17:38:36+08:00https://flcube.com/gileads-lenacapavir-shows-100-efficacy-in-phase-iii-hiv-prep-study/2024-10-17T17:37:33+08:00https://flcube.com/starrygene-initiates-phase-i-clinical-trial-for-xmva09-gene-therapy-in-wamd/2024-10-17T17:36:14+08:00https://flcube.com/sichuan-biokin-pharmaceutical-gets-nmpa-go-ahead-for-bl-m17d1-solid-tumor-clinical-study/2024-10-17T17:35:33+08:00https://flcube.com/shanghai-pharmaceuticals-subsidiary-shaphar-med-collaborates-with-magic-med-to-enter-oncology/2024-10-17T17:33:38+08:00https://flcube.com/immuneonco-biopharmaceuticals-receives-nmpa-approval-for-cd47-and-cd20-dual-targeted-bsab-in-sle/2024-10-17T17:31:37+08:00https://flcube.com/cloudr-secures-exclusive-sub-licensing-rights-for-iloprost-infusion-solution/2024-10-17T17:29:09+08:00https://flcube.com/takedas-fruquintinib-for-metastatic-colorectal-cancer-receives-european-commission-marketing-approval/2024-10-17T17:27:50+08:00https://flcube.com/innovent-biologics-mazdutide-shows-promise-in-phase-iii-obesity-trial/2024-10-17T17:24:43+08:00https://flcube.com/novo-nordisks-once-weekly-insulin-awiqli-approved-by-chinas-nmpa-for-type-2-diabetes/2024-10-17T17:23:32+08:00https://flcube.com/gan-lee-pharmaceuticals-gzr18-outperforms-market-similars-in-weight-reduction-study/2024-10-17T17:22:14+08:00https://flcube.com/haisco-pharmaceutical-gets-nmpa-green-light-for-cofrogliptin-to-treat-type-2-diabetes/2024-10-17T17:21:13+08:00https://flcube.com/andiconbio-secures-over-rmb-200-million-in-series-a-financing-to-advance-respiratory-and-pain-therapies/2024-10-17T17:20:05+08:00https://flcube.com/sun-yat-sen-university-and-kingmed-diagnostics-collaborate-on-talent-development-and-research/2024-10-17T17:18:34+08:00https://flcube.com/shanghai-haihe-pharmaceuticals-glumetinib-earns-marketing-approval-in-japan-for-nsclc-treatment/2024-10-17T17:17:50+08:00https://flcube.com/fosun-pharma-to-take-henlius-private-in-deal-valued-at-hkd-5-407-billion/2024-10-17T17:17:03+08:00https://flcube.com/hybio-pharmaceuticals-biosimilar-liraglutide-gets-temporary-fda-nod-pending-patent-expiry/2024-10-17T17:12:57+08:00https://flcube.com/jiangsu-jibeier-pharm-completes-private-placement-to-fund-rd-center-on-star-market/2024-10-17T17:11:53+08:00https://flcube.com/kintor-pharmaceutical-initiates-phase-ii-iii-trial-for-kx-826-tincture-1-0-in-treating-male-androgenetic-alopecia/2024-10-17T14:50:14+08:00https://flcube.com/novocures-optune-lua-wins-fda-approval-for-mnsclc-treatment-in-combination-with-immunotherapies/2024-10-17T14:36:01+08:00https://flcube.com/innovent-biologics-picankibart-achieves-positive-results-in-phase-ii-uc-study/2024-10-17T14:13:18+08:00https://flcube.com/bayer-ag-launches-china-innovation-hub-to-boost-local-rd-and-global-integration/2024-10-17T13:57:57+08:00https://flcube.com/lexicon-pharmaceuticals-strikes-licensing-deal-with-viatris-for-global-expansion-of-sotagliflozin/2024-10-17T13:49:27+08:00https://flcube.com/johnson-johnsons-nipocalimab-shows-promise-in-treating-adolescent-myasthenia-gravis-in-phase-ii-iii-trial/2024-10-17T13:39:43+08:00https://flcube.com/nhsa-standardizes-nrdl-drug-purchases-to-combat-prescription-fraud/2024-10-17T13:33:50+08:00https://flcube.com/shanxi-province-announces-historic-drug-procurement-batch-with-81-products-for-2024/2024-10-17T13:28:13+08:00https://flcube.com/alphamab-oncology-and-cspc-pharmas-kn026-phase-iii-trial-for-breast-cancer-gets-nmpa-approval/2024-10-17T13:09:31+08:00https://flcube.com/kobayashi-pharmaceutical-recalls-red-yeast-rice-pills-in-china-amid-health-concerns/2024-10-17T11:14:10+08:00https://flcube.com/surprise-resignation-congressman-gallagher-steps-down-as-biosecure-act-faces-uncertainty/2024-10-17T11:11:15+08:00https://flcube.com/nuvation-bio-to-acquire-anheart-therapeutics-in-all-stock-deal-amid-biotech-pressures/2024-10-17T11:08:54+08:00https://flcube.com/fda-grants-full-approval-to-abbvies-elahere-for-advanced-ovarian-cancer-treatment/2024-10-17T11:06:01+08:00https://flcube.com/fosun-health-and-adventist-medical-center-partner-to-enhance-gba-medical-services/2024-10-17T11:03:02+08:00https://flcube.com/hitgen-secures-strategic-partnerships-to-enhance-drug-discovery-for-startups/2024-10-17T10:56:17+08:00https://flcube.com/novo-nordisk-acquires-cardior-for-e1-025-billion-to-strengthen-cardiovascular-portfolio/2024-10-17T10:50:40+08:00https://flcube.com/kelun-biotech-reports-robust-91-6-revenue-growth-amid-strategic-licensing-efforts/2024-10-17T10:45:57+08:00https://flcube.com/guangdong-zhongsheng-reports-positive-phase-i-results-for-innovative-weight-loss-drug-ray1225/2024-10-17T10:43:03+08:00https://flcube.com/zylox-tonbridge-secures-nmpa-approval-for-advanced-flow-diverter-targeting-intracranial-aneurysms/2024-10-17T10:39:22+08:00https://flcube.com/novo-nordisk-expands-benzalkonium-chloride-distribution-with-actylis-across-europe/2024-10-17T10:36:08+08:00https://flcube.com/wuxi-xdc-reports-114-4-yoy-revenue-growth-in-2023-driven-by-adc-crdmo-business/2024-10-17T10:33:09+08:00https://flcube.com/merck-expands-global-footprint-with-largest-m-lab-collaboration-center-in-shanghai/2024-10-17T10:26:00+08:00https://flcube.com/wuhan-yzy-biopharma-initiates-phase-ii-study-for-m701-in-malignant-pleural-effusion-treatment/2024-10-17T10:17:01+08:00https://flcube.com/acotec-scientific-receives-nmpa-approval-for-innovative-cardiovascular-devices/2024-10-17T10:14:06+08:00https://flcube.com/sanofi-launches-kids-program-in-china-to-boost-health-literacy-in-schools/2024-10-17T10:11:26+08:00https://flcube.com/innovent-biologics-initiates-phase-iii-neoshot-study-for-msi-h-dmmr-colon-cancer-treatment/2024-10-17T10:05:34+08:00https://flcube.com/alexions-ultomiris-secures-fda-approval-for-anti-aqp4-positive-nmosd-treatment/2024-10-17T10:01:39+08:00https://flcube.com/nmpa-mandates-electronic-permits-for-anesthetic-drugs-and-psychotropic-substances/2024-10-17T09:58:45+08:00https://flcube.com/shanghai-fosun-pharma-reports-2023-revenues-highlights-innovation-and-rd-progress/2024-10-17T09:55:16+08:00https://flcube.com/abbvie-acquires-landos-biopharma-to-boost-autoimmune-disease-pipeline/2024-10-17T09:51:36+08:00https://flcube.com/national-drug-sampling-inspection-report-reveals-high-compliance-rates-in-2023/2024-10-17T09:48:50+08:00https://flcube.com/chinas-national-adverse-drug-reaction-report-for-2023-highlights-stability-in-reporting-trends/2024-10-17T09:43:59+08:00https://flcube.com/lees-pharmaceutical-holdings-ltd-reports-2023-financials-with-focus-shift-to-patented-and-generic-drugs/2024-10-17T09:41:23+08:00https://flcube.com/shanghai-pharmaceuticals-shc-and-cemcs-cas-renew-partnership-to-incubate-pharmaceutical-innovations/2024-10-17T09:38:32+08:00https://flcube.com/hansoh-pharmaceutical-group-reports-7-7-yoy-revenue-growth-and-expands-rd-spending/2024-10-17T09:37:14+08:00https://flcube.com/staidson-pharmaceutical-gets-fda-clearance-for-tnfr2-targeted-mab-sbt-1901/2024-10-17T00:29:25+08:00https://flcube.com/alebund-pharmaceuticals-ap306-earns-breakthrough-designation-for-chronic-kidney-disease/2024-10-17T00:27:16+08:00https://flcube.com/jjs-tecvayli-earns-nmpa-approval-for-relapsed-or-refractory-multiple-myeloma/2024-10-17T00:26:50+08:00https://flcube.com/suzhou-porton-biologics-becomes-first-chinese-cdmo-to-adopt-maxcytes-expert-gtx-platform/2024-10-17T00:13:45+08:00https://flcube.com/merck-kgaas-xevinapant-misses-primary-endpoint-in-phase-iii-head-and-neck-cancer-trial/2024-10-17T00:12:19+08:00https://flcube.com/novo-nordisk-to-pump-usd-4-1-billion-into-u-s-manufacturing-expansion/2024-10-17T00:11:07+08:00https://flcube.com/u-s-lawmakers-question-fda-on-discrepancies-in-foreign-inspections-of-china-and-india/2024-10-17T00:08:39+08:00https://flcube.com/walvax-biotechnology-halts-covid-19-mrna-vaccine-trials-co-developed-with-abogen-biosciences/2024-10-17T00:07:55+08:00https://flcube.com/jiangsu-simcere-pharmaceutical-wins-nmpa-nod-for-biosimilar-version-of-erbitux/2024-10-17T00:07:00+08:00https://flcube.com/novo-nordisks-semaglutide-for-long-term-weight-management-receives-nmpa-approval/2024-10-17T00:06:03+08:00https://flcube.com/cspc-pharmaceuticals-bcma-targeted-car-t-therapy-sys6020-receives-nmpa-clinical-trial-approval/2024-10-17T00:04:38+08:00https://flcube.com/sino-biopharmaceutical-gains-nmpa-approval-for-liraglutide-biosimilar-for-type-2-diabetes/2024-10-17T00:03:33+08:00https://flcube.com/eli-lilly-co-partners-with-openai-to-use-generative-ai-in-antimicrobial-drug-discovery/2024-10-17T00:01:07+08:00https://flcube.com/chinas-nmpa-proposes-expedited-review-for-clinically-urgent-overseas-drugs/2024-10-17T00:00:10+08:00https://flcube.com/sanofi-invites-bids-starting-at-20-billion-for-consumer-health-unit/2024-10-16T23:59:32+08:00https://flcube.com/astrazenecas-tagrisso-wins-nmpa-approval-for-first-line-egfr-mutated-nsclc-treatment/2024-10-16T23:58:08+08:00https://flcube.com/jj-halts-mid-stage-trial-for-tremfya-in-giant-cell-arteritis-due-to-efficacy-concerns/2024-10-16T23:57:10+08:00https://flcube.com/casi-pharmaceuticals-secures-usd-15-million-in-pipe-transaction-for-anti-cd38-monoclonal-antibody-development/2024-10-16T23:56:18+08:00https://flcube.com/modernas-rsv-vaccine-efficacy-wanes-to-50-after-18-months-shares-slide/2024-10-16T23:55:13+08:00https://flcube.com/novo-nordisks-ocedurenone-misses-primary-endpoint-in-chronic-kidney-disease-trial/2024-10-16T23:50:55+08:00https://flcube.com/novartiss-scemblix-stamp-inhibitor-for-cml-accepted-for-review-by-chinas-nmpa/2024-10-16T23:49:46+08:00https://flcube.com/revvity-and-sanyou-biopharmaceuticals-deepen-partnership-to-advance-biologic-drug-development/2024-10-16T23:48:31+08:00https://flcube.com/bio-thera-solutions-bat1806-biosimilar-receives-european-commission-approval/2024-10-16T23:47:45+08:00https://flcube.com/antengenes-xpovio-included-in-south-koreas-nhis-reimbursement-drug-list/2024-10-16T23:46:55+08:00https://flcube.com/shanghais-phrontline-biopharma-secures-over-rmb-100-million-in-pre-series-a-funding-for-adc-development/2024-10-16T23:45:48+08:00https://flcube.com/harbour-biomed-resubmits-biological-license-application-for-batoclimab-in-china/2024-10-16T23:45:00+08:00https://flcube.com/shanghai-junshi-biosciences-toripalimab-gains-nmpa-nod-for-first-line-tnbc-treatment/2024-10-16T23:43:13+08:00https://flcube.com/hightide-therapeutics-completes-enrollment-for-two-phase-iii-trials-of-t2dm-drug-candidate-htd1801/2024-10-16T23:41:34+08:00https://flcube.com/cde-seeks-public-input-on-latest-batch-of-generic-chemical-reference-preparations/2024-10-16T23:40:12+08:00https://flcube.com/amoy-diagnostics-partners-with-servier-to-develop-companion-diagnostic-reagent-for-idh-mutations-in-china/2024-10-16T23:39:33+08:00https://flcube.com/jianke-com-chinas-leading-chronic-disease-management-platform-files-for-hong-kong-ipo/2024-10-16T23:37:28+08:00https://flcube.com/genscript-biotech-receives-over-usd-410-million-in-milestone-payments-for-car-t-therapy-from-janssen-biotech/2024-10-16T23:36:39+08:00https://flcube.com/shanghai-kehua-bioengineerings-subsidiary-to-acquire-remaining-stake-in-technogenetics-s-p-a/2024-10-16T23:34:06+08:00https://flcube.com/abbisko-therapeutics-presents-positive-phase-ii-results-for-hcc-treatment-at-esmo-gi/2024-10-16T23:31:12+08:00https://flcube.com/hybio-pharmaceutical-gets-fda-nod-for-tirzepatide-raw-materials-in-dmf-filing/2024-10-16T23:30:14+08:00https://flcube.com/novo-nordisk-moves-to-acquire-2seventy-bios-hemophilia-a-program-and-gene-editing-technology/2024-10-16T23:29:09+08:00https://flcube.com/novo-nordisk-plans-cautious-wegovy-launch-in-china-to-preserve-global-supply/2024-10-16T23:26:27+08:00https://flcube.com/abbvie-bolsters-inflammatory-disease-portfolio-with-celsius-therapeutics-acquisition/2024-10-16T23:24:45+08:00https://flcube.com/genmab-and-abbvies-epcoritamab-earns-fda-accelerated-approval-for-follicular-lymphoma/2024-10-16T23:23:38+08:00https://flcube.com/shandong-junxiu-biotechnology-partners-with-swiss-firm-geistlich-to-boost-regenerative-medicine/2024-10-16T23:21:57+08:00https://flcube.com/sirnaomics-stp707-shows-promising-results-in-phase-i-pancreatic-cancer-trial/2024-10-16T23:21:21+08:00https://flcube.com/luye-pharmas-manufacturing-facility-passes-fda-inspection-for-paliperidone-palmitate-product/2024-10-16T23:19:42+08:00https://flcube.com/takedas-ceo-weber-eyes-further-partnerships-with-chinese-biotechs-amid-innovation-surge/2024-10-16T23:18:56+08:00https://flcube.com/bio-thera-solutions-bat2094-wins-nmpa-nod-for-acute-coronary-syndrome-treatment/2024-10-16T23:16:19+08:00https://flcube.com/hasten-biopharmaceutical-expands-into-pan-asia-regions-with-celltrion-asset-acquisition/2024-10-16T23:15:10+08:00https://flcube.com/johnson-johnson-achieves-positive-phase-iii-results-for-nipocalimab-in-generalized-myasthenia-gravis/2024-10-16T23:13:53+08:00https://flcube.com/reckitts-new-shanghai-rd-center-to-boost-innovation-in-health-and-hygiene-products/2024-10-16T23:12:49+08:00https://flcube.com/cspc-pharmaceuticals-enronsubaimab-gets-nmpa-nod-for-recurrent-cervical-cancer/2024-10-16T23:11:05+08:00https://flcube.com/henlius-pharmaceuticals-hlx15-biosimilar-meets-phase-i-clinical-endpoints/2024-10-16T23:10:00+08:00https://flcube.com/chinas-nhsa-releases-2024-national-reimbursement-drug-list-adjustment-plan/2024-10-16T23:08:46+08:00https://flcube.com/yunnan-baiyao-group-secures-global-rights-to-kyinno-biotechnologys-antibody-drug-ka-1641/2024-10-16T23:08:10+08:00https://flcube.com/iaso-biotherapeutics-rd118-car-t-therapy-receives-clinical-trial-approval-for-multiple-myeloma/2024-10-16T23:07:01+08:00https://flcube.com/grand-pharmaceutical-group-ltds-sir-spheres-set-to-reach-wider-patient-base-through-meditrust-health-deal/2024-10-16T23:05:50+08:00https://flcube.com/cigna-cmb-life-insurance-partners-with-cleveland-clinic-foundation-to-enhance-medical-diagnosis-for-chinese-patients/2024-10-16T23:04:47+08:00https://flcube.com/hisense-medical-teams-up-with-tianjin-government-and-yujin-ai-for-intelligent-medical-rd/2024-10-16T23:03:01+08:00https://flcube.com/winning-health-partners-with-unicom-digitization-medical-to-boost-medical-industry-innovation/2024-10-16T23:01:36+08:00https://flcube.com/hinova-pharmaceuticals-hp518-earns-fda-fast-track-designation-for-ar-triple-negative-breast-cancer/2024-10-16T22:57:13+08:00https://flcube.com/healthcare-firms-line-up-for-hkex-ipos-as-biotech-market-recovery-gains-momentum/2024-10-16T22:54:54+08:00https://flcube.com/supercede-therapeutics-partners-with-shanghai-universities-for-anti-tumor-cachexia-drug-developmen/2024-10-16T22:51:19+08:00https://flcube.com/microport-endovascular-to-fully-acquire-optimum-medical-device-in-65m-deal/2024-10-16T22:49:33+08:00https://flcube.com/chinas-henlius-biotech-partners-with-sermonix-for-japan-development-of-breast-cancer-drug/2024-10-16T22:48:27+08:00https://flcube.com/chinas-sichuan-huiyu-pharmaceutical-halts-generic-cytosar-launch-following-strategy-review/2024-10-16T22:47:28+08:00https://flcube.com/chinas-cde-launches-pilot-program-for-electronic-drug-registration-filings/2024-10-16T22:46:35+08:00https://flcube.com/moon-biotech-secures-exclusive-state-owned-fund-investment-in-series-c-round/2024-10-16T22:45:56+08:00https://flcube.com/huadong-medicines-ror1-targeting-adc-hdm2005-receives-fda-clinical-trial-approval/2024-10-16T22:44:47+08:00https://flcube.com/boao-lecheng-approves-use-of-sanofis-tzield-as-first-line-therapy-for-type-1-diabetes-delay/2024-10-16T22:43:45+08:00https://flcube.com/scg-cell-therapy-receives-fda-approval-for-hpv-targeted-scg142-clinical-trial/2024-10-16T22:43:06+08:00https://flcube.com/yantai-dongcheng-pharmaceuticals-177lulnc1011-gets-fda-green-light-for-prostate-cancer-clinical-trial/2024-10-16T22:42:29+08:00https://flcube.com/ningbo-based-jenscare-scientific-announces-successful-follow-up-data-for-transjugular-tricuspid-valve-device/2024-10-16T22:40:33+08:00https://flcube.com/innovent-biologics-presents-positive-phase-i-results-for-ibi343-at-esmo-gi-congress-2024/2024-10-16T22:38:52+08:00https://flcube.com/pw-medtech-group-ltd-plans-independent-listing-of-rekind-medtec-on-neeq-to-boost-growth/2024-10-16T22:37:53+08:00https://flcube.com/us-forms-bio-5-coalition-with-global-powers-to-reduce-reliance-on-chinese-apis/2024-10-16T22:34:44+08:00https://flcube.com/tracon-pharmaceuticals-halts-development-of-envafolimab-after-clinical-trial-failure/2024-10-16T22:33:45+08:00https://flcube.com/boehringer-ingelheim-initiates-clinical-trial-for-novel-anti-obesity-drug/2024-10-16T22:32:29+08:00https://flcube.com/eli-lilly-co-strikes-deal-for-radionetics-gpcr-targeted-radiopharmaceuticals/2024-10-16T22:30:53+08:00https://flcube.com/lek-consultings-survey-reveals-biosecure-acts-impact-on-life-sciences-companies/2024-10-16T22:27:50+08:00https://flcube.com/johnson-johnsons-talvey-gets-green-light-in-south-korea-for-multiple-myeloma/2024-10-16T22:26:51+08:00https://flcube.com/legend-biotechs-carvykti-shows-significant-overall-survival-improvement-in-phase-iii-cartitude-4-study/2024-10-16T22:25:46+08:00https://flcube.com/mabpharms-biosimilar-infliximab-cmab807-receives-market-approval-in-peru/2024-10-16T22:24:25+08:00https://flcube.com/shanghai-henlius-biotech-advances-serplulimab-phase-iii-trial-for-first-line-metastatic-colorectal-cancer/2024-10-16T22:23:21+08:00https://flcube.com/remegen-reports-40-revenue-growth-in-2023-but-net-losses-widen-amid-pipeline-investments/2024-10-16T21:59:29+08:00https://flcube.com/everest-medicines-reports-884-revenue-surge-amid-rising-losses-and-strategic-shifts/2024-10-16T21:53:59+08:00https://flcube.com/astrazenecas-soriot-discusses-us-biosecure-acts-impact-amid-china-expansion-plans/2024-10-16T21:51:25+08:00https://flcube.com/shanghai-medicilon-forms-strategic-partnerships-with-binhui-biopharmaceutical-and-innoforce-pharmaceuticals/2024-10-16T21:48:37+08:00https://flcube.com/hutchmeds-orpathys-files-for-expanded-indication-in-nsclc-treatment-in-china/2024-10-16T21:45:04+08:00https://flcube.com/astellas-pharmas-padcev-combo-therapy-accepted-for-review-in-china-for-urothelial-carcinoma/2024-10-16T21:42:13+08:00https://flcube.com/china-unveils-management-measures-to-strengthen-national-health-emergency-teams/2024-10-16T21:39:13+08:00https://flcube.com/chinas-nhc-mandates-enhanced-management-and-accessibility-of-midwifery-services/2024-10-16T21:36:28+08:00https://flcube.com/astrazenecas-tralokinumab-trial-data-spurs-development-of-brainomixs-e-lung-software/2024-10-16T21:33:23+08:00https://flcube.com/luye-pharma-group-posts-2-7-yoy-revenue-growth-in-2023-with-strong-market-performance/2024-10-16T21:27:49+08:00https://flcube.com/microport-cardioflow-medtech-reports-33-9-yoy-revenue-growth-in-2023-financials/2024-10-16T21:24:55+08:00https://flcube.com/ascentage-pharma-reports-5-9-yoy-revenue-growth-in-2023-driven-by-product-sales/2024-10-16T21:21:44+08:00https://flcube.com/recbio-and-rongsheng-biotech-join-forces-to-develop-new-adjuvant-vaccine-technologies/2024-10-16T21:16:26+08:00https://flcube.com/tianjin-university-team-develops-self-sustaining-na-o2-battery-for-implantable-devices/2024-10-16T21:14:17+08:00https://flcube.com/zai-lab-and-novocure-report-positive-phase-iii-results-for-ttfields-in-nsclc-brain-metastases/2024-10-16T21:12:38+08:00https://flcube.com/shanghai-junshi-biosciences-reports-3-38-yoy-revenue-growth-in-2023-financials/2024-10-16T21:09:10+08:00https://flcube.com/shenzhen-hepalink-reports-2023-revenue-dip-amid-sector-demand-declines/2024-10-16T21:06:28+08:00https://flcube.com/innocare-pharma-reports-2023-revenue-growth-and-pipeline-expansion/2024-10-16T21:03:56+08:00https://flcube.com/regenxbio-reports-stable-visual-acuity-improvements-with-abbvies-gene-therapy-in-wet-amd-trial/2024-10-16T20:59:05+08:00https://flcube.com/gilead-strikes-deal-with-xilio-therapeutics-for-tumor-activated-il-12-candidate/2024-10-16T20:55:49+08:00https://flcube.com/alphamab-oncology-reports-31-12-revenue-growth-in-2023-with-continued-rd-focus/2024-10-16T20:53:40+08:00https://flcube.com/bio-thera-solutions-reports-54-86-yoy-revenue-growth-in-2023-led-by-biosimilar-sales/2024-10-16T20:50:05+08:00https://flcube.com/broncus-medical-inc-reports-32-yoy-growth-in-2023-highlighted-by-strength-in-china/2024-10-16T20:47:09+08:00https://flcube.com/allergan-aesthetics-launches-skinmedica-in-china-targeting-booming-skincare-market/2024-10-16T20:37:56+08:00https://flcube.com/innocare-pharma-initiates-phase-ib-study-combining-icp-189-with-furmonertinib-for-nsclc/2024-10-16T20:34:35+08:00https://flcube.com/novatim-immune-therapeutics-kq-2003-gains-tacit-approval-for-poems-syndrome-clinical-trial-in-china/2024-10-16T20:30:58+08:00https://flcube.com/harbour-biomed-reports-triple-digit-revenue-growth-and-first-ever-net-profit-in-2023-financial-results/2024-10-16T20:28:53+08:00https://flcube.com/hepalinks-enoxaparin-sodium-injection-receives-marketing-approval-in-new-zealand/2024-10-16T20:26:14+08:00https://flcube.com/iaso-biotherapeutics-gets-nmpa-go-ahead-for-bcma-targeted-car-t-therapy-clinical-trial/2024-10-16T20:21:05+08:00https://flcube.com/wuxi-apptec-denies-us-allegations-of-unauthorized-intellectual-property-transfer/2024-10-16T20:18:57+08:00https://flcube.com/chinas-national-joint-procurement-office-announces-renewal-of-insulin-procurement-contracts-valued-at-1-59-billion/2024-10-16T20:15:20+08:00https://flcube.com/fda-reviews-eisais-leqembi-for-expanded-use-as-monthly-alzheimers-therapy/2024-10-16T20:09:46+08:00https://flcube.com/wuxi-apptec-denies-unauthorized-ip-transfer-allegations-amidst-strong-financial-performance/2024-10-16T20:07:37+08:00https://flcube.com/boehringer-ingelheim-pledges-usd-5-million-to-who-foundation-for-global-healthcare-advancement/2024-10-16T16:06:04+08:00https://flcube.com/jj-reports-q3-2024-revenue-growth-raises-full-year-guidance-on-strong-pipeline-progress/2024-10-16T15:59:10+08:00https://flcube.com/shanghai-junshi-biosciences-toripalimab-wins-marketing-approvals-in-india-and-hong-kong-for-nasopharyngeal-carcinoma/2024-10-16T15:32:23+08:00https://flcube.com/eli-lilly-launches-medical-innovation-center-and-gateway-labs-in-beijing-to-accelerate-clinical-trials-and-rd/2024-10-16T15:25:36+08:00https://flcube.com/hinova-pharmaceuticals-gets-nmpa-green-light-for-hp568-clinical-study-in-breast-cancer/2024-10-16T14:20:24+08:00https://flcube.com/boehringer-ingelheim-partners-with-circle-pharma-to-develop-first-in-class-cyclin-inhibitor/2024-10-16T14:12:09+08:00https://flcube.com/tennor-therapeutics-secures-usd-42-16-million-in-series-e-financing-for-antibacterial-pipeline/2024-10-16T14:05:10+08:00https://flcube.com/huadong-medicine-gets-nmpa-green-light-for-bcma-targeted-adc-hdm2027-phase-i-iia-study/2024-10-16T14:00:06+08:00https://flcube.com/lepu-medical-receives-approval-for-noninvasive-blood-glucose-meter-neoglu-01-in-china/2024-10-16T13:53:55+08:00https://flcube.com/jiangsu-vcare-pharma-partners-with-geneseeq-technology-to-develop-companion-diagnostic-for-ntrk-inhibitor/2024-10-16T13:30:15+08:00https://flcube.com/eslicarbazepine-makes-first-appearance-in-china-at-sichuan-universitys-west-china-lecheng-hospital/2024-10-16T13:29:22+08:00https://flcube.com/novartis-launches-construction-of-first-radioligand-manufacturing-site-in-china/2024-10-16T13:28:00+08:00https://flcube.com/astellas-pharmas-xtandi-secures-third-market-approval-in-china-for-prostate-cancer-treatment/2024-10-16T13:26:39+08:00https://flcube.com/chengdu-based-vaccine-specialist-maxvax-biotechnology-raises-usd-41-3-million-in-latest-funding-round/2024-10-16T13:25:03+08:00https://flcube.com/astrazenecas-voydeya-receives-south-korean-approval-for-pnh-treatment/2024-10-16T13:21:12+08:00https://flcube.com/lg-chem-and-yifan-pharmaceutical-launch-hyruan-one-for-knee-osteoarthritis-in-china/2024-10-16T13:19:38+08:00https://flcube.com/chinas-hiro-expands-us-presence-with-acquisition-of-new-jersey-based-deltamed-solutions/2024-10-16T13:17:40+08:00https://flcube.com/gsk-secures-global-rights-to-curevacs-mrna-vaccine-candidates-in-expanded-partnership/2024-10-16T13:16:54+08:00https://flcube.com/amgen-secures-commercialization-rights-for-avacopan-in-asia-and-latin-america/2024-10-16T13:14:52+08:00https://flcube.com/cstone-pharmaceuticals-partners-with-hengrui-for-promotion-of-ayvakit-in-china/2024-10-16T13:13:26+08:00https://flcube.com/philips-appoints-liu-ling-as-greater-china-president-amid-leadership-changes/2024-10-16T13:11:27+08:00https://flcube.com/blue-sail-medicals-fastroad-catheter-earns-nmpa-marketing-approval/2024-10-16T13:10:51+08:00https://flcube.com/hutchmeds-tazverik-for-follicular-lymphoma-accepted-for-review-by-chinas-nmpa/2024-10-16T13:09:40+08:00https://flcube.com/full-life-technologies-%c2%b2%c2%b2%e2%81%b5ac-fl-020-earns-fda-fast-track-status-for-mcrpc/2024-10-16T13:08:26+08:00https://flcube.com/ascentage-pharma-receives-usd-100-million-option-rights-payment-from-takeda/2024-10-16T13:07:37+08:00https://flcube.com/united-imaging-healthcare-to-launch-financial-leasing-arm-with-rmb-450-million-investment/2024-10-16T13:06:10+08:00https://flcube.com/guangzhou-pluslife-partners-with-gates-foundation-to-combat-stis-in-low-income-countries/2024-10-16T13:04:53+08:00https://flcube.com/genertec-and-cthg-fund-invest-in-neusoft-medical-systems-to-boost-medical-imaging/2024-10-16T13:03:45+08:00https://flcube.com/sanofis-rsv-preventative-therapy-beyfortus-launches-in-china/2024-10-16T11:30:46+08:00https://flcube.com/jjs-rybrevant-earns-first-line-nsclc-approval-in-canada-a-milestone-for-egfr-exon-20-patients/2024-10-16T11:29:17+08:00https://flcube.com/semaglutide-use-linked-to-rare-eye-condition-naion-in-new-study/2024-10-16T11:28:11+08:00https://flcube.com/luye-pharmas-oxycodone-naloxone-product-receives-nmpa-approval-for-severe-pain-management/2024-10-16T11:27:16+08:00https://flcube.com/doma-biopharmaceuticals-bispecific-adc-dm001-receives-fda-clearance-for-clinical-trial/2024-10-16T11:25:17+08:00https://flcube.com/singlera-genomics-secures-over-rmb-100-million-in-strategic-financing-to-boost-rd-and-commercialization/2024-10-16T11:24:06+08:00https://flcube.com/microport-scientific-corps-subsidiaries-forecast-significant-h1-2024-revenue-growth/2024-10-16T11:23:20+08:00https://flcube.com/medigene-ag-secures-chinese-patent-for-tcr-t-therapy-targeting-ny-eso-1-and-lage-1a/2024-10-16T11:21:09+08:00https://flcube.com/pharmaceutical-giants-face-uk-industry-code-breach-allegations-including-novartis-and-pfizer/2024-10-16T11:19:21+08:00https://flcube.com/kindstar-global-and-mgi-tech-co-ltd-form-partnership-to-establish-multi-omics-service-center-in-china/2024-10-16T11:16:00+08:00https://flcube.com/sirnaomics-stp122g-achieves-phase-i-milestone-with-positive-interim-data-for-anticoagulation-treatment/2024-10-16T11:14:17+08:00https://flcube.com/antengenes-xpovio-secures-nmpa-approval-for-r-r-diffuse-large-b-cell-lymphoma/2024-10-16T11:13:00+08:00https://flcube.com/daiichi-sankys-mirogabalin-gets-green-light-from-china-for-diabetic-neuropathic-pain/2024-10-16T11:11:27+08:00https://flcube.com/amoytop-biotechs-peginterferon-%ce%b1-2b-receives-nmpa-approval-for-primary-thrombocytosis-clinical-trial/2024-10-16T11:10:07+08:00https://flcube.com/easton-pharmaceutical-receives-nmpa-approval-for-generic-oxcarbazepine/2024-10-16T11:08:42+08:00https://flcube.com/hinova-pharmaceuticals-hp537-receives-fda-approval-for-phase-i-ii-clinical-trial-in-hematologic-malignancies/2024-10-16T11:07:23+08:00https://flcube.com/pharmaessentias-besremi-receives-approval-for-polycythemia-vera-treatment-in-china/2024-10-16T11:05:37+08:00https://flcube.com/chinas-national-joint-procurement-office-unveils-renewed-insulin-procurement-contracts/2024-10-16T10:55:26+08:00https://flcube.com/fda-reviews-eisais-monthly-maintenance-therapy-for-early-alzheimers-with-leqembi/2024-10-16T10:52:11+08:00https://flcube.com/chinese-scientists-discover-breakthrough-biodegradable-piezoelectric-material-for-medical-implants/2024-10-16T10:46:22+08:00https://flcube.com/chinas-cnipa-upholds-patent-for-nobel-winning-crispr-cas9-gene-editing-technology/2024-10-16T10:43:14+08:00https://flcube.com/shanghai-unveils-massive-investment-projects-and-funds-to-boost-high-tech-industries/2024-10-16T10:40:49+08:00https://flcube.com/kobayashi-pharmaceutical-faces-expanding-scandal-over-contaminated-red-yeast-rice-supplements/2024-10-16T10:32:50+08:00https://flcube.com/beijings-changping-district-and-state-owned-capital-firm-launch-rmb-20-billion-healthcare-fund/2024-10-16T10:30:26+08:00https://flcube.com/abiomed-recalls-over-66000-impella-heart-pumps-due-to-serious-injury-risk-fda-classifies-as-class-i-event/2024-10-16T10:27:43+08:00https://flcube.com/zai-lab-announces-positive-phase-iii-data-for-krazati-in-krasg12c-mutated-nsclc-plans-nda-filing-in-china/2024-10-16T10:24:31+08:00https://flcube.com/alexions-voydeya-earns-fda-nod-as-add-on-therapy-for-pnh-associated-extravascular-hemolysis/2024-10-16T10:20:54+08:00https://flcube.com/viatris-launches-ryzumvi-in-the-us-for-rapid-reversal-of-pharmacologically-induced-pupil-dilation/2024-10-16T10:18:33+08:00https://flcube.com/huihe-healthcares-vispearl-microsphere-earns-marketing-approval-in-china-for-innovative-cancer-treatment/2024-10-16T10:16:21+08:00https://flcube.com/jjs-nipocalimab-fast-tracked-by-fda-for-reducing-fnait-risk-in-pregnant-adults/2024-10-16T10:12:52+08:00https://flcube.com/us-lawmakers-expand-scrutiny-on-chinese-biotech-firms-with-potential-military-ties/2024-10-16T10:10:18+08:00https://flcube.com/legend-biotech-and-janssen-pharmaceutical-expand-partnership-with-novartis-for-carvykti-production/2024-10-16T10:03:08+08:00https://flcube.com/danaher-corporation-partners-with-chongqing-liang-jiang-new-area-to-establish-western-innovation-center/2024-10-16T09:59:27+08:00https://flcube.com/china-medical-system-expands-portfolio-with-incytes-povorcitinib-for-autoimmune-diseases/2024-10-16T09:57:05+08:00https://flcube.com/shanghai-fosun-pharma-and-meiji-seika-pharma-launch-phase-iii-studies-for-anti-infective-nacubactam/2024-10-16T09:53:58+08:00https://flcube.com/johnson-johnson-medtech-launches-cpx4-plus-tissue-expander-for-breast-reconstruction-in-china/2024-10-16T09:48:39+08:00https://flcube.com/etern-therapeutics-secures-funding-to-advance-llps-platform-and-clinical-trials-for-anti-tumor-drugs/2024-10-16T09:45:57+08:00https://flcube.com/junshi-biosciences-gets-green-light-for-global-phase-iii-study-of-tifcemalimab-combination-therapy-in-ls-sclc/2024-10-16T09:43:59+08:00https://flcube.com/novo-nordisks-esperoct-receives-nmpa-approval-first-long-acting-factor-viii-for-hemophilia-a-in-china/2024-10-16T00:44:15+08:00https://flcube.com/roches-alecensa-secures-nmpa-approval-as-adjuvant-therapy-for-early-stage-nsclc/2024-10-16T00:41:39+08:00https://flcube.com/shenzhen-salubris-pharmaceuticals-fotagliptin-receives-nmpa-approval-for-type-2-diabetes-treatment/2024-10-16T00:40:27+08:00https://flcube.com/yantai-dongcheng-pharmaceutical-gets-nmpa-approval-for-%e2%81%b9%e2%81%b9%e1%b5%90tc-tetrofosmin-imaging-agent/2024-10-16T00:38:56+08:00https://flcube.com/ausperbios-ahb-137-antiviral-candidate-on-path-to-breakthrough-designation-for-chronic-hepatitis-b-in-china/2024-10-16T00:37:21+08:00https://flcube.com/chinas-state-council-reportedly-approves-plan-to-support-full-industry-chain-of-innovative-drug-development/2024-10-16T00:36:29+08:00https://flcube.com/allist-pharmaceuticals-receives-nmpa-approval-for-phase-iii-trial-of-furmonertinib-in-egfr-mutated-nsclc/2024-10-16T00:35:48+08:00https://flcube.com/cspc-pharmaceuticals-sys6023-receives-fda-approval-for-clinical-study-in-advanced-solid-tumors/2024-10-16T00:34:44+08:00https://flcube.com/shanghai-fosun-pharmaceutical-gets-nmpa-green-light-for-fh-2001-and-serplulimab-combo-clinical-trial/2024-10-16T00:33:09+08:00https://flcube.com/keymed-biosciences-strikes-licensing-deal-with-belenos-biosciences-for-global-bsab-rights/2024-10-16T00:28:36+08:00https://flcube.com/ascentage-pharmas-olverembatinib-receives-marketing-approval-from-macau-sar-for-cml-treatment/2024-10-16T00:27:30+08:00https://flcube.com/boston-scientifics-farapulse-pulse-field-ablation-system-earns-nmpa-approval/2024-10-16T00:25:02+08:00https://flcube.com/roches-susvimo-implant-cleared-for-relaunch-in-us-after-voluntary-recall/2024-10-16T00:23:49+08:00https://flcube.com/eli-lilly-co-to-acquire-morphic-holding-inc-in-a-usd-3-2-billion-deal/2024-10-16T00:22:18+08:00https://flcube.com/moderna-partners-with-mitsubishi-tanabe-for-mrna-vaccine-promotion-in-japan/2024-10-16T00:21:03+08:00https://flcube.com/hugo-biotech-partners-with-watchmaker-genomics-to-develop-infectious-disease-detection-solutions/2024-10-16T00:19:54+08:00https://flcube.com/hob-biotech-receives-nmpa-approval-for-clinical-trials-of-mm09-sublingual-spray/2024-10-16T00:19:16+08:00https://flcube.com/shandong-buchang-pharmaceuticals-receives-nmpa-approval-for-bc008-1a-biologic-product-clinical-trial/2024-10-16T00:17:52+08:00https://flcube.com/us-house-speaker-mike-johnson-revives-possibility-of-biosecure-act-vote/2024-10-16T00:16:07+08:00https://flcube.com/grit-biotechnology-and-quangang-pharmaceutical-co-ltd-partner-to-develop-til-and-il-2-combination-therapy/2024-10-16T00:15:36+08:00https://flcube.com/gsk-china-vaccine-head-peggy-fung-resigns-departure-set-for-mid-august/2024-10-16T00:14:40+08:00https://flcube.com/johnson-johnsons-opsumit-faces-generic-competition-with-qilu-pharmaceuticals-entry/2024-10-16T00:11:36+08:00https://flcube.com/shanghai-junshi-biosciences-hdac-inhibitor-js125-clinical-trial-application-accepted-by-nmpa/2024-10-16T00:09:42+08:00https://flcube.com/suzhou-sanegene-bio-receives-nmpa-approval-for-clinical-trial-of-antihypertensive-sirna-drug/2024-10-16T00:08:06+08:00https://flcube.com/kintor-pharmaceutical-launches-global-cosmetic-line-with-hair-loss-treatment-pyrilutamide/2024-10-16T00:06:43+08:00https://flcube.com/shanghai-vitalgen-biopharma-launches-phase-i-ii-gene-therapy-trial-for-parkinsons-disease/2024-10-16T00:05:33+08:00https://flcube.com/bgi-genomics-subsidiary-inks-3-year-noninvasive-prenatal-test-agreement-with-heilongjiang-province/2024-10-16T00:04:30+08:00https://flcube.com/kymera-therapeutics-stock-soars-on-sanofis-plans-to-expand-kt-474-clinical-trials/2024-10-16T00:03:38+08:00https://flcube.com/amgen-halts-development-of-claudin-6-targeting-bite-immune-therapy-amg-794/2024-10-16T00:02:09+08:00https://flcube.com/aft-pharmaceuticals-partners-with-hainan-haiyao-for-distribution-of-crystaderm-cream-in-china/2024-10-16T00:00:42+08:00https://flcube.com/junshi-biosciences-subsidiary-secures-eu-gmp-certification-strengthening-loqtorzis-market-prospects/2024-10-15T23:58:46+08:00https://flcube.com/abbisko-therapeutics-forecasts-profits-and-revenue-boost-in-h1-2024-on-merck-deal/2024-10-15T23:56:54+08:00https://flcube.com/novo-nordisk-partners-with-indonesias-bio-farma-to-boost-asia-pacific-diabetes-drug-production/2024-10-15T23:55:55+08:00https://flcube.com/pfizer-collaborates-with-evotec-for-drug-candidates-in-metabolic-and-infectious-diseases/2024-10-15T23:49:38+08:00https://flcube.com/pfizer-and-abbvie-announce-leadership-changes-in-global-rd-divisions/2024-10-15T23:48:46+08:00https://flcube.com/digital-health-china-partners-with-huawei-to-launch-intelligent-multimodal-big-data-system-for-healthcare/2024-10-15T23:47:20+08:00https://flcube.com/bayer-restructures-china-business-into-five-sectors-and-six-departments/2024-10-15T23:46:43+08:00https://flcube.com/allist-pharmaceuticals-faces-arbitration-over-promotion-agreement-for-furmonertinib/2024-10-15T23:45:38+08:00https://flcube.com/biokin-pharmaceutical-co-ltd-eyes-secondary-listing-on-hkex-co-sponsored-by-goldman-sachs-and-others/2024-10-15T23:44:57+08:00https://flcube.com/kechow-pharmas-keluping-first-nras-mutant-melanoma-therapy-hits-the-market/2024-10-15T23:43:34+08:00https://flcube.com/salus-biotech-partners-with-xian-jiaotong-university-for-single-cell-omics-innovation/2024-10-15T23:42:45+08:00https://flcube.com/danaher-corporation-launches-western-innovation-center-in-chongqing/2024-10-15T23:42:04+08:00https://flcube.com/sichuan-biokin-pharmaceutical-gets-nmpa-approval-for-bl-m14d1-clinical-trial-in-solid-tumors/2024-10-15T23:32:12+08:00https://flcube.com/cspc-pharmaceuticals-rsv-mrna-vaccine-sys6016-receives-clinical-trial-approval-from-nmpa/2024-10-15T23:30:41+08:00https://flcube.com/novo-nordisks-awiqli-faces-fda-setback-as-bla-draws-complete-response-letter/2024-10-15T23:29:28+08:00https://flcube.com/pfizers-once-daily-danuglipron-selected-for-full-clinical-development-for-type-2-diabetes-and-obesity/2024-10-15T23:27:54+08:00https://flcube.com/eisai-and-biogens-alzheimers-therapy-leqembi-receives-marketing-approval-in-hong-kong/2024-10-15T23:26:12+08:00https://flcube.com/ipsen-strikes-global-licensing-deal-with-foreseen-biotechnology-for-first-in-class-adc-fs001/2024-10-15T23:24:58+08:00https://flcube.com/shanghai-escugen-initiates-phase-iii-clinical-trial-for-breast-cancer-drug-candidate-esg401/2024-10-15T23:23:18+08:00https://flcube.com/medtronic-launches-advanced-signia-stapler-in-china-expanding-surgical-capabilities/2024-10-15T23:22:29+08:00https://flcube.com/beijing-tsingke-biotech-partners-with-zhejiang-universitys-innovation-center-for-nucleic-acid-drug-delivery/2024-10-15T23:19:26+08:00https://flcube.com/simcere-pharmaceuticals-covid-19-therapy-xiannuoxin-earns-full-approval-in-china/2024-10-15T23:18:43+08:00https://flcube.com/oxford-study-clears-semaglutide-of-neuro-psychiatric-risks-suggests-cognitive-and-addiction-benefits/2024-10-15T23:17:22+08:00https://flcube.com/legend-biotechs-shares-leap-on-acquisition-rumors-parent-genscript-biotech-corp-follows-suit/2024-10-15T23:16:08+08:00https://flcube.com/leqembi-alzheimers-drug-by-eisai-and-biogen-now-covered-by-qihuibao-insurance-in-china/2024-10-15T16:59:02+08:00https://flcube.com/bayer-ag-and-meituan-deepen-partnership-to-transform-skin-health-market-in-china/2024-10-15T16:51:33+08:00https://flcube.com/eli-lillys-mirikizumab-shows-statistically-significant-improvement-in-crohns-disease-vivid-1-study/2024-10-15T16:27:39+08:00https://flcube.com/humanwell-healthcare-secures-nmpa-approval-for-clinical-trial-of-hw211026-to-treat-actinic-keratosis/2024-10-15T16:22:21+08:00https://flcube.com/thermo-fisher-faces-fda-scrutiny-over-syringe-air-bubble-protocols-at-north-carolina-plant/2024-10-15T16:17:23+08:00https://flcube.com/united-laboratories-tul12101-eye-drops-enter-phase-iia-clinical-trial-for-dry-eye-syndrome/2024-10-15T16:08:20+08:00https://flcube.com/3d-medicines-envafolimab-earns-nmpa-breakthrough-designation-for-tmb-h-solid-tumors/2024-10-15T16:02:27+08:00https://flcube.com/roches-vabysmo-receives-nmpa-approval-for-macular-edema-treatments-in-china/2024-10-15T15:54:05+08:00https://flcube.com/intas-pharmaceuticals-receives-fda-approval-for-biosimilar-stelara-expanding-treatment-options-for-autoimmune-diseases/2024-10-15T15:48:11+08:00https://flcube.com/beijing-aims-to-build-a-leading-cell-and-gene-therapy-hub-by-2026-with-new-action-plan/2024-10-15T15:34:24+08:00https://flcube.com/remegens-disitamab-vedotin-receives-priority-review-for-new-indication-in-breast-cancer-by-chinas-nmpa/2024-10-15T15:25:57+08:00https://flcube.com/stemirna-therapeutics-once-a-leading-mrna-developer-in-china-enters-bankruptcy-proceedings/2024-10-15T15:07:40+08:00https://flcube.com/novo-nordisk-expands-legal-campaign-to-50-cases-against-semaglutide-compounders/2024-10-15T15:03:12+08:00https://flcube.com/oricell-therapeutics-gprc5d-targeted-car-t-therapy-earns-fda-fast-track-for-multiple-myeloma/2024-10-15T14:52:57+08:00https://flcube.com/nmpa-accepts-3sbios-filing-for-anemia-treatment-sss06-potential-game-changer-for-dialysis-patients/2024-10-15T14:48:35+08:00https://flcube.com/shanghai-duoning-biotechnology-partners-with-basf-se-to-commercialize-medical-materials-in-china/2024-10-15T14:47:07+08:00https://flcube.com/mabwell-biosciences-9mw2821-earns-fda-fast-track-designation-for-triple-negative-breast-cancer/2024-10-15T14:45:59+08:00https://flcube.com/ausperbio-secures-37-million-in-series-a-funding-to-advance-hepatitis-b-therapy-ahb-137/2024-10-15T14:44:25+08:00https://flcube.com/merck-kgaa-launches-first-gmp-cell-culture-medium-production-line-in-china/2024-10-15T14:43:14+08:00https://flcube.com/e-health-now-secures-usd-13-8-million-in-series-c-financing-to-expand-ai-medical-services/2024-10-15T14:40:32+08:00https://flcube.com/shenzhen-based-national-biological-manufacturing-innovation-center-breaks-ground/2024-10-15T14:39:51+08:00https://flcube.com/mindray-bio-medical-partners-with-nanjing-municipal-government-to-boost-healthcare-innovation/2024-10-15T14:38:52+08:00https://flcube.com/huadong-medicines-partner-arcutis-gets-fda-nod-for-roflumilast-cream/2024-10-15T14:37:19+08:00https://flcube.com/everest-medicines-velsipity-shows-positive-results-in-largest-asian-phase-iii-uc-trial/2024-10-15T14:34:20+08:00https://flcube.com/eisais-next-gen-serd-orserdu-begins-real-world-study-in-shanghai-ruijin-hospitals-hainan-subsidiary/2024-10-15T14:32:46+08:00https://flcube.com/nona-biosciences-partners-with-alaya-bio-to-revolutionize-car-t-therapy-development/2024-10-15T14:30:27+08:00https://flcube.com/u-s-senate-passes-affordable-prescriptions-for-patients-act-to-limit-patent-thicketing/2024-10-15T14:29:17+08:00https://flcube.com/ipsen-s-a-receives-nmpa-green-light-for-six-month-diphereline-dosage-in-central-precocious-puberty/2024-10-15T14:26:19+08:00https://flcube.com/novo-nordisk-faces-us-senators-scrutiny-over-levemir-withdrawal/2024-10-15T14:21:25+08:00https://flcube.com/lionco-pharmaceutical-partners-with-laboratoire-bailly-creat-to-expand-overseas/2024-10-15T14:08:08+08:00https://flcube.com/mabwell-bioscience-receives-nmpa-approval-for-phase-ii-tnbc-clinical-trial-of-9mw2821/2024-10-15T14:06:19+08:00https://flcube.com/shenzhen-tyercan-bio-pharmas-tye1001-earns-tacit-ind-approval-from-fda-for-advanced-solid-tumors/2024-10-15T14:04:49+08:00https://flcube.com/betta-pharmaceuticals-eyp-1901-implant-secures-nmpa-clinical-trial-nod-for-wet-amd/2024-10-15T14:03:43+08:00https://flcube.com/sichuan-huiyus-hy07121-antifungal-protein-earns-nmpa-review-for-clinical-trials/2024-10-15T14:01:29+08:00https://flcube.com/sino-biopharmaceuticals-rovadicitinib-gets-cde-nod-for-review-in-myelofibrosis/2024-10-15T14:00:04+08:00https://flcube.com/celling-biotechnologys-cel001-earns-tacit-approval-for-clinical-trials-in-china/2024-10-15T13:58:42+08:00https://flcube.com/eli-lillys-lupus-treatment-ly3361237-misses-mark-in-phase-ii-trial/2024-10-15T13:56:54+08:00https://flcube.com/mgi-tech-partners-with-predica-diagnostics-to-advance-rna-sequencing-in-cancer-detection/2024-10-15T13:55:16+08:00https://flcube.com/united-imaging-expands-latin-america-footprint-with-pediatric-umi-550-pet-ct-launch-in-mexico/2024-10-15T13:54:12+08:00https://flcube.com/full-life-technologies-strikes-usd-571-5-million-licensing-deal-with-sk-biopharmaceuticals-for-radiopharmaceutical-asset/2024-10-15T13:40:52+08:00https://flcube.com/sino-biopharmaceuticals-anlotinib-achieves-milestones-in-phase-iii-trial-for-soft-tissue-sarcoma/2024-10-15T13:39:16+08:00https://flcube.com/ocumension-therapeutics-and-shandong-boan-biotechnology-file-for-market-approval-of-biosimilar-aflibercept-in-china/2024-10-15T13:37:32+08:00https://flcube.com/jiangsu-simcere-pharmaceuticals-quviviq-approval-application-accepted-for-review-by-chinas-nmpa/2024-10-15T13:33:20+08:00https://flcube.com/shanghai-pharmaceuticals-secures-nmpa-nod-for-roches-valcyte-generic/2024-10-15T13:29:20+08:00https://flcube.com/mabwell-bioscience-lands-orphan-drug-status-for-b7-h3-targeting-adc-in-small-cell-lung-cancer/2024-10-15T13:25:04+08:00https://flcube.com/zai-lab-and-argenx-receive-nmpa-approval-for-vygart-hytrulo-efgartigimod-alfa-sc-in-gmg/2024-10-15T13:00:03+08:00https://flcube.com/sionna-therapeutics-secures-cystic-fibrosis-portfolio-in-licensing-deal-with-abbvie/2024-10-15T12:28:53+08:00https://flcube.com/eisai-co-ltd-secures-asia-pacific-rights-for-fungal-drug-with-sato-pharma-deal/2024-10-15T12:27:19+08:00https://flcube.com/guotai-junan-and-haitong-securities-to-launch-10-billion-in-industry-funds-in-shanghai/2024-10-15T12:25:32+08:00https://flcube.com/cr-boya-bio-pharmaceuticals-strategic-foray-acquiring-green-cross-hk-for-250m-to-expand-biopharma-dominance/2024-10-15T12:24:14+08:00https://flcube.com/sanofi-to-bolster-hyderabad-facility-with-437m-investment-eyeing-tech-upgrades/2024-10-15T12:22:31+08:00https://flcube.com/everest-medicines-nefecon-receives-nmpa-review-signaling-potential-treatment-milestone-for-igan-patients/2024-10-15T12:20:35+08:00https://flcube.com/china-grand-pharmaceutical-expands-with-mitsubishi-tanabe-pharma-and-baiji-pharma-acquisitions/2024-10-15T12:18:43+08:00https://flcube.com/boston-scientific-secures-silk-road-medical-in-a-1-16b-deal-to-fortify-stroke-prevention-portfolio/2024-10-15T12:17:12+08:00https://flcube.com/synyi-ai-secures-new-funding-to-accelerate-digital-transformation-in-healthcare/2024-10-15T12:15:06+08:00https://flcube.com/junshi-biosciences-loqtorzi-inches-closer-to-expanded-indication-with-nmpa-filing-acceptance/2024-10-15T12:13:21+08:00https://flcube.com/shanghai-escugen-and-sidewinder-therapeutics-form-strategic-alliance-for-adc-development/2024-10-15T12:10:55+08:00https://flcube.com/johnson-johnson-reports-robust-q2-2024-earnings-bolstered-by-pharma-and-medtech-growth/2024-10-15T12:10:10+08:00https://flcube.com/roches-genentech-terminates-relay-therapeutics-collaboration-for-shp2-inhibitor/2024-10-15T12:08:48+08:00https://flcube.com/shanghai-ruijin-hospitals-hainan-subsidiary-adopts-ani-pharmaceuticals-veregen-for-hpv-treatment/2024-10-15T12:07:29+08:00https://flcube.com/consun-pharmaceutical-gets-nmpa-go-ahead-for-ckd-drug-clinical-trial/2024-10-15T12:06:06+08:00https://flcube.com/neushen-therapeutics-and-livzon-pharma-strike-deal-for-greater-china-rights-to-ns-041/2024-10-15T12:03:07+08:00https://flcube.com/suzhou-new-district-hi-tech-industrial-co-ltd-and-subsidiaries-to-establish-biopharmaceutical-fof-with-snd-group/2024-10-15T12:01:49+08:00https://flcube.com/shanghai-sanyou-medicals-cervical-thoracic-internal-fixation-system-earns-nmpa-approval/2024-10-15T11:59:47+08:00https://flcube.com/anhui-anke-biotechnology-receives-nmpa-clearance-for-clinical-trial-of-mrna-drug-afn0328-for-hpv-related-cancers/2024-10-15T11:58:25+08:00https://flcube.com/venus-medtechs-venusp-valve-receives-marketing-approval-in-venezuela-expanding-global-reach/2024-10-15T11:56:48+08:00https://flcube.com/microport-medtechs-vepack-filter-retriever-earns-nmpa-marketing-approval/2024-10-15T11:55:26+08:00https://flcube.com/bain-capital-backed-tenacia-wins-nmpa-approval-for-ganaxolone-oral-suspension-for-cdkl5-deficiency/2024-10-15T11:54:03+08:00https://flcube.com/chinas-nmpa-suspends-daewoong-bios-cefodizime-over-inspection-refusal/2024-10-15T11:52:18+08:00https://flcube.com/china-issues-ethical-guidelines-for-human-genome-editing-prohibits-germline-editing/2024-10-15T11:51:01+08:00https://flcube.com/eli-lillys-mounjaro-approved-by-chinas-nmpa-for-long-term-weight-management/2024-10-15T11:50:19+08:00https://flcube.com/sino-biopharmaceutical-submits-market-approval-filing-for-cdk2-4-6-inhibitor-culmerciclib-in-breast-cancer/2024-10-15T11:48:28+08:00https://flcube.com/abbott-laboratories-reports-q2-2024-sales-growth-of-9-3-led-by-medical-devices-and-diabetes-sales/2024-10-15T11:46:55+08:00https://flcube.com/jj-halts-development-of-epilepsy-therapy-adx71149-after-phase-ii-trial-failure/2024-10-15T11:45:51+08:00https://flcube.com/novartis-delivers-strong-q2-2024-results-with-11-yoy-net-sales-increase/2024-10-15T11:44:21+08:00https://flcube.com/bio-thera-solutions-submits-blas-for-stelara-biosimilar-bat2206-to-fda-and-ema/2024-10-15T11:43:20+08:00https://flcube.com/apeiron-therapeutics-sells-rights-to-cdk7-inhibitor-gtaexs617-to-exscientia-for-usd-30-million/2024-10-15T11:40:39+08:00https://flcube.com/bgi-genomics-and-technopark-biogen-launch-astana-genetic-center-to-boost-genetic-testing-in-central-asia/2024-10-15T11:38:58+08:00https://flcube.com/beijing-x-magtech-secures-over-rmb-100-million-in-series-a-funding-for-magnetic-field-measurement-tech/2024-10-15T11:37:44+08:00https://flcube.com/huadong-medicine-to-expand-tcm-footprint-with-acquisition-of-hengba-pharmaceutical/2024-10-15T11:36:57+08:00https://flcube.com/rona-therapeutics-secures-usd-35-million-in-series-a-round-to-advance-nucleic-acid-therapies/2024-10-15T11:35:48+08:00https://flcube.com/medsci-healthcares-bioon-com-partners-with-wego-group-to-boost-local-innovation-and-product-promotion/2024-10-15T11:34:58+08:00https://flcube.com/eisai-forges-partnerships-with-chinese-firms-to-strengthen-alzheimers-disease-market-presence/2024-10-15T11:33:57+08:00https://flcube.com/hansoh-pharmaceuticals-egfr-inhibitor-ameile-files-for-adjuvant-therapy-approval-with-nmpa/2024-10-15T11:28:15+08:00https://flcube.com/china-unveils-ambitious-healthcare-reforms-at-20th-central-committee-plenary-session/2024-10-15T11:23:40+08:00https://flcube.com/innovent-biologics-mazdutide-achieves-primary-and-secondary-endpoints-in-phase-iii-t2d-trial/2024-10-15T11:22:54+08:00https://flcube.com/jiangsu-qyuns-therapeutics-and-huadong-medicine-partner-on-qx005n-injection-development-and-promotion/2024-10-15T11:20:43+08:00https://flcube.com/chinas-nmpa-and-nhc-implement-new-rules-for-temporary-import-of-urgent-medical-devices/2024-10-15T11:12:02+08:00https://flcube.com/microport-cardioflow-secures-exclusive-distribution-rights-for-evermend-occluders-in-china/2024-10-15T11:11:20+08:00https://flcube.com/beijing-launches-bio-park-a-new-hub-for-international-pharmaceutical-innovation/2024-10-15T11:09:43+08:00https://flcube.com/icer-analysis-flags-pfizers-attr-cm-therapy-vyndamax-vyndaqel-as-costly-suggests-price-cut/2024-10-15T11:07:40+08:00https://flcube.com/luye-pharma-group-secures-rmb-1-6-billion-investment-to-boost-financials-and-rd/2024-10-15T11:06:06+08:00https://flcube.com/accuredit-therapeutics-receives-cde-approval-for-gene-editing-drug-art001-targeting-amyloidosis/2024-10-15T11:04:18+08:00https://flcube.com/fosun-pharma-and-kite-pharma-inject-usd-28-5-million-into-joint-venture-for-car-t-therapy-development/2024-10-15T10:56:12+08:00https://flcube.com/nmpa-suspends-import-and-sale-of-samo-s-p-a-knee-and-hip-prosthesis-systems/2024-10-15T10:53:25+08:00https://flcube.com/remegens-telitacicept-earns-full-nmpa-approval-for-ra-treatment-and-pmn-clinical-study-green-light/2024-10-15T10:52:49+08:00https://flcube.com/chinas-triastek-and-germanys-biontech-join-forces-for-3d-printed-oral-therapeutics/2024-10-15T10:51:40+08:00https://flcube.com/wuxi-apptec-spends-over-usd-360000-on-us-lobbying-amid-biosecure-act-deliberations/2024-10-15T10:49:34+08:00https://flcube.com/johnson-johnson-pursues-fda-approval-for-spravato-as-monotherapy-for-treatment-resistant-depression/2024-10-15T10:48:00+08:00https://flcube.com/chinas-nmpa-considers-breakthrough-designations-for-xiangxue-and-innostellars-therapies/2024-10-15T10:44:21+08:00https://flcube.com/innovax-biotech-and-gsk-terminate-collaboration-on-next-generation-hpv-vaccine/2024-10-15T10:42:37+08:00https://flcube.com/jiangsu-hansohs-loxenatide-matches-dapagliflozin-in-diabetes-nephropathy-clinical-trial/2024-10-15T10:40:36+08:00https://flcube.com/chinas-nhsa-updates-drg-dip-payment-reform-program-with-new-exclusion-mechanisms-and-timelines/2024-10-15T10:39:09+08:00https://flcube.com/pfizer-launches-sgd-1-billion-api-plant-expansion-in-singapore-creating-250-new-jobs/2024-10-15T10:38:23+08:00https://flcube.com/viiv-healthcares-dovato-shows-non-inferior-efficacy-and-less-weight-gain-in-pivotal-paso-doble-study/2024-10-15T10:37:00+08:00https://flcube.com/shanghai-desano-and-chongqing-kangfude-partner-to-establish-peptide-drug-production-base-in-china/2024-10-15T10:35:22+08:00https://flcube.com/anhui-anke-biotechnology-receives-nmpa-approval-for-clinical-trial-of-hpv-targeting-mrna-drug-afn0328/2024-10-15T10:32:58+08:00https://flcube.com/bayers-bay-3375968-receives-nmpa-approval-for-clinical-trial-in-advanced-solid-tumors/2024-10-15T10:30:22+08:00https://flcube.com/innornas-herpes-zoster-mrna-vaccine-in001-receives-clinical-trial-approval-in-china/2024-10-15T10:28:07+08:00https://flcube.com/hangzhou-jianjia-medicals-arthbot-surgical-robot-receives-nmpa-approval-for-orthopedic-procedures/2024-10-15T10:26:38+08:00https://flcube.com/shanghai-rightongene-biotechnology-co-ltd-executives-under-investigation-by-chinese-authorities/2024-10-15T10:25:58+08:00https://flcube.com/novo-nordisks-wegovy-approved-in-the-uk-to-reduce-cardiovascular-risks-in-overweight-adults/2024-10-15T10:20:32+08:00https://flcube.com/pfizers-hemophilia-a-gene-therapy-shows-promise-in-phase-iii-affine-study/2024-10-14T23:55:06+08:00https://flcube.com/novartis-partners-with-dren-bio-to-develop-next-generation-cancer-therapies/2024-10-14T23:53:36+08:00https://flcube.com/pinetree-therapeutics-strikes-egfr-degrader-deal-with-astrazeneca-worth-over-usd-500-million/2024-10-14T23:52:15+08:00https://flcube.com/belief-biomed-and-takedas-hemophilia-b-gene-therapy-bbm-h901-accepted-for-nmpa-review/2024-10-14T23:51:01+08:00https://flcube.com/hinova-pharmaceuticals-receives-nmpa-approval-to-test-myelofibrosis-drug-candidate-hp560/2024-10-14T23:50:07+08:00https://flcube.com/hainan-poly-pharms-novel-nanomedicine-plat001-cleared-for-clinical-trial-by-nmpa/2024-10-14T23:48:29+08:00https://flcube.com/chinas-nmpa-suspends-daewoong-bios-antibiotic-excludes-firm-from-national-procurement-program/2024-10-14T23:47:23+08:00https://flcube.com/remegen-scales-back-private-placement-to-fund-new-drug-rd/2024-10-14T23:46:39+08:00https://flcube.com/edwards-lifesciences-to-acquire-peijia-medicals-us-partner-jenavalve-impact-on-licensing-deal-minimal/2024-10-14T23:45:42+08:00https://flcube.com/jiangsu-suzhong-pharmas-sutetinib-earns-breakthrough-designation-for-nsclc-from-chinas-nmpa/2024-10-14T23:44:44+08:00https://flcube.com/nanjing-sanhome-pharmaceutical-and-china-resource-pharma-deepen-collaboration-for-market-expansion/2024-10-14T23:43:32+08:00https://flcube.com/agilent-technologies-and-shanghai-majorbio-bio-pharm-ink-deal-to-transform-life-science-research-in-china/2024-10-14T23:42:41+08:00https://flcube.com/sanofis-q2-2024-results-showcase-robust-growth-in-pharma-and-consumer-health-divisions/2024-10-14T23:41:26+08:00https://flcube.com/amoytop-biotech-opts-for-nash-drug-candidate-kn069-in-licensing-deal-with-alphamab-oncology/2024-10-14T23:38:17+08:00https://flcube.com/astrazenecas-q2-2024-results-highlight-strong-growth-across-therapies-excluding-vaccines/2024-10-14T23:36:34+08:00https://flcube.com/roches-h124-financials-show-5-growth-eye-care-and-cancer-therapies-drive-sales/2024-10-14T23:34:42+08:00https://flcube.com/abbvies-q2-2024-results-show-resilience-amid-humira-biosimilar-challenges/2024-10-14T23:32:27+08:00https://flcube.com/luye-pharmas-subsidiary-gets-nmpa-go-ahead-for-first-cd228-targeted-adc-ba1302/2024-10-14T23:31:33+08:00https://flcube.com/amoy-diagnostics-apace-receives-japanese-approval-as-companion-diagnostic-for-met-inhibiting-therapies/2024-10-14T23:29:00+08:00https://flcube.com/lepu-scientech-secures-nmpa-approval-for-rf-lance-advancing-atrial-septal-puncture-technology/2024-10-14T23:28:04+08:00https://flcube.com/sinqi-pharmaceutical-gets-nmpa-green-light-for-sq-22031-eye-drops-to-treat-dry-eye-syndrome-and-neurotrophic-keratitis/2024-10-14T23:27:06+08:00https://flcube.com/united-imaging-healthcare-invests-rmb-120-million-in-particle-accelerator-specialist-long-beam-technology/2024-10-14T23:25:45+08:00https://flcube.com/innovent-biologics-partners-with-wecomput-technology-to-accelerate-ai-in-drug-development/2024-10-14T23:24:43+08:00https://flcube.com/shanghai-gentech-expands-into-life-sciences-with-acquisition-of-konosai-biotechnology/2024-10-14T23:23:47+08:00https://flcube.com/shanghais-spectrum-dynamics-medical-secures-major-financing-for-molecular-imaging-innovations/2024-10-14T23:23:09+08:00https://flcube.com/nhsa-report-chinas-medical-insurance-fund-records-significant-growth-and-savings-in-2023/2024-10-14T23:21:34+08:00https://flcube.com/belief-biomeds-hemophilia-b-gene-therapy-bbm-h901-slated-for-priority-review-in-china/2024-10-14T23:20:49+08:00https://flcube.com/shanghai-escugen-partners-with-innolake-biopharma-to-develop-novel-adcs-using-ezwi-fit-platfo/2024-10-14T23:19:23+08:00https://flcube.com/tigermed-expands-asia-pacific-presence-with-acquisition-of-japanese-cro-medical-edge/2024-10-14T23:18:42+08:00https://flcube.com/cnbg-and-university-of-macau-ink-deal-to-establish-joint-biotech-lab/2024-10-14T23:17:27+08:00https://flcube.com/china-unveils-comprehensive-2030-plan-to-combat-diabetes/2024-10-14T23:16:44+08:00https://flcube.com/microport-medtechs-aortic-occlusion-catheter-gets-green-light-from-chinas-nmpa/2024-10-14T23:14:20+08:00https://flcube.com/akeso-biopharmas-ivonescimab-nda-accepted-by-nmpa-strengthening-nsclc-treatment-options/2024-10-14T23:09:59+08:00https://flcube.com/junshi-biosciences-toripalimab-recommended-for-eu-approval-for-two-indications/2024-10-14T23:07:57+08:00https://flcube.com/alphamabs-kn057-earns-fda-orphan-drug-designation-for-hemophilia-b-treatment/2024-10-14T23:05:57+08:00https://flcube.com/cstone-pharmaceuticals-sugemalimab-wins-eu-nod-as-first-line-nsclc-treatment/2024-10-14T23:04:36+08:00https://flcube.com/3sbios-thrombopoietin-meets-primary-endpoint-in-phase-iii-trial-for-chronic-liver-disease-patients/2024-10-14T23:02:58+08:00https://flcube.com/astrazeneca-charts-comprehensive-anti-obesity-strategy-with-glp-1-and-amylin-therapies/2024-10-14T23:00:25+08:00https://flcube.com/luye-pharmas-antipsychotic-erzofri-gains-fda-nod-for-schizophrenia-treatment/2024-10-14T22:59:24+08:00https://flcube.com/yipinhong-pharmacy-repays-36-7-million-in-bromhexine-marketing-settlement/2024-10-14T22:56:51+08:00https://flcube.com/chinas-nhc-reports-2023-county-hospital-medical-service-capability-evaluation-results/2024-10-14T22:55:23+08:00https://flcube.com/chinas-h1-2024-pharmaceutical-trade-data-indicates-mixed-performance-in-global-markets/2024-10-14T22:54:45+08:00https://flcube.com/guangzhou-red-pine-medical-secures-series-d-funding-to-accelerate-global-expansion/2024-10-14T22:54:08+08:00https://flcube.com/shanghai-sanyou-medical-gains-nmpa-approval-for-3d-printed-cervical-fusion-device/2024-10-14T22:53:36+08:00https://flcube.com/ltz-therapeutics-secures-over-usd-20-million-in-series-a-financing-to-advance-immunotherapy-pipeline/2024-10-14T22:52:31+08:00https://flcube.com/organons-liptruzet-launches-in-china-for-hypercholesterolemia-treatment/2024-10-14T22:51:34+08:00https://flcube.com/livzon-pharmaceutical-group-to-establish-joint-venture-with-pt-kalbe-farma-in-indonesia/2024-10-14T22:50:22+08:00https://flcube.com/shuwen-biotechs-preeclampsia-self-test-receives-nmpa-approval-marking-a-global-first/2024-10-14T22:39:54+08:00https://flcube.com/porton-pharma-solutions-partners-with-guangzhou-geneseed-biotech-to-advance-circrna-therapies/2024-10-14T22:39:10+08:00https://flcube.com/novartiss-scemblix-receives-fda-priority-review-for-first-line-cml-treatment/2024-10-14T22:36:53+08:00https://flcube.com/gsk-enters-into-strategic-partnership-with-flagship-pioneering-to-develop-novel-medicines-and-vaccines/2024-10-14T22:35:28+08:00https://flcube.com/philips-posts-2-q2-2024-sales-growth-boosted-by-north-american-demand/2024-10-14T22:30:49+08:00https://flcube.com/roche-completes-acquisition-of-lumiradxs-point-of-care-solutions-business/2024-10-14T22:29:40+08:00https://flcube.com/wuxi-apptecs-h1-2024-financials-reflect-decline-amid-biosecure-act-challenges/2024-10-14T22:27:28+08:00https://flcube.com/chinas-nmpa-issues-guidelines-for-onsite-inspections-of-medical-device-companies/2024-10-14T22:25:46+08:00https://flcube.com/cutia-therapeutics-cu-30101-nda-accepted-for-review-by-chinas-nmpa/2024-10-14T22:25:03+08:00https://flcube.com/brii-biosciences-us-partner-vbi-vaccines-initiates-bankruptcy-reorganization/2024-10-14T22:23:41+08:00https://flcube.com/microport-scientifics-fully-biodegradable-cardiac-stent-earns-nmpa-nod/2024-10-14T22:20:39+08:00https://flcube.com/bio-thera-solutions-bevacizumab-biosimilar-avzivi-receives-european-commission-approval/2024-10-14T22:19:29+08:00https://flcube.com/gan-lee-pharmaceuticals-gains-market-foothold-in-algeria-with-insulin-product-approvals/2024-10-14T22:18:43+08:00https://flcube.com/chinas-nmpa-approves-pilot-plan-to-streamline-clinical-trial-reviews-for-innovative-drugs/2024-10-14T22:15:15+08:00https://flcube.com/shenzhen-based-synthetica-secures-initial-funding-to-advance-oncolytic-bacteria-pipeline/2024-10-14T22:14:38+08:00https://flcube.com/chinas-nhsa-and-nhc-to-integrate-village-clinics-into-basic-medical-insurance-system/2024-10-14T22:14:00+08:00https://flcube.com/national-comprehensive-cancer-network-renews-partnership-with-medlive-for-oncology-guidelines-access-in-china/2024-10-14T22:13:24+08:00https://flcube.com/fibrogen-inc-enters-restructuring-mode-after-late-stage-trial-failures-for-pamrevlumab/2024-10-14T22:12:36+08:00https://flcube.com/pfizer-inc-reports-q2-2024-earnings-with-first-positive-growth-since-q4-2022-peak/2024-10-14T22:10:01+08:00https://flcube.com/biontechs-mrna-cancer-immunotherapy-bnt111-achieves-primary-endpoint-in-phase-ii-trial/2024-10-14T22:08:48+08:00https://flcube.com/shanghai-unveils-comprehensive-measures-to-strengthen-biopharmaceutical-industry/2024-10-14T22:07:18+08:00https://flcube.com/nice-and-astrazeneca-fail-to-reach-agreement-on-enhertu-reimbursement-for-nhs/2024-10-14T22:06:24+08:00https://flcube.com/astrazeneca-and-daiichi-sankyos-enhertu-receives-fourth-indication-approval-in-china/2024-10-14T18:06:49+08:00https://flcube.com/janssen-and-yuhan-halt-development-of-next-gen-egfr-inhibitor-for-nsclc/2024-10-14T17:34:31+08:00https://flcube.com/lillys-kisunla-poised-to-shake-up-alzheimers-treatment-market-with-fda-approval/2024-10-14T17:30:56+08:00https://flcube.com/eu-regulator-rejects-marketing-authorization-for-biogen-and-eisais-alzheimers-drug-leqembi/2024-10-14T17:29:31+08:00https://flcube.com/eli-lillys-kisunla-secures-market-approval-in-japan-for-early-symptomatic-alzheimers/2024-10-14T17:26:57+08:00https://flcube.com/fda-committee-backs-eli-lillys-donanemab-for-early-symptomatic-alzheimers-disease/2024-10-14T17:25:34+08:00https://flcube.com/biocon-biologics-resolves-patent-dispute-with-jj-secures-market-entry-for-biosimilar-stelara/2024-10-14T17:22:07+08:00https://flcube.com/wedoctor-partners-with-shanghai-childrens-medical-center-to-enhance-pediatric-care/2024-10-14T17:19:28+08:00https://flcube.com/pfizers-hympavzi-secures-fda-nod-offering-novel-once-weekly-treatment-for-hemophilia-b/2024-10-14T17:16:37+08:00https://flcube.com/dizal-pharmaceuticals-golidocitinib-breaks-record-with-rapid-market-launch-in-china/2024-10-14T17:06:19+08:00https://flcube.com/dizal-pharmaceuticals-financial-turnaround-continues-with-33-net-loss-reduction-in-h1-2024/2024-10-14T17:03:44+08:00https://flcube.com/dizal-pharmaceuticals-sunvozertinib-logs-rmb-91-29-million-in-sales-following-egfr-inhibitor-approval/2024-10-14T17:02:22+08:00https://flcube.com/dizal-pharmaceuticals-sunvozertinib-shows-promising-results-in-wu-kong-series-study-at-esmo-2024/2024-10-14T17:00:13+08:00https://flcube.com/sunvozertinibs-companion-diagnostic-gets-nmpa-nod-fortifying-targeted-therapy-arsenal-for-nsclc-in-china/2024-10-14T16:58:56+08:00https://flcube.com/chugai-seeks-approval-for-elevidys-gene-therapy-in-japan-targeting-duchenne-muscular-dystrophy/2024-10-14T16:56:42+08:00https://flcube.com/sichuan-kelun-pharmaceuticals-h1-2024-report-highlights-msd-collaboration-milestones/2024-10-14T16:52:02+08:00https://flcube.com/haisco-pharmaceuticals-crisugabalin-gains-nmpa-approval-for-post-herpes-neuralgia-treatment/2024-10-14T16:44:32+08:00https://flcube.com/sichuan-biokin-pharmaceutical-gets-fda-approval-for-cd33-targeting-adc-in-acute-myeloid-leukemia/2024-10-14T16:22:32+08:00https://flcube.com/iregene-therapeutics-secures-over-usd-14-million-in-series-b-financing-to-advance-cell-therapies/2024-10-14T16:13:02+08:00https://flcube.com/dizal-pharmaceuticals-sunvozertinib-earns-breakthrough-designation-for-nsclc-from-chinas-nmpa/2024-10-14T15:57:06+08:00https://flcube.com/nmpa-sets-forthcoming-guidelines-for-domestic-drug-refiling-procedures/2024-10-14T15:38:48+08:00https://flcube.com/huawei-partners-with-medical-university-hospital-to-boost-healthcare-innovation/2024-10-14T15:32:13+08:00https://flcube.com/reforgene-medicines-gene-editing-therapy-rm-101-clears-ind-hurdle-for-usher-syndrome-treatment/2024-10-14T15:22:36+08:00https://flcube.com/akeso-biopharma-secures-usd-250-million-in-share-placement-bolstering-drug-development-war-chest/2024-10-14T15:12:22+08:00https://flcube.com/novartiss-brolucizumab-accepted-for-review-by-chinas-cde-for-potential-dme-treatment/2024-10-14T14:50:00+08:00https://flcube.com/pfizers-talzenna-combo-shows-improved-survival-in-mcrpc-patients-according-to-talapro-2-study/2024-10-14T14:39:34+08:00https://flcube.com/teva-pharmaceutical-reaches-settlement-with-doj-over-alleged-kickbacks-and-price-fixing/2024-10-14T14:32:01+08:00https://flcube.com/cspc-pharma-initiates-phase-iii-trial-for-jmt101-in-first-line-egfr-positive-nsclc-treatment/2024-10-14T14:19:58+08:00https://flcube.com/takeda-reports-q1-fy2024-earnings-with-growth-in-key-therapies-and-new-launches/2024-10-14T14:06:07+08:00https://flcube.com/tonghua-dongbao-pharmaceuticals-launches-phase-iii-clinical-trial-for-semaglutide-biosimilar-in-china/2024-10-14T11:34:58+08:00https://flcube.com/gsk-reports-q2-2024-earnings-with-13-growth-vaccines-unit-sees-mixed-results/2024-10-14T11:33:52+08:00https://flcube.com/pfizer-enters-multi-year-rd-collaboration-with-telescope-innovations-to-leverage-ai-and-robotics/2024-10-14T11:32:45+08:00https://flcube.com/hutchmed-reports-2024-h1-financials-with-mixed-results-amid-strategic-focus-on-rd-and-commercial-efficiency/2024-10-14T11:24:47+08:00https://flcube.com/microport-scientifics-bioabsorbable-stent-system-gains-nmpa-nod-for-ischemic-heart-disease-treatment/2024-10-14T11:23:30+08:00https://flcube.com/sirnaomics-ltd-forms-jv-with-gore-range-capital-to-pioneer-medical-aesthetics-innovations/2024-10-14T11:22:23+08:00https://flcube.com/shanghai-aims-to-become-capital-market-hub-for-high-quality-science-and-innovation-companies/2024-10-14T11:21:19+08:00https://flcube.com/chinas-state-council-unveils-five-year-plan-to-enhance-urbanization-and-address-three-rural-issues/2024-10-14T11:20:36+08:00https://flcube.com/chinas-health-authorities-set-standards-for-key-central-township-health-centers/2024-10-14T11:19:59+08:00https://flcube.com/us-lawmakers-probe-clinical-trials-at-hospitals-linked-to-chinese-military-potential-impact-on-pharma-industry/2024-10-14T11:19:22+08:00https://flcube.com/otsuka-pharmaceutical-to-acquire-us-biotech-jnana-therapeutics-in-1-1-billion-deal/2024-10-14T11:18:41+08:00https://flcube.com/kyowa-kirin-revamps-apac-strategy-exits-china-and-shifts-rd-focus/2024-10-14T11:17:59+08:00https://flcube.com/fapon-biotech-expands-global-footprint-with-new-ivd-manufacturing-facility-in-indonesia/2024-10-14T11:16:06+08:00https://flcube.com/gsks-jemperli-receives-ec-approval-for-endometrial-cancer-treatment-in-combination-therapy/2024-10-14T11:15:19+08:00https://flcube.com/innovent-biologics-mazdutide-nda-for-type-2-diabetes-accepted-for-review-in-china/2024-10-14T11:13:34+08:00https://flcube.com/abbvies-allergan-aesthetics-wins-nmpa-approval-for-juvederm-dermal-filler-in-china/2024-10-14T11:12:03+08:00https://flcube.com/sino-biopharmaceuticals-benmelstobart-files-for-new-indication-in-china-for-advanced-rcc-treatment/2024-10-14T11:10:26+08:00https://flcube.com/immuneonco-biopharmaceuticals-strikes-licensing-deal-with-instil-bio-for-global-rights-to-dual-targeted-antibodies/2024-10-14T11:09:09+08:00https://flcube.com/suzhou-zelgens-jacktinib-tablets-achieve-positive-results-in-phase-ii-ipf-clinical-trial/2024-10-14T11:07:53+08:00https://flcube.com/mabwell-bioscience-secures-rights-to-risen-pharmaceuticals-oa-treatment-in-greater-china/2024-10-14T11:06:16+08:00https://flcube.com/roches-alzheimers-disease-diagnostic-kits-gain-approval-in-hainan-set-for-use-in-shanghai-ruijin-hospital/2024-10-14T11:05:05+08:00https://flcube.com/lees-pharmaceutical-commences-phase-i-clinical-trial-for-ai-discovered-hcc-drug-au409/2024-10-14T10:57:18+08:00https://flcube.com/sino-medical-sciences-ht-supreme-drug-eluting-stent-system-gains-market-approval-in-mexico/2024-10-14T10:55:54+08:00https://flcube.com/abbvie-completes-acquisition-of-cerevel-therapeutics-in-8-7-billion-deal/2024-10-14T10:54:11+08:00https://flcube.com/chinas-state-council-unveils-guidelines-to-enhance-basic-medical-insurance-system/2024-10-14T10:52:39+08:00https://flcube.com/chinas-nmpa-launches-pilot-programs-in-beijing-and-shanghai-for-innovative-drug-approvals/2024-10-14T10:52:01+08:00https://flcube.com/astellas-pharma-reports-robust-q1-fy2024-results-highlighting-growth-in-core-therapies/2024-10-14T10:49:43+08:00https://flcube.com/akeso-biopharma-initiates-phase-ii-global-study-for-ligafulimab-in-high-risk-mds/2024-10-14T10:48:22+08:00https://flcube.com/walvax-biotechnologys-bivalent-hpv-vaccine-earns-who-pre-qualification-status/2024-10-14T10:44:27+08:00https://flcube.com/hutchmed-establishes-global-rd-hub-in-hong-kong-science-park-to-accelerate-translational-medicine/2024-10-14T10:42:08+08:00https://flcube.com/innovent-biologics-and-sanegene-bio-commence-phase-i-clinical-trial-for-hypertension-sirna-drug/2024-10-14T10:40:20+08:00https://flcube.com/chinas-cde-releases-draft-guidelines-for-car-t-cell-therapy-clinical-trials/2024-10-14T10:30:10+08:00https://flcube.com/yantai-dongcheng-pharmaceutical-secures-nmpa-nod-for-psma-targeted-radiotherapeutic-drug/2024-10-14T10:29:19+08:00https://flcube.com/takeda-to-slash-1000-us-jobs-as-part-of-broader-restructuring-effort/2024-10-14T10:27:20+08:00https://flcube.com/chinas-cde-seeks-public-comment-on-latest-generic-drug-reference-preparations/2024-10-14T10:25:20+08:00https://flcube.com/ge-healthcares-q1-2024-earnings-hit-by-china-adjusts-annual-guidance/2024-10-14T10:24:34+08:00https://flcube.com/united-imaging-healthcare-launches-medical-grade-hearing-aid-uorigin-in-china/2024-10-14T10:20:52+08:00https://flcube.com/huadong-medicine-secures-exclusive-rights-to-immunochinas-car-t-therapy-in-china/2024-10-14T10:20:05+08:00https://flcube.com/degen-biopharmaceuticals-dg01-protac-drug-receives-nmpa-clearance-for-solid-tumor-studies/2024-10-14T10:16:35+08:00https://flcube.com/genor-biopharma-strikes-licensing-deal-with-trc-2004-for-global-rights-to-gb261-outside-greater-china/2024-10-14T10:15:17+08:00https://flcube.com/shionogi-files-for-chinese-approval-of-cefiderocol-to-combat-gram-negative-bacterial-infections/2024-10-14T10:13:31+08:00https://flcube.com/daiichi-sankyo-reports-24-3-yoy-revenue-growth-driven-by-enhertu-and-lixiana/2024-10-14T10:12:20+08:00https://flcube.com/eisais-q1-fy2024-revenues-reflect-mixed-results-with-leqembi-sales-doubling/2024-10-14T10:10:51+08:00https://flcube.com/biontech-ends-collaboration-with-genmab-on-acasunlimab-development/2024-10-14T10:09:50+08:00https://flcube.com/takedas-vonicog-alfa-receives-nmpa-approval-for-von-willebrand-disease-treatment-in-china/2024-10-14T10:07:46+08:00https://flcube.com/sihuan-pharmaceutical-gains-exclusive-rights-to-cellontechs-cartilage-treatment-in-china/2024-10-14T10:05:32+08:00https://flcube.com/northeast-pharmaceutical-to-acquire-majority-stake-in-cell-therapy-specialist-dingcheng-taiyuan/2024-10-14T10:04:36+08:00https://flcube.com/cmss-methotrexate-injection-gains-nmpa-approval-for-active-rheumatoid-arthritis-treatment/2024-10-14T10:03:34+08:00https://flcube.com/luye-pharmas-ly03020-receives-nmpa-approval-for-schizophrenia-and-alzheimers-psychosis-treatment/2024-10-14T10:01:22+08:00https://flcube.com/gan-lee-pharmaceuticals-gets-fda-green-light-for-phase-i-clinical-trial-of-insulin-aspart-biosimilar/2024-10-14T09:59:57+08:00https://flcube.com/suzhou-zelgen-biopharmaceuticals-zg005-receives-nmpa-approval-for-clinical-trials-in-solid-tumors/2024-10-14T09:57:04+08:00https://flcube.com/hotgen-biotechs-sgc001-receives-nmpa-approval-for-clinical-trials-in-myocardial-infarction/2024-10-14T09:55:39+08:00https://flcube.com/antengenes-xpovio-receives-nda-approval-in-malaysia-for-multiple-myeloma-treatment/2024-10-14T09:53:17+08:00https://flcube.com/bayer-ags-q2-2024-global-group-sales-rise-3-1-driven-by-pharmaceuticals-and-consumer-healthcare/2024-10-14T09:51:30+08:00https://flcube.com/walvax-biotechnologys-hpv-vaccine-price-cut-sparks-potential-market-price-war-in-china/2024-10-14T09:47:33+08:00https://flcube.com/shanghai-vitalgen-biopharma-partners-with-novoprotein-to-commercialize-aacas12bmax-gene-editor/2024-10-14T09:46:07+08:00https://flcube.com/cybernax-secures-licensing-deal-with-merck-kgaa-for-advanced-lipid-storage-technology/2024-10-14T09:45:13+08:00https://flcube.com/cloudbreak-pharma-partners-with-santen-pharmaceutical-for-cbt-001-commercialization-in-southeast-asia/2024-10-14T09:43:36+08:00https://flcube.com/zai-labs-q2-2024-revenues-soar-47-yoy-driven-by-vyvgart-and-zejula-sales/2024-10-14T09:42:44+08:00https://flcube.com/merck-kgaa-posts-1-7-q2-growth-amid-varied-business-segment-performance/2024-10-14T09:41:13+08:00https://flcube.com/sangamo-therapeutics-and-genentech-join-forces-to-develop-genomic-therapies-for-neurodegenerative-diseases/2024-10-14T09:39:49+08:00https://flcube.com/jiantebo-and-sanyou-biopharmaceuticals-join-forces-to-discover-metabolic-disease-targets-and-develop-agonistic-antibodies/2024-10-14T09:38:46+08:00https://flcube.com/chinas-nmpa-proposes-new-rules-for-export-drug-manufacturing-and-management/2024-10-14T09:37:28+08:00https://flcube.com/akeso-biopharma-initiates-phase-iii-clinical-trial-for-cadonilimab-in-hepatocellular-carcinoma/2024-10-14T09:29:35+08:00https://flcube.com/organons-q2-2024-revenues-grow-2-yoy-sets-sights-on-fertility-business-rebound-in-2025/2024-10-14T09:25:12+08:00https://flcube.com/eisai-and-seed-therapeutics-join-forces-on-molecular-glue-degraders-for-neurodegeneration-and-cancer/2024-10-13T23:23:19+08:00https://flcube.com/vazyme-biotech-secures-nmpa-nod-for-two-rsv-antigen-detection-kits/2024-10-13T23:21:53+08:00https://flcube.com/haisco-pharmaceuticals-pde4b-inhibitor-hsk44459-gets-nmpa-green-light-for-interstitial-lung-disease-clinical-trial/2024-10-13T23:20:47+08:00https://flcube.com/hygeia-healthcare-holdings-acquires-chang-an-hospital-in-deal-valued-at-rmb-1-66-billion/2024-10-13T23:16:54+08:00https://flcube.com/shanghai-pharmaceuticals-sh-inno-incubator-to-drive-biopharmaceutical-innovation-and-collaboration/2024-10-13T23:16:17+08:00https://flcube.com/nhsa-preliminary-review-identifies-potential-nrdl-additions-including-novel-therapies-and-adcs/2024-10-13T23:14:51+08:00https://flcube.com/betta-pharmaceuticals-reports-strong-h1-2024-revenue-growth-and-advances-in-drug-development/2024-10-13T23:14:10+08:00https://flcube.com/insilico-medicines-ism6331-earns-fda-orphan-drug-designation-for-mesothelioma-treatment/2024-10-13T23:12:13+08:00https://flcube.com/viatris-inc-reports-2-operational-growth-in-q224-driven-by-generics-and-brands/2024-10-13T23:11:00+08:00https://flcube.com/ai-driven-drug-firms-recursion-and-exscientia-to-merge-in-a-deal-valued-at-approximately-usd-850-million/2024-10-13T23:10:15+08:00https://flcube.com/eli-lilly-co-resolves-manufacturing-constraints-reports-37-yoy-sales-growth-in-q2-2024/2024-10-13T23:08:21+08:00https://flcube.com/wuxi-biologics-partners-with-medigene-for-tcr-tce-development-in-refractory-tumors/2024-10-13T23:07:12+08:00https://flcube.com/pfizer-astellas-and-university-of-california-sue-qilu-pharma-over-xtandi-patent-infringement/2024-10-13T23:06:05+08:00https://flcube.com/novo-nordisk-reports-25-yoy-sales-growth-in-h1-and-q2-2024-led-by-glp-1-drugs/2024-10-13T23:03:31+08:00https://flcube.com/zelgen-biopharmaceuticals-zg006-earns-orphan-drug-designation-from-fda-for-small-cell-lung-cancer/2024-10-13T23:02:24+08:00https://flcube.com/hansoh-pharmaceutical-secures-rights-to-lupengs-btk-inhibitor-lp-168-in-licensing-deal/2024-10-13T23:00:50+08:00https://flcube.com/westgene-biopharmas-eb-virus-targeting-mrna-vaccine-wgc-043-clears-for-clinical-trials-in-china/2024-10-13T22:59:15+08:00https://flcube.com/wondfo-biotech-and-university-of-science-malaysia-deepen-ties-with-formal-partnership/2024-10-13T22:58:11+08:00https://flcube.com/harbour-biomed-reclaims-rights-to-hbm7008-as-cullinan-therapeutics-cancels-licensing-deal/2024-10-13T22:56:53+08:00https://flcube.com/huadong-medicine-expands-global-footprint-with-launch-of-aesthetic-injection-maili-in-singapore/2024-10-13T22:55:34+08:00https://flcube.com/sansure-biotechs-mthfr-gene-detection-kit-receives-nmpa-approval-aids-in-pregnancy-health-management/2024-10-13T22:54:06+08:00https://flcube.com/innovent-biologics-reports-over-rmb-2-billion-in-q2-2024-sales-highlighting-50-yoy-growth/2024-10-13T22:52:05+08:00https://flcube.com/fosun-pharmas-west-african-project-nears-first-phase-completion-aims-for-5-billion-drug-units-annually/2024-10-13T22:46:57+08:00https://flcube.com/sichuan-huiyu-pharmaceuticals-chairman-ding-zhao-faces-csrc-investigation-for-short-term-stock-trading/2024-10-13T22:45:23+08:00https://flcube.com/amgen-to-establish-new-site-in-hyderabad-india-with-focus-on-technology-and-digital-innovation/2024-10-13T22:43:15+08:00https://flcube.com/lees-pharma-subsidiary-receives-green-light-for-phase-iii-dry-eye-study-and-completes-myopia-trial/2024-10-13T22:42:04+08:00https://flcube.com/3sbios-subsidiary-achieves-milestone-in-phase-ii-study-for-chronic-sinusitis-treatment-ssgj-611/2024-10-13T22:39:46+08:00https://flcube.com/guangdong-zhongsheng-pharmaceuticals-covid-19-drug-leritrelvir-approved-in-macau/2024-10-13T22:38:17+08:00https://flcube.com/3sbio-subsidiary-achieves-milestone-in-phase-iii-psoriasis-trial-with-ssgj-608/2024-10-13T22:36:44+08:00https://flcube.com/fujian-cosunters-innovative-drug-gst-hg141-exceeds-efficacy-in-reducing-hbv-dna-in-phase-ii-study/2024-10-13T22:34:41+08:00https://flcube.com/shineyo-medical-secures-rmb-100-million-in-series-a-funding-for-cardiac-and-vascular-devices/2024-10-13T22:33:23+08:00https://flcube.com/mabwells-nectin-4-targeting-adc-9mw2821-on-path-to-breakthrough-designation-in-china-for-urothelial-carcinoma/2024-10-13T22:32:36+08:00https://flcube.com/cspc-pharmaceuticals-sys6020-receives-nmpa-approval-for-clinical-trials-in-systemic-lupus-erythematosus/2024-10-13T22:30:59+08:00https://flcube.com/mindray-medical-forges-comprehensive-partnership-with-cuhk-shenzhen-school-of-medicine/2024-10-13T22:29:22+08:00https://flcube.com/tyk-medicines-inc-targets-hkd-506-3-million-in-hong-kong-ipo-for-drug-pipeline-expansion/2024-10-13T22:26:38+08:00https://flcube.com/pfizers-rsv-vaccine-abrysvo-shows-strong-protection-in-immunocompromised-adults-phase-iii-sub-study-reveals/2024-10-13T22:25:12+08:00https://flcube.com/former-hainan-medical-university-president-li-jingquan-expelled-for-serious-disciplinary-violations/2024-10-13T22:23:23+08:00https://flcube.com/artech-medicals-balloon-cryoablation-catheter-wins-nmpa-nod-for-atrial-fibrillation-treatment/2024-10-13T22:22:31+08:00https://flcube.com/siemens-healthineers-partners-with-cedars-sinai-to-boost-medical-cooperation-and-education/2024-10-13T22:21:47+08:00https://flcube.com/ascendis-pharmas-hypoparathyroidism-therapy-yorvipath-wins-fda-nod-fills-market-gap/2024-10-13T22:20:01+08:00https://flcube.com/chinas-samr-proposes-antitrust-guidelines-to-regulate-pharmaceutical-industry/2024-10-13T22:15:33+08:00https://flcube.com/boehringer-ingelheims-zongertinib-earns-breakthrough-designation-in-china-for-her2-mutated-nsclc/2024-10-13T22:11:38+08:00https://flcube.com/nanjing-sanhomes-oritinib-ships-widely-for-egfr-mutated-nsclc-treatment-in-china/2024-10-13T22:09:47+08:00https://flcube.com/junshi-biosciences-submits-twelfth-indication-for-pd-1-inhibitor-loqtorzi-in-china/2024-10-13T22:08:51+08:00https://flcube.com/pfizers-hemophilia-treatment-marstacimab-accepted-for-review-in-china/2024-10-13T22:06:48+08:00https://flcube.com/ocumension-therapeutics-partners-with-alcon-laboratories-secures-rights-to-ophthalmic-products-in-china/2024-10-13T21:59:48+08:00https://flcube.com/legend-biotech-ceo-addresses-biosecure-act-concerns-amid-q2-2024-earnings-report/2024-10-13T21:58:23+08:00https://flcube.com/gilead-buys-out-janssens-royalty-rights-to-seladelpar-for-primary-biliary-cholangitis-treatment/2024-10-13T21:42:44+08:00https://flcube.com/sihuan-pharmaceutical-secures-nmpa-approval-for-first-biosimilars-of-novo-nordisks-diabetes-drugs/2024-10-13T21:40:59+08:00https://flcube.com/gsk-initiates-phase-iii-study-for-rsv-vaccine-in-china-following-u-s-approval/2024-10-13T21:38:00+08:00https://flcube.com/wantai-biologicals-hpv-vaccine-receives-priority-review-from-chinas-cde/2024-10-13T21:33:14+08:00https://flcube.com/sino-biopharmaceutical-reports-record-h1-revenues-of-rmb-15-87-billion-net-profit-soars-139-7/2024-10-13T21:31:55+08:00https://flcube.com/novartis-intensifies-legal-action-against-fda-over-entresto-generic-approval/2024-10-13T21:30:55+08:00https://flcube.com/lepu-medicals-peakheat-vascular-sheath-gains-regulatory-green-light-for-market-launch/2024-10-13T21:29:38+08:00https://flcube.com/new-agreement-enhances-myopia-solutions-hong-kong-polytechnic-and-zeiss-collaborate/2024-10-13T21:28:26+08:00https://flcube.com/enhertu-gains-conditional-approval-in-china-for-advanced-her2-positive-gastric-cancer/2024-10-13T21:27:46+08:00https://flcube.com/ascentage-pharma-secures-nmpa-approval-for-phase-iii-trial-of-lisaftoclax-in-mds/2024-10-13T21:25:00+08:00https://flcube.com/eli-lilly-unveils-700-million-rd-center-in-boston-to-boost-genetic-medicine-efforts/2024-10-13T21:23:25+08:00https://flcube.com/chinas-sansure-biotech-launches-approved-kit-for-alzheimers-and-cardiovascular-risk-assessment/2024-10-13T21:20:46+08:00https://flcube.com/shaanxi-leads-new-provincial-alliance-for-volume-based-procurement-of-medical-products/2024-10-13T21:17:00+08:00https://flcube.com/biogen-and-eisai-secure-uae-approval-for-alzheimers-therapy-leqembi/2024-10-13T21:16:20+08:00https://flcube.com/shandong-buchang-pharmaceuticals-partners-with-lancet-for-bc001-licensing-in-eurasia/2024-10-13T21:14:59+08:00https://flcube.com/shanghai-sanyou-medical-to-acquire-full-control-of-smtp-technology-for-rmb-415-7-million/2024-10-13T21:13:18+08:00https://flcube.com/gsks-ma-zheng-to-depart-as-head-of-communication-and-government-affairs-in-china/2024-10-13T21:12:18+08:00https://flcube.com/astellas-pharma-secures-uk-approval-for-first-in-class-gastric-cancer-therapy-vyloy/2024-10-13T21:10:59+08:00https://flcube.com/gilead-secures-fda-accelerated-approval-for-livdelzi-in-liver-disease-treatment/2024-10-13T21:09:37+08:00https://flcube.com/vimgreen-pharma-launches-phase-ii-trial-for-a2ar-antagonist-vg081821ac-in-parkinsons-disease/2024-10-13T21:06:48+08:00https://flcube.com/sino-medical-secures-moroccan-approvals-for-nc-rockstar-catheter-and-ht-supreme-stent-system/2024-10-13T21:05:21+08:00https://flcube.com/lepu-scientech-secures-nmpa-approval-for-memosorb-biodegradable-atrial-septal-defect-occluder/2024-10-13T21:01:04+08:00https://flcube.com/lykos-therapeutics-faces-setback-as-fda-rejects-midomafetamine-for-ptsd-treatment/2024-10-13T20:54:06+08:00https://flcube.com/huadong-medicine-secures-licensing-deal-with-imbiologics-for-autoimmune-drug-candidates/2024-10-13T20:42:41+08:00https://flcube.com/kelun-pharmaceuticals-sacituzumab-tirumotecan-receives-priority-review-for-nsclc-treatment/2024-10-13T20:41:23+08:00https://flcube.com/remegen-appoints-he-ruyi-as-chief-strategy-officer-transitioning-from-cmo-role/2024-10-13T20:39:30+08:00https://flcube.com/kintor-pharmaceuticals-gt20029-meets-primary-endpoint-in-phase-ii-aga-trial/2024-10-13T19:58:01+08:00https://flcube.com/chinese-authorities-launch-special-plan-to-rectify-medical-insurance-fraud-and-non-compliance/2024-10-13T19:55:44+08:00https://flcube.com/china-unveils-2024-plan-to-combat-fraud-in-medical-insurance-funds/2024-10-13T19:55:39+08:00https://flcube.com/jjs-medical-technology-sector-rises-6-3-yoy-despite-chinas-vbp-impact/2024-10-13T19:55:33+08:00https://flcube.com/carvykti-car-t-therapy-sales-reach-157-million-in-q1-2024-reports-genscript-subsidiary-legend-biotech/2024-10-13T19:55:29+08:00https://flcube.com/abbvie-partners-with-medincell-for-development-of-long-acting-injectable-therapies/2024-10-13T19:55:24+08:00https://flcube.com/kpc-pharmaceuticals-gets-nmpa-green-light-for-clinical-trial-on-familial-mediterranean-fever-treatment/2024-10-13T19:55:16+08:00https://flcube.com/boehringer-ingelheim-surpasses-bayer-in-pharma-sales-with-eur-20-8-billion-in-2023/2024-10-13T19:55:11+08:00https://flcube.com/shionogis-xofluza-gains-approval-in-taiwan-for-pediatric-influenza-treatment-and-prophylaxis/2024-10-13T19:55:00+08:00https://flcube.com/innovent-biologics-ibi133-receives-tacit-approval-for-clinical-trial-from-chinas-cde/2024-10-13T19:54:55+08:00https://flcube.com/sichuan-biokins-bl-b01d1-earns-breakthrough-designation-for-nasopharyngeal-carcinoma-treatment/2024-10-13T19:54:49+08:00https://flcube.com/amgens-tezspire-shows-promise-in-phase-iia-copd-trial-reduces-exacerbations/2024-10-13T19:54:46+08:00https://flcube.com/shanghai-henlius-biotech-advances-tigit-targeting-hlx53-to-phase-ii-clinical-trial-for-hepatocellular-carcinoma/2024-10-13T19:54:42+08:00https://flcube.com/cspc-pharmaceutical-posts-1-7-revenue-growth-in-2023-bolstered-by-patent-medicine-sales/2024-10-13T19:54:27+08:00https://flcube.com/abbott-reports-q1-2024-organic-sales-growth-of-4-7-led-by-pharmaceuticals-and-devices/2024-10-13T19:54:23+08:00https://flcube.com/chinas-cnipa-and-uspto-pledge-to-deepen-intellectual-property-cooperation/2024-10-13T19:54:14+08:00https://flcube.com/shanghai-escugen-and-anke-bio-partner-to-develop-adc-products-with-ezwi-fit-platform/2024-10-13T19:54:10+08:00https://flcube.com/roche-chinas-talent-and-culture-vice-president-chen-yanli-departs-for-new-opportunities/2024-10-13T19:53:07+08:00https://flcube.com/i-mab-ceo-outlines-streamlined-us-entitys-focus-and-potential-for-in-licensing/2024-10-13T19:52:54+08:00https://flcube.com/fda-advisory-committee-backs-mrd-as-accelerated-approval-endpoint-for-multiple-myeloma/2024-10-13T19:52:50+08:00https://flcube.com/jd-healthcare-forges-partnerships-with-top-medical-device-firms-at-cmef/2024-10-13T19:52:45+08:00https://flcube.com/shanghai-electric-group-and-siemens-healthineers-unveil-ultramarine-series-medical-imaging-devices/2024-10-13T19:52:39+08:00https://flcube.com/89bio-partners-with-bibio-biopharma-to-build-api-facility-for-pegozafermin-in-china/2024-10-13T19:52:35+08:00https://flcube.com/keymed-biosciences-achieves-first-dosing-in-global-phase-iii-trial-for-claudin-18-2-targeting-adc/2024-10-13T19:52:30+08:00https://flcube.com/vazyme-partners-with-yufang-medical-to-boost-alzheimers-blood-test-sales-online/2024-10-13T19:52:26+08:00https://flcube.com/ningbo-menovo-partners-with-university-of-michigan-to-develop-glp-1-delivery-system/2024-10-13T19:52:20+08:00https://flcube.com/eu-set-to-investigate-chinas-medical-device-procurement-practices-amid-fairness-concerns/2024-10-13T19:52:17+08:00https://flcube.com/novartiss-fabhalta-shows-promise-in-phase-iii-iga-nephropathy-trial/2024-10-13T19:52:13+08:00https://flcube.com/roches-columvi-meets-overall-survival-endpoint-in-diffuse-large-b-cell-lymphoma-trial/2024-10-13T19:52:09+08:00https://flcube.com/sanofi-advances-phase-i-ii-trial-of-trifunctional-nk-cell-engager-in-blood-cancers/2024-10-13T19:52:02+08:00https://flcube.com/easton-pharmaceutical-gets-nmpa-nod-for-generic-version-of-merck-kgaas-concor/2024-10-13T19:51:56+08:00https://flcube.com/china-medical-systems-opzelura-approved-in-macau-for-vitiligo-treatment/2024-10-13T19:51:47+08:00https://flcube.com/sirnaomics-receives-fda-feedback-on-stp705-development-plan-for-isscc-treatment/2024-10-13T19:51:43+08:00https://flcube.com/beijing-airdoc-leads-rmb-500-million-joint-venture-to-invest-in-ai-powered-healthcare/2024-10-13T19:51:38+08:00https://flcube.com/chinas-nmpa-launches-2024-medical-device-industry-standard-revision-plan/2024-10-13T19:51:33+08:00https://flcube.com/astrazenecas-imfinzi-shows-sustained-survival-benefit-in-advanced-biliary-tract-cancer-trial/2024-10-13T19:51:28+08:00https://flcube.com/chinas-nmpa-releases-79th-batch-of-reference-drugs-for-generic-quality-evaluation/2024-10-13T19:51:23+08:00https://flcube.com/sino-biopharmaceutical-to-present-phase-ii-data-for-garsorasib-at-aacr-2024/2024-10-13T19:00:36+08:00https://flcube.com/yantai-dongcheng-secures-approval-for-phase-i-study-of-68ga-lnc1007-in-singapor/2024-10-13T19:00:31+08:00https://flcube.com/enhertu-shows-58-3-response-rate-in-phase-ii-lung-cancer-study-astrazeneca-and-daiichi-sankyo-report/2024-10-13T19:00:26+08:00https://flcube.com/tevas-ajovy-achieves-positive-results-in-phase-iii-migraine-prevention-trial-in-china/2024-10-13T19:00:16+08:00https://flcube.com/vertex-pharmaceuticals-to-acquire-alpine-immune-sciences-in-a-4-9-billion-deal/2024-10-13T19:00:12+08:00https://flcube.com/haisco-pharmaceutical-gets-nmpa-green-light-for-hsk31858-copd-trial/2024-10-13T19:00:08+08:00https://flcube.com/suzhou-zelgen-receives-nmpa-approval-for-jacktinib-cream-trial-in-vitiligo-patients/2024-10-13T19:00:03+08:00https://flcube.com/qilu-pharmaceutical-gets-nmpa-green-light-for-generic-romiplostim-for-itp-treatment/2024-10-13T18:59:59+08:00https://flcube.com/astrazenecas-fasenra-gains-fda-approval-for-pediatric-severe-asthma-treatment/2024-10-13T18:59:52+08:00https://flcube.com/sanofi-explores-sale-of-amunix-pharmaceuticals-as-it-shifts-focus-to-immunology/2024-10-13T18:59:45+08:00https://flcube.com/nhsa-reports-2023-milestones-in-basic-medical-insurance-participation-and-financials/2024-10-13T18:59:41+08:00https://flcube.com/abbvies-aquipta-qulipta-shows-promise-in-migraine-prevention-trial/2024-10-13T18:59:31+08:00https://flcube.com/bayer-partners-with-hologic-to-develop-contrast-enhanced-mammography-solution-for-breast-cancer-diagnosis/2024-10-13T18:59:28+08:00https://flcube.com/3sbio-secures-nmpa-approval-for-pediatric-thrombopoietin-treatment-of-itp/2024-10-13T18:59:24+08:00https://flcube.com/roche-and-eli-lillys-elecsys-ptau217-blood-test-earns-fda-breakthrough-designation-for-alzheimers-detection/2024-10-13T18:59:16+08:00https://flcube.com/hainan-medical-zone-launches-lecheng-global-special-medical-insurance-for-wider-drug-access/2024-10-13T18:59:01+08:00https://flcube.com/arnatar-therapeutics-secures-50-million-in-series-a-funding-to-expand-into-china/2024-10-13T18:57:45+08:00https://flcube.com/suzhou-smartnuclide-biopharmaceutical-secures-13-8-million-in-series-c-funding-to-advance-radiopharmaceutical-pipeline/2024-10-13T18:57:41+08:00https://flcube.com/apeloa-pharmaceutical-partners-with-heze-pharmaceutical-for-semaglutide-biosimilar-development/2024-10-13T18:57:36+08:00https://flcube.com/sichuan-biokin-pharmaceuticals-initiates-phase-iii-trial-for-bl-m05d1-in-esophageal-cancer/2024-10-13T18:57:27+08:00https://flcube.com/roches-inavolisib-earns-priority-review-status-in-china-for-pik3ca-mutated-breast-cancer/2024-10-13T18:57:22+08:00https://flcube.com/simcere-pharmaceuticals-sim0500-earns-fda-fast-track-designation-for-multiple-myeloma/2024-10-13T18:57:10+08:00https://flcube.com/bayer-partners-with-google-cloud-to-develop-ai-powered-medical-imaging-solutions/2024-10-13T18:57:03+08:00https://flcube.com/novartis-announces-layoffs-to-streamline-operations-and-boost-portfolio-value/2024-10-13T18:56:51+08:00https://flcube.com/genesis-medtech-secures-hundreds-of-millions-in-funding-to-boost-rd-and-manufacturing-in-china/2024-10-13T18:56:41+08:00https://flcube.com/sanofi-extends-collaboration-with-nurix-therapeutics-targeting-stat6-in-type-2-inflammation/2024-10-13T18:56:35+08:00https://flcube.com/boehringer-ingelheims-shanghai-unit-secures-ema-and-fda-approval-for-biopharmaceutical-supply/2024-10-13T18:56:28+08:00https://flcube.com/pfizer-reports-positive-phase-iii-results-for-rsv-vaccine-abrysvo-in-younger-adults/2024-10-13T18:56:23+08:00https://flcube.com/roche-secures-ce-mark-for-ventana-her2-test-enhancing-access-to-astrazenecas-enhertu/2024-10-13T18:56:19+08:00https://flcube.com/bios-chief-lobbyist-nick-shipley-resigns-amid-controversy-over-wuxi-apptec/2024-10-13T18:56:15+08:00